<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Breast And Endocrine - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Surgery
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">101</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 11462,
    "choices": [
      {
        "id": 45814,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcohol </span></span></span></p>"
      },
      {
        "id": 45815,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Early age of first live childbirth</span></span></span></p>"
      },
      {
        "id": 45816,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Early menarche </span></span></span></p>"
      },
      {
        "id": 45817,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nulliparity</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which out of these is not a risk factor for breast carcinoma?</span></span></span></p>",
    "unique_key": "Q4817063",
    "question_audio": null,
    "question_video": null,
    "map_id": 36893,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Early age of first live child birth.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Early age of first live childbirth&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">an <strong>early age at first full-term pregnancy</strong> is generally considered a <strong>protective factor against breast cancer.</strong> This <strong>protection</strong> may be due to <strong>hormonal changes</strong> that occur during pregnancy that have a long-term effect on the cells in the breast. <strong>Having the first child after 35 years of age (late parity) is a risk factor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: Alcohol.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alcohol consumption</strong> is a well-established <strong>risk factor for the development of breast cancer</strong>. The risk increases with the amount of alcohol consumed, and this association is thought to be due to alcohol&#39;s effects on estrogen and other hormonal levels, as well as its ability to damage DNA in cells.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Early menarche.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Early onset of menstruation</strong> (menarche) is a <strong>risk factor for breast cancer</strong>. The earlier a woman begins menstruating, the longer her breast tissue is exposed to estrogen, which can promote the growth of cancer cells.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Nulliparity.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nulliparity, or <strong>never having given birth to a child</strong>, is also a recognized <strong>risk factor for breast cancer</strong>. This is thought to be due to the absence of the protective hormonal changes that occur during pregnancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protective factors for carcinoma breast:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Early age at first pregnancy</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multiparity</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breastfeeding</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oophorectomy</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exercise </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen and aromatase inhibitors</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risk factors for breast carcinoma:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age: incidence increases with increasing age.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sex: more common in females.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Personal history and family history of breast cancer</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Race, ethnicity (white women have increased risk compared to women of other races)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">History of radiation exposure</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mammographically dense breast </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic factors:</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mutations in tumor suppressor genes</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA 1</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA 2</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TP53</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CHEK2</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hereditary syndromes</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Li Fraumeni syndrome</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cowden&rsquo;s syndrome</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HNPCC syndrome</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peutz - Jeghers syndrome</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ataxia telangiectasia </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormonal factors (hypercarotenemia is the risk factor)</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Early menarche (&lt;12 years)</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Late gmenopause (&gt; 55 years)</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">First full-term pregnancy &gt;35 years</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nulliparity</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obesity (Postmenopausal)</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Higher socioeconomic status, high fat diet, alcohol intake, chest wall radiation</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">OCPills and smoking have a low risk association</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -28<sup>th</sup> edition page no 931, table 58.3</span></strong></span></span></p>",
    "correct_choice_id": 45815,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11463,
    "choices": [
      {
        "id": 45818,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apocrine metaplasia </span></span></span></p>"
      },
      {
        "id": 45819,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Florid hyperplasia </span></span></span></p>"
      },
      {
        "id": 45820,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atypical hyperplasia </span></span></span></p>"
      },
      {
        "id": 45821,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LCIS</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is not a pre malignant lesion associated with breast cancer?</span></span></span></p>",
    "unique_key": "Q1033182",
    "question_audio": null,
    "question_video": null,
    "map_id": 36894,
    "difficulty_level": "difficult",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Apocrine metaplasia </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apocrine metaplasia&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is seen in <strong>breast cysts</strong> and is <strong>always benign.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apocrine Metaplasia&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong>benign change</strong> in the <strong>breast</strong> where <strong>ductal epithelial cells transform into cells resembling those of the apocrine glands</strong>. It is often <strong>found in fibrocystic</strong> changes and is not associated with an increased risk of developing breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Florid Hyperplasia&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Florid hyperplasia, also known as <strong>usual ductal hyperplasia,</strong> is an <strong>overgrowth of the cells lining the ducts of the breast tissue</strong>. While it is not in itself considered premalignant, there is a slight increase in the risk of developing breast cancer compared to the general population, particularly when the hyperplasia is moderate to florid.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Atypical Hyperplasia&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atypical hyperplasia is a condition <strong>where there is an overgrowth of cells in the breast with some atypical</strong> (abnormal) <strong>appearance</strong>. This includes both atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). It is a recognized premalignant lesion and is associated with a higher risk of developing breast cancer &mdash; approximately four to five times the risk compared to women without these lesions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: LCIS&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lobular Carcinoma in Situ (LCIS) is a condition in which <strong>abnormal cells are found in the lobules of the breast.</strong> This is considered a marker for an increased risk of developing breast cancer in either breast and is therefore often categorized as a premalignant lesion.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apocrine metaplasia&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Option A) is <strong>not a premalignant lesion</strong> associated with <strong>breast cancer</strong>; it is a <strong>benign finding commonly seen in breast cysts</strong> and does not confer an <strong>increased risk for developing breast cancer</strong>. Conversely, conditions like <strong>florid hyperplasia, atypical hyperplasia</strong>, and <strong>LCIS</strong> are associated with a <strong>higher risk</strong> and are considered premalignant to varying degrees.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No increased risk</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenosis, sclerosing or florid</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apocrine metaplasia </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cysts, macro and / or micro</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Duct ectasia</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibrosis</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperplasia</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mastitis (inflammation)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Periductal mastitis</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Slightly increased risk (1.5-2 times)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperplasia, moderate or florid, solid, or papillary </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Papilloma with a fibrovascular core (relative risk =3)</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Moderately increased risk (5 times)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atypical hyperplasia (ductal or lobular) (Relative risk = 4 or 5)</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insufficient data to assign a risk</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Solitary papilloma of lactiferous sinus</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Radial scar lesion</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-171352.png\" style=\"height:187px; width:800px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -27<sup>th</sup> edition page no 871</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">28<sup>th</sup> Ed. Table 58.3</span></strong></span></span></p>",
    "correct_choice_id": 45818,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11464,
    "choices": [
      {
        "id": 45822,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1 is associated with 50 to 85% lifetime risk of Ca Breast. </span></span></span></p>"
      },
      {
        "id": 45823,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA2 is located in chromosome 13. </span></span></span></p>"
      },
      {
        "id": 45824,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1 is mostly associated with triple receptor-negative cancers. </span></span></span></p>"
      },
      {
        "id": 45825,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1 is highly associated with male breast carcinoma.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about BRCA genes is incorrect?</span></span></p>",
    "unique_key": "Q6233524",
    "question_audio": null,
    "question_video": null,
    "map_id": 36895,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) BRCA1 is highly associated with male breast carcinoma. </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1 is highly associated with male breast carcinoma.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>not correct</strong>. <strong>While mutations in both BRCA1 and BRCA2 can increase</strong> the risk of <strong>male breast cancer</strong>, <strong>BRCA2</strong> mutations are more <strong>commonly associated with breast cancer</strong> in men than BRCA1 mutations.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Comparison between BRCA 1 and BRCA 2:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Both BRCA1 and BRCA2 are tumor suppressor genes with Autosomal dominant inheritance.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carcinoma breast occurs at an earlier age and is bilateral and multicentric inherited form compared to sporadic cases.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: BRCA1 is associated with a 50 to 85% lifetime risk of Ca Breast.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>correct</strong>. Women with mutations in the BRCA1 gene have a significantly increased risk of developing breast cancer, with lifetime risks ranging from 50% to 85%.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: BRCA2 is located on chromosome 13.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>correct</strong>. The BRCA2 gene is indeed located on chromosome 13q.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: BRCA1 is mostly associated with triple receptor-negative cancers.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>correct</strong>. BRCA1 mutations are often associated with breast cancers that are triple-negative, meaning they lack estrogen receptors, progesterone receptors, and HER2/neu expression.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-171906.png\" style=\"height:446px; width:1000px\" /></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Schwartz&rsquo;s principle of surgery-10<sup>th</sup> edition page no 515</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Devita-cancer principle and practice of oncology; 10<sup>th</sup> edition page no 1109</span></strong></span></span></p>",
    "correct_choice_id": 45825,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11465,
    "choices": [
      {
        "id": 45826,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Upper inner quadrant</span></span></span></p>"
      },
      {
        "id": 45827,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lower inner quadrant</span></span></span></p>"
      },
      {
        "id": 45828,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Upper outer quadrant</span></span></span></p>"
      },
      {
        "id": 45829,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lower outer quadrant</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which quadrant is most commonly involved with breast carcinoma?</span></span></p>",
    "unique_key": "Q7732430",
    "question_audio": null,
    "question_video": null,
    "map_id": 36896,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Upper outer quadrant</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Upper Outer Quadrant&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The upper outer quadrant of the breast is the <strong>most common site for the occurrence of breast carcinoma</strong>. This <strong>quadrant</strong> contains a <strong>greater volume of breast tissue</strong>, including a significant <strong>portion of the mammary gland</strong>, making it <strong>more susceptible</strong> to the <strong>development of cancerous growths</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><strong><u> </u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>upper outer quadrant of the breast</strong> is the most <strong>common site for the development of breast carcinoma</strong> due to the greater volume of breast tissue present in this area (&gt;50% Terminal ductal units).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -28<sup>th</sup> edition page no 932</span></strong></span></span></p>",
    "correct_choice_id": 45828,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11466,
    "choices": [
      {
        "id": 45830,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infiltration of Cooper&rsquo;s ligaments</span></span></span></p>"
      },
      {
        "id": 45831,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obstruction of subcutaneous lymphatics</span></span></span></p>"
      },
      {
        "id": 45832,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infiltration of lactiferous duct</span></span></span></p>"
      },
      {
        "id": 45833,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infiltration of subcutaneous veins</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A woman presents with rapidly progressive breast lump with skin changes as shown. What is the likely pathology responsible for this finding?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-172458.png\" style=\"height:288px; width:300px\" /></span></span></p>",
    "unique_key": "Q6123732",
    "question_audio": null,
    "question_video": null,
    "map_id": 36897,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Obstruction of subcutaneous lymphatics</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The characteristic <strong>Peau d&#39;orange appearance in breast carcinoma is due to specific pathological changes associated with dermal subcutaneous lymphatics obstruction</strong>, typically by <strong>cancer cells</strong>, leading to <strong>lymphatic edema</strong>. This edema causes the skin to take on a texture reminiscent of an orange peel, with enlarged pores and thickened skin</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Infiltration of Lactiferous Duct&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While the infiltration of lactiferous ducts can <strong>lead to nipple retraction or inversion</strong>, it is <strong>not the cause of Peau d&#39;orange</strong>. Nipple retraction occurs because the ducts shorten as they are invaded by cancer cells, which pulls the nipple inward.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peau d&#39;orange in breast carcinoma&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is specifically <strong>caused by the obstruction of subcutaneous lymphatics,</strong> leading to <strong>lymphatic edema</strong> and the <strong>characteristic orange peel-like texture of the skin</strong>, an indicator of advanced disease (T4b).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peau D&#39;orange&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is caused by <strong>cutaneous lymphatic edema</strong> due to the <strong>obstruction of subcutaneous lymphatics</strong>. It is French for &ldquo;<strong>orange skin</strong>&rdquo;.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other appearances due to local invasion are as follows:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infiltration of single cooper&#39;s ligaments leads to dimpling of skin while multiple ligaments leads to puckering/wrinkling. Simple maneuvers such as stretching the arms high above the head or tensing the pectoralis muscles may accentuate asymmetries and dimpling.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infiltration of the lactiferous ducts leads to nipple retraction. Note: an inverted nipple can be simply pulled out, however a retracted nipple cannot be pulled out.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cancer-en-cuirasse: in this condition, the skin of the chest is infiltrated with carcinoma and its appearance has been compared to that of a coat. It occurs in local recurrence after mastectomy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peau D&#39;orange indicates skin involvement (T4b)&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">in breast carcinoma.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dimpling of the skin and nipple retraction do not indicate skin involvement.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/picture1.png\" style=\"height:196px; width:300px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -28<sup>th</sup> edition page 932, Schwartz&rsquo;s principles of surgery- 10<sup>th</sup> edition page no 518, Sabiston textbook of surgery 20<sup>th</sup> edition page no 849</span></strong></span></span></p>",
    "correct_choice_id": 45831,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11467,
    "choices": [
      {
        "id": 45834,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,2,4,3</span></span></span></p>"
      },
      {
        "id": 45835,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2,1,3,4</span></span></span></p>"
      },
      {
        "id": 45836,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3,1,2,4</span></span></span></p>"
      },
      {
        "id": 45837,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,3,2,4</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Arrange the following types of carcinomas in the order of best to worse prognosis:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tubular carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inflammatory carcinoma</span></span></span></li>\r\n</ol>",
    "unique_key": "Q9484194",
    "question_audio": null,
    "question_video": null,
    "map_id": 36898,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) 2,1,3,4 </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Following flowchart depicts the order of prognosis from best to worst.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-172941.png\" style=\"height:320px; width:500px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Order of other breast carcinomas from worst to best prognosis:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inflammatory carcinoma breast (worst prognosis)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive lobular carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Colloid carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Papillary carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cribriform carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenoid cystic</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tubular carcinoma (Best prognosis)</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Schwartz&rsquo;s principles of surgery -10<sup>th</sup> edition page no. 521 and 522</span></strong></span></span></p>",
    "correct_choice_id": 45835,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11469,
    "choices": [
      {
        "id": 45842,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRM in node negative patients</span></span></span></p>"
      },
      {
        "id": 45843,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRM in node positive patients</span></span></span></p>"
      },
      {
        "id": 45844,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BCT in node negative patients</span></span></span></p>"
      },
      {
        "id": 45845,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BCT in node positive patients</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In which of the given cases is this procedure usually performed?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/picture1_bjxNn3P.png\" style=\"height:202px; width:300px\" /></span></span></p>",
    "unique_key": "Q1337056",
    "question_audio": null,
    "question_video": null,
    "map_id": 36899,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) BCT in node negative patients</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The following image shows a <strong>sentinel lymph node biopsy using a gamma camera</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BCT in Node-Negative Patients</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Breast-conserving therapy&nbsp;</strong>(BCT) in <strong>node-negative patients</strong> is the typical indication for<strong> SLNB.</strong> The procedure is <strong>used to assess whether breast cancer has spread to the sentinel node</strong>, which is the <strong>first lymph node to which cancer cells are likely to spread from the primary tumor</strong>. If the sentinel node is free of cancer, it suggests that the other nodes are also likely to be cancer-free, potentially obviating the need for full axillary lymph node dissection.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A and B: MRM:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Axillary lymph node dissection</strong> is usually <strong>performed as part of the surgical treatment</strong> rather than SLNB in all cases of MRM.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: BCT in Node-Positive Patients&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In node-positive patients, <strong>BCT would include an axillary lymph node dissection to address the known nodal involvement</strong>, rather than just an SLNB, because the presence of cancer cells in the lymph nodes is already confirmed.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sentinel lymph node biopsy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is most commonly performed as part of <strong>breast-conserving therapy</strong> in patients with <strong>no clinical evidence of lymph node involvement</strong> (node-negative) to determine the <strong>presence of metastatic cancer cells</strong> in the <strong>sentinel lymph node</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sentinel lymph node biopsy:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">First performed by Dr. Cabana for penile carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sentinel lymph node is the first draining lymph node</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only done on node-negative tumors as a part of BCS/BCT. In node positive patients, BCT includes axillary lymph node clearance directly (without SLNB).</span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In MRM, axillary clearance is done irrespective of clinical nodal status.</span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Technique: methylene blue dye or radioisotope (technetium)-labeled albumin is injected into breast tissue (or subdermal tissue) at the site of the primary tumor or at the subareolar position. The sentinel node is identified as a blue node or as a radioactive node (using a gamma camera).</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The frozen section biopsy is sent to the pathologist for identification of cancer cells. If the biopsy is positive for cancer cells, then axillary dissection is simultaneously performed.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of blue dye and technetium-labeled colloid has been reported to improve the detection of sentinel lymph nodes.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Newer techniques involve the use of a fluorescent or magnetic tracer instead of the radiolabeled dye.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s practice of surgery -28<sup>th</sup> edition page no 936-37.</span></strong></span></span></p>",
    "correct_choice_id": 45844,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11473,
    "choices": [
      {
        "id": 45858,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T3</span></span></span></p>"
      },
      {
        "id": 45859,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T4a</span></span></span></p>"
      },
      {
        "id": 45860,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T4b</span></span></span></p>"
      },
      {
        "id": 45861,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T4c</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A woman presents with a breast tumor of size 6 x 3cm, with adherence to the pectoralis major muscle. Overlying skin shows dimpling. As her surgeon, what will you designate her T staging as?</span></span></p>",
    "unique_key": "Q5602129",
    "question_audio": null,
    "question_video": null,
    "map_id": 36900,
    "difficulty_level": "difficult",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) T3</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>tumor is of size 6cm</strong>. Hence it is stage <strong>T3 (&gt;5cm).</strong> <strong>Fixity to pectoralis major doesn&rsquo;t affect staging</strong>. Skin dimpling is <strong>not</strong> classified as T4b.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Irrelevant to the size of the tumor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, if the <strong>tumor shows extension to the chest wall or skin</strong>, it is classified as <strong>T4</strong>. However, there are two exceptions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasion or adherence to pectoralis muscle in the absence of chest wall involvement does not qualify as T4.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Similarly, involvement of the dermis in the form of dimpling/puckering/retraction of nipple does not qualify as T4.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Points to Remember</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In tumor size assessment, the greatest dimension is taken into consideration. For example, in a 6*3 cm lump, 6 cm is taken into account, and the tumor is classified as T3(&gt;5 cm).</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skin involvement does not include nipple retraction and skin dimpling.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Supraclavicular lymph node involvement indicates N3c.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Any contralateral lymph node involvement is considered as distant metastasis.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If 2 lumps are present in the same breast, staging is according to the bigger lump.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If lumps are present in both breasts, separate staging is done for both the lumps.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TNM Staging of carcinoma breast.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-173615.png\" style=\"height:878px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-173816.png\" style=\"height:601px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">#Chest wall includes serratus anterior, intercostal muscles, ribs. Pectoralis muscle is not a part of the chest wall.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">*Inflammatory breast carcinoma (stage IIIB) is characterized by the skin changes of brawny induration, erythema with a raised edge, and edema (peau d&#39;orange) involving &ge; 1/3<sup>rd</sup> of breast.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note: LCIS (lobular carcinoma in situ) is considered as a benign condition and not included under Tis.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Sabiston textbook of surgery 20<sup>th</sup> edition page no 843 and 844, Schwartz&rsquo;s principle of surgery -10<sup>th</sup> edition page no 532, Journal AJCC-2017, Pg 674.</span></strong></span></span></p>",
    "correct_choice_id": 45858,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11476,
    "choices": [
      {
        "id": 45870,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T2 N2a M0</span></span></span></p>"
      },
      {
        "id": 45871,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T4b N3c M0</span></span></span></p>"
      },
      {
        "id": 45872,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T2 N3c M1</span></span></span></p>"
      },
      {
        "id": 45873,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T4b N3c M1</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient present with a left breast lump of size 3cm x 4cm. The overlying skin has a &lsquo;orange-like skin&rsquo; appearance. On the right side, mobile axillary nodes are palpable. On the left side, supraclavicular lymph nodes are palpable. The most appropriate tumor staging is:</span></span></p>",
    "unique_key": "Q8918584",
    "question_audio": null,
    "question_video": null,
    "map_id": 36901,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) T4b N3c M1</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the <strong>TNM staging system for breast cancer</strong>, <strong>T</strong> refers to the <strong>size and extent of the main tumor</strong>, <strong>N</strong> describes the <strong>absence or presence and extent of regional lymph node involvement</strong>, and <strong>M</strong> indicates the <strong>absence or presence of distant metastases.</strong> </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor of any size with overlying skin involvement</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (Peau d&#39;orange appearance): T4b</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ipsilateral supraclavicular lymph node involvement</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: N3c</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Involvement of any contralateral lymph nodes</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> indicates metastasis in the case of breast carcinoma: M1</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, the staging is <strong>T4b N3c M1</strong>.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 45873,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11478,
    "choices": [
      {
        "id": 45878,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luminal A: ER/PR +, Her 2 -, Ki67 high</span></span></span></p>"
      },
      {
        "id": 45879,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"DE\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luminal B: ER +, Her 2 -, Ki 67 high</span></span></span></p>"
      },
      {
        "id": 45880,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triple negative: ER/PR -, Her 2 -, Ki 67 high</span></span></span></p>"
      },
      {
        "id": 45881,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Her 2 enriched: ER/PR -, Her 2 +, Ki 67 high</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the mismatch receptor profile of breast cancer:</span></span></span></p>",
    "unique_key": "Q2934648",
    "question_audio": null,
    "question_video": null,
    "map_id": 36902,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Luminal A: ER/PR +, Her 2 -, Ki67 high</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luminal A: ER/PR +, Her 2 -, Ki67 high&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luminal A breast cancers are typically <strong>ER and/or PR positive</strong>, <strong>HER2 negative</strong>, and have a <strong>low Ki-67 index</strong>, which indicates a <strong>lower rate of cell proliferation</strong>. This <strong>subtype</strong> generally has a <strong>better prognosis and is more responsive to hormonal therapy</strong>. Therefore, the presence of a high Ki-67 labeling index in this option is mismatched with the typical profile of Luminal A.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>molecular subtypes of breast cancer</strong> are characterized <strong>based on the presence or absence of hormone receptors</strong> (estrogen and progesterone receptors) and <strong>HER2 status</strong>, as well as proliferation rates, typically indicated by Ki-67 labeling index. Let&#39;s go through each </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Luminal B: ER +, Her 2 -, Ki 67 high.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luminal B cancers are <strong>ER-positive and tend to have a higher Ki-67 index than Luminal A</strong>, indicating a <strong>higher proliferation rate</strong>. They can be HER2 negative. This option is a correct match for the Luminal B subtype.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Triple Negative: ER, PR -, Her 2 -, Ki 67 high.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triple-negative breast cancers <strong>lack ER, PR, and HER2 expression.</strong> They often have a higher Ki-67 index, which is consistent with their more aggressive behavior. This option correctly describes the Triple Negative subtype.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Her 2 enriched: ER/PR -, Her 2 +, Ki 67 high.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HER2-enriched cancers are <strong>characterized by the absence of hormone receptors</strong> (ER and PR negative) and <strong>overexpression/amplification of HER2</strong>. They often exhibit high Ki-67 levels, which correlates with the aggressive nature of this subtype. This option correctly represents the HER2-enriched subtype.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luminal A breast cancers&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are typically <strong>ER/PR positive, HER2 negative,</strong> and have a <strong>low Ki-67 index</strong>, indicating <strong>lower proliferation rates</strong>. The presence of a high Ki-67 index in this subtype, as indicated in Option A, is a mismatch.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Along with ER, PR, and Her-2, a proliferation index known as ki-67 index is also used. Ki 67 is a nuclear protein associated with cellular proliferation.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Molecular classification of cancers:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-174420.png\" style=\"height:712px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 28<sup>th</sup> Ed. Pg 931, Table 58.4</span></strong></span></span></p>",
    "correct_choice_id": 45878,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11482,
    "choices": [
      {
        "id": 45894,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The axillary nodes receive approximately 80-85% of the drainage. </span></span></span></p>"
      },
      {
        "id": 45895,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The lateral group is located along the axillary vein.</span></span></span></p>"
      },
      {
        "id": 45896,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The anterior group is usually the sentinel node for CA breast</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>"
      },
      {
        "id": 45897,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymph nodes of Rotor belong to level III</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given below are 4 statements regarding the lymphatic drainage of the breast. Choose the false statement: </span></span></p>",
    "unique_key": "Q2066348",
    "question_audio": null,
    "question_video": null,
    "map_id": 36903,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Lymph nodes of Rotor belong to level III. </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymph nodes of Rotor belong to level III.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is false. Rotter&#39;s nodes (interpectoral nodes) are located between the pectoralis major and minor muscles, and <strong>they are considered part of Level II</strong>, not Level III. <strong>Level III nodes are those located medial to the pectoralis minor muscle and include the apical group</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: The axillary nodes receive approximately 80-85% of the drainage.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. The axillary lymph nodes are the primary drainage site for the lymphatics of the breast, receiving the majority of the lymphatic flow.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: The lateral group is located along the axillary vein.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is also <strong>true</strong>. The lateral group of axillary lymph nodes is found along the axillary vein and is often involved in the lymphatic drainage from the upper limb and breast.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: The anterior group is usually the sentinel node for CA breast.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>true</strong>. The anterior group of axillary lymph nodes, located along the lateral thoracic vessels, often contains the sentinel lymph node in cases of breast cancer, which is the first node to receive lymphatic drainage from a tumor.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>false statement regarding the lymphatic drainage of the breast is that Rotter&#39;s nodes belong to level III</strong>; instead, they are <strong>part of Level II axillary nodes</strong>, situated <strong>between the pectoralis major and minor muscles.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymph nodes&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are <strong>divided on the basis of their relation to the pectoralis minor</strong>, not the pectoralis major.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphatic drainage of breast:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The lymphatics of breast drain predominantly into:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The axillary lymph nodes (85%)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Internal mammary lymph nodes</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Posterior intercostal/ interpectoral/Rotter&rsquo;s lymph nodes</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The axillary nodes are arranged in the following groups:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Level I&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(<strong>lymph nodes located lateral to pectoralis minor muscle</strong>):</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lateral, along the axillary vein-drains most of upper limb</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anterior (external mammary group or pectoral group), along the lateral thoracic vessels- drains most of the breast. (1<sup>st</sup> relay station for lymph)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Posterior (scapular group), along the subscapular vessels </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Level II&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(<strong>lymph nodes nodes located superficial or deep to pectoralis minor muscle</strong>):</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Central, embedded in at in the center of the axilla- receive drainage from level I groups</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interpectoral (Rotter&#39;s node)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- a few nodes lying between the pectoralis major and minor muscles.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Level III&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(<strong>lymph nodes located medial to pectoralis minor muscle</strong>):</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apical (sub-clavicular group), which lie above the level of the pectoralis minor tendon in continuity with the lateral nodes and which receive the efferent of all the other axillary groups and drains into subclavian lymphatic trunk.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Internal mammary nodes drain the posterior one-third of the breast.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-180553.png\" style=\"height:366px; width:500px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and love&rsquo;s short practice of surgery -28<sup>th</sup> edition page no 915, Schwartz&rsquo;s principles of surgery &ndash; 10<sup>th</sup> edition page no 502</span></strong></span></span></p>",
    "correct_choice_id": 45897,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11487,
    "choices": [
      {
        "id": 45914,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Used for hormone receptor -negative cancers</span></span></span></p>"
      },
      {
        "id": 45915,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Provides risk of recurrence and chemotherapy benefit after surgery</span></span></span></p>"
      },
      {
        "id": 45916,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lower scores predict higher risk of recurrence</span></span></span></p>"
      },
      {
        "id": 45917,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Used for lymph node-positive cancers</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true about the oncotype Dx, a molecular test used for breast cancer?</span></span></p>",
    "unique_key": "Q2407603",
    "question_audio": null,
    "question_video": null,
    "map_id": 36904,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Provides risk of recurrence and chemotherapy benefit after surgery</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Oncotype DX test is a genomic assay</strong> that <strong>helps evaluate the likelihood of breast cancer recurrence</strong> and the <strong>potential benefit of chemotherapy in early-stage breast cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. <strong>Oncotype DX</strong> provides a <strong>Recurrence Score</strong>, which is a <strong>numeric value that correlates with the risk of recurrence for hormone receptor-positive breast cancer</strong>. It also gives information about how much benefit a patient is likely to receive from chemotherapy, helping to guide treatment decisions post-surgery.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Used for hormone receptor-negative cancers.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is not true. The <strong>Oncotype DX test is specifically used for hormone receptor-positive</strong>, HER2-negative breast cancers. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Lower scores predict higher risk of recurrence.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is false. In the <strong>Oncotype DX assay</strong>, <strong>lower scores</strong> actually predict a <strong>lower risk of recurrence</strong> and a lesser benefit from chemotherapy. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Used for lymph node-positive cancers.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>initial validation of the Oncotype DX test</strong> was for <strong>use in lymph node-negative patients</strong>. It is not generally used for cancers with high lymph node positivity.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oncotype DX test&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is used to <strong>determine the risk of recurrence and potential chemotherapy benefit in early-stage</strong>, <strong>hormone receptor-positive</strong>, <strong>HER2-negative breast cancer</strong>, with <strong>lower scores</strong> indicating a <strong>lower risk of recurrence</strong> and a lesser benefit from chemotherapy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oncotype Dx assay is a molecular test based on the assessment of 21 genes. It is a 21-gene recurrence score assay, in which higher recurrence scores predict increased benefit from chemotherapy. On the other hand, lower scores in this assay predict lesser benefit from chemotherapy and increased benefit from endocrine therapy.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used for patients with <strong>lymph node-negative, ER-positive early breast cancer (Stage 1 or 2)</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Newer molecular tests for breast cancer have been developed, which help in predicting the advantage of adding <strong>chemotherapy</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Newer molecular tests for breast cancer:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oncotype Dx</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MammaPrint</span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endo Predict PAM50&nbsp;&nbsp; </span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-181033.png\" style=\"height:270px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Using these molecular tests, a recurrence score (0-100) is calculated. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If the score is low, then there is no advantage of adding chemotherapy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love 28<sup>th</sup> Ed. Pg 940, American joint cancer committee 8<sup>th</sup> edition Pg 622-623, Sabiston textbook of surgery 20<sup>th</sup> edition page no 855.</span></strong></span></span></p>",
    "correct_choice_id": 45915,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11488,
    "choices": [
      {
        "id": 45918,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lumbar vertebrae</span></span></span></p>"
      },
      {
        "id": 45919,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thoracic vertebrae</span></span></span></p>"
      },
      {
        "id": 45920,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Femur</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>"
      },
      {
        "id": 45921,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skull</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common site for the hematogenous spread of breast carcinoma is:</span></span></p>",
    "unique_key": "Q1561504",
    "question_audio": null,
    "question_video": null,
    "map_id": 36905,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Lumbar vertebrae</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lumbar vertebrae</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, followed by the <strong>femur and thoracic vertebrae</strong>, are the <strong>most common&nbsp;</strong></span></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">sites for hematogenous spread</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> of <strong>carcinoma breast.</strong> </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">They occur via: <strong>Breast &rarr; Posterior intercostal vein &rarr; Bateson&rsquo;s plexus &rarr; Lumbar vertebrae</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These bone metastases are more osteolytic than osteoblastic.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common sites of blood borne metastases (bone) are as follows:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align: justify;\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L= Lumbar vertebrae (due to Bateson&rsquo;s plexus)</span></span></span></li>\r\n\t<li style=\"text-align: justify;\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">F= Femur</span></span></span></li>\r\n\t<li style=\"text-align: justify;\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T= Thoracic vertebrae</span></span></span></li>\r\n\t<li style=\"text-align: justify;\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">R= Ribs</span></span></span></li>\r\n\t<li style=\"text-align: justify;\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S= Skull</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metastasis to the brain occurs via: <strong>Posterior intercostal vein</strong></span><strong><span style=\"font-family:Wingdings\">&rarr;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Bateson&rsquo;s plexus</span><span style=\"font-family:Wingdings\">&rarr;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dural venous sinus</span><span style=\"font-family:Wingdings\">&rarr;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Leptomeninges.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note: In prostate cancer, the bone metastases are more osteoblastic than osteolytic.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -27<sup>th</sup> edition page no 874, 28<sup>th</sup> Ed. Pg 932.</span></span></strong></p>",
    "correct_choice_id": 45918,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11489,
    "choices": [
      {
        "id": 45922,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor is located in multiple quadrants</span></span></span></p>"
      },
      {
        "id": 45923,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patient is not compliant with radiotherapy</span></span></span></p>"
      },
      {
        "id": 45924,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patient has ipsilateral palpable axillary lymph node</span></span></span></p>"
      },
      {
        "id": 45925,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patient has received prior radiotherapy on neck and chest for lymphoma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with early breast carcinoma of stage T2 N1 M0 doesn&rsquo;t want to undergo mastectomy. Which of these is not a contra-indication for breast conservation in this patient?</span></span></p>",
    "unique_key": "Q9837889",
    "question_audio": null,
    "question_video": null,
    "map_id": 36906,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Patient has ipsilateral palpable axillary lymph node</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>involvement of axillary lymph nodes</strong> alone <strong>does not necessarily rule out breast conservation</strong>, especially if the <strong>lymph node involvement is limited</strong>. In this case, up front axillary clearance will be done instead of SLNB.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast conservation therapy</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, which typically includes <strong>breast-conserving surgery</strong> (lumpectomy or partial mastectomy) followed by <strong>radiation therapy</strong>, is a suitable option for many patients with early-stage breast carcinoma, as seen here. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tumor is located in multiple quadrants:&nbsp;</strong>This can be a <strong>consideration against breast conservation</strong> because it <strong>may be challenging to achieve clear margins</strong> and <strong>adequate tumor removal</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Patient is not compliant with radiotherapy:&nbsp;</strong><strong>Compliance with radiation therapy</strong> is crucial for the <strong>success of breast conservation</strong>. If a patient is unwilling or unable to comply with the recommended course of radiation therapy, breast conservation may not be the best option.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Patient has received prior radiotherapy on neck and chest for lymphoma: </strong><strong>Prior radiation</strong> <strong>therapy</strong> in the <strong>region may impact the ability to deliver additional radiation safely</strong>. The presence of prior radiation to the chest is contraindication to further radiation therapy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast conservative surgery&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is also known as <strong>segmental mastectomy, lumpectomy, partial mastectomy, wide local excision, and tylectomy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Contraindications for breast conservative surgery.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Absolute contraindication:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pregnancy, except 3<sup>rd</sup> trimester</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diffuse microcalcifications</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Positive pathologic margin</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">History of therapeutic radiation exposure to chest wall</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multicentric tumor</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Relative contraindication:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Connective tissues disorders like systemic lupus erythematosus (SLE) and scleroderma, excluding rheumatoid arthritis</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Large lump-to-breast ratio, i.e., big lump in small breast</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lump beneath the nipple-areola complex</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multifocal tumor</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:48px; text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love 28<sup>th</sup> Ed. Pg 935, Schwartz&rsquo;s principle of surgery 10<sup>th</sup> edition Pg 538, Devita-cancer principles and practice of oncology: 10<sup>th</sup> edition pg. 1131</span></strong></span></span></p>",
    "correct_choice_id": 45924,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11490,
    "choices": [
      {
        "id": 45926,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pectoralis major</span></span></span></p>"
      },
      {
        "id": 45927,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary lymph nodes</span></span></span></p>"
      },
      {
        "id": 45928,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nipple-areola complex</span></span></span></p>"
      },
      {
        "id": 45929,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pectoral fascia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following structures is not usually removed in modified radical mastectomy?</span></span></p>",
    "unique_key": "Q1668029",
    "question_audio": null,
    "question_video": null,
    "map_id": 36907,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Pectoralis major</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Modified radical mastectomy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(MRM) is a <strong>common surgical procedure for breast cancer</strong> that involves the <strong>removal of the breast tissue</strong>, including the nipple-areola complex, and axillary lymph nodes (Level 1 to 3), while preserving the pectoralis major muscle</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pectoralis Major&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">in a <strong>modified radical mastectomy</strong>, the pectoralis major muscle is preserved. <strong>This distinguishes MRM from the Halsted&rsquo;s radical mastectomy</strong>, which involves the <strong>removal of this muscle</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Axillary Lymph Nodes&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary lymph nodes are typically <strong>removed during a modified radical mastectomy.</strong> The extent of lymph node removal includes levels I, II, and sometimes III.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Nipple-areola Complex&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The nipple-areola complex is <strong>removed during a modified radical mastectomy</strong> to ensure the complete excision of potentially involved ductal tissue that converges towards the nipple.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Pectoral Fascia&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The pectoral fascia is <strong>removed during a modified radical mastectomy</strong> to ensure complete removal of breast tissue that may be intimately involved with the fascia overlying the pectoralis major muscle.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>modified radical mastectomy</strong>, the <strong>pectoralis major muscle is not removed</strong>, distinguishing it from the more extensive Halsted&rsquo;s radical mastectomy.Top of Form</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patey&rsquo;s modified radical mastectomy removes:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All breast tissue</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nipple-areola complex</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skin overlying tumor</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Levels I, II, and III axillary lymph nodes.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pectoralis minor.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Scanlon&rsquo;s modification of MRM: Pectoralis minor is cut, then sutured back</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Auchincloss&rsquo; modification of MRM: Pectoralis minor is retracted only.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Important surgeries for breast cancer:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lumpectomy/Wide local excision: Excision of lump with 1 cm gross margin.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Simple mastectomy: Entire breast + Nipple &ndash; areola complex + overlying skin.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Subcutaneous mastectomy: Palpable extent of breast without overlying skin (inframammary incision). Done for gynacomastia</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Modified radical mastectomy: entire breast tissue + NAC + lymph nodes (levels I + II <u>+</u> III)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Halsted&rsquo;s radical mastectomy: Entire breast tissue + Nipple- areola complex + skin +levels I + II + III axillary lymph nodes + Pectoralis major and minor.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:48px; text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love 28<sup>th</sup> Ed. Pg Table 58.4, Schwartz&rsquo;s principles of surgery -10<sup>th</sup> edition page no 547</span></strong></span></span></p>",
    "correct_choice_id": 45926,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11491,
    "choices": [
      {
        "id": 45930,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Seroma</span></span></span></p>"
      },
      {
        "id": 45931,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphedema</span></span></span></p>"
      },
      {
        "id": 45932,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intercostobrachial nerve injury</span></span></span></p>"
      },
      {
        "id": 45933,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wound infection</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common complication following mastectomy is: </span></span></p>",
    "unique_key": "Q7611334",
    "question_audio": null,
    "question_video": null,
    "map_id": 36908,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Seroma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Seromas&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are <strong>collections of fluid that build up under the skin flaps or in the axilla after a mastectomy</strong>. They are indeed the <strong>most common complication</strong>, occurring due to the <strong>disruption of lymphatic channels</strong> and <strong>local inflammatory responses</strong>. <strong>Seromas</strong> can be <strong>managed with aspiration</strong> and sometimes require repeated interventions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Lymphedema&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphedema refers to <strong>swelling that generally occurs in the arm and is caused by the removal of or damage to axillary lymph nodes during surgery</strong>, which results in a <strong>blockage in lymphatic drainage</strong>. While significant, lymphedema is less common immediately post-operatively compared to seroma formation but can be a chronic issue.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Intercostobrachial Nerve Injury:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Injury to the intercostobrachial nerve can <strong>occur during mastectomy or axillary dissection</strong>, leading to <strong>numbness, paresthesia, or pain in the upper arm</strong>. It is the most common nerve injury in MRM.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Wound Infection&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Postoperative wound infections can <strong>happen after any surgical procedure</strong>, including <strong>mastectomy</strong>. While these are taken very seriously, strict surgical asepsis and the use of prophylactic antibiotics have made them less frequent than seroma formation.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most common complication</strong> following <strong>mastectomy is seroma formation</strong>, occurring in <strong>up to 30% of cases</strong> due to the <strong>disruption of lymphatic drainage and local inflammatory responses post-surgery</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Seromas beneath the skin flaps&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">or in the <strong>axilla</strong> represent the most frequent complication of mastectomy and axillary lymph node dissection. It has been reported to occur in as many as 30% of the cases.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Schwartz&rsquo;s principles of surgery -10<sup>th</sup> edition page no 549, Bailey &amp; love&rsquo;s short practice of surgery -27<sup>th</sup> edition page no 281</span></strong></span></span></p>",
    "correct_choice_id": 45930,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11492,
    "choices": [
      {
        "id": 45934,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intercostobrachial nerve</span></span></span></p>"
      },
      {
        "id": 45935,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long thoracic nerve</span></span></span></p>"
      },
      {
        "id": 45936,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thoracodorsal nerve</span></span></span></p>"
      },
      {
        "id": 45937,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary nerve</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient underwent a modified radical mastectomy. Later she complained of loss of sensation over the medial aspect of the right upper arm. The nerve most likely damaged is:</span></span></span></p>",
    "unique_key": "Q1019092",
    "question_audio": null,
    "question_video": null,
    "map_id": 36909,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Intercostobrachial nerve</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the context of a <strong>modified radical mastectomy</strong> and the <strong>associated nerve injury</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intercostobrachial Nerve&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The intercostobrachial nerve, which is the <strong>lateral cutaneous branch of the second intercostal nerve</strong>, provides <strong>sensation to the upper medial aspect of the arm</strong>. Injury to this nerve during mastectomy or axillary dissection can lead to loss of sensation in this area, as described in the patient&#39;s complaint.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Long Thoracic Nerve&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The long thoracic nerve<strong> innervates</strong> the <strong>serratus anterior muscle</strong>. Damage to this nerve would lead to winged scapula but would not cause sensory loss in the upper arm.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Thoracodorsal Nerve&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The thoracodorsal nerve <strong>innervates the latissimus dorsi muscle</strong>. Its injury would result in weakness of the arm adduction and internal rotation but not in sensory loss.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Axillary Nerve&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The axillary nerve provides motor <strong>innervation to the deltoid and teres minor muscles</strong> and <strong>sensory innervation to the regimental badge area</strong> (lateral aspect of the shoulder). Damage to this nerve would not present with loss of sensation in the medial upper arm.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>intercostobrachial nerve</strong>, when <strong>damaged during a modified radical mastectomy</strong>, is likely responsible for the <strong>loss of sensation over the medial aspect of the upper arm</strong> due to its <strong>sensory innervation in that area</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Structures preserved in MRM: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:upper-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary vein</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bell&rsquo;s nerve to serratus anterior</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cephalic vein</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dorsal/thoracodorsal nerve and pedicle</span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"margin-left:48px; text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Sabiston Textbook of surgery 20<sup>th</sup> edition</span></strong></span></span></p>",
    "correct_choice_id": 45934,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11494,
    "choices": [
      {
        "id": 45942,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deep inferior epigastric perforators flap</span></span></span></p>"
      },
      {
        "id": 45943,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Latissimus dorsi musculocutaneous flap</span></span></span></p>"
      },
      {
        "id": 45944,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transverse rectus abdominis myocutaneous flap</span></span></span></p>"
      },
      {
        "id": 45945,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anterolateral thigh flap</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old female underwent modified radical mastectomy for carcinoma of breast. She is desirous of breast reconstruction. Which of these tissue flaps will yield the best outcome?</span></span></p>",
    "unique_key": "Q7085156",
    "question_audio": null,
    "question_video": null,
    "map_id": 36910,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Deep inferior epigastric perforators flap</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>DIEP free flap</strong> is considered the <strong>gold standard for breast reconstruction</strong> using <strong>autogenous tissue</strong>. It involves <strong>harvesting skin and fat from the lower abdomen without sacrificing the rectus abdominis muscle</strong>, thus <strong>preserving abdominal wall integrity</strong> and reducing the risk of complications like hernia or muscle weakness.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Latissimus Dorsi Musculocutaneous Flap&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>pedicled latissimus dorsi flap</strong> uses <strong>muscle, skin, and fat from the upper back</strong> and is <strong>tunneled to the mastectomy site</strong> to create a new breast mound. It&#39;s a reliable flap but is not the gold standard because it can lead to weakness in the back and shoulder.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Transverse Rectus Abdominis Myocutaneous Flap (TRAM)&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The TRAM flap <strong>uses skin, fat, and a portion of the rectus abdominis muscle from the lower abdomen</strong>. It can be pedicled (attached to its original blood supply) or free (detached and reattached to blood vessels at the new site). While it is a commonly used flap, it is not the gold standard due to the risk of abdominal wall weakness.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Anterolateral thigh Flap&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It&#39;s a <strong>free flap used for complete breast reconstruction</strong>, but is not as common as DIEP flap.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>gold standard for breast reconstruction with autogenous tissue is the Deep Inferior Epigastric Perforators</strong> (DIEP) <strong>flap</strong>, which <strong>uses skin and fat from the lower abdomen</strong> without sacrificing the <strong>rectus abdominis muscle</strong>, thus minimizing the risk of abdominal complications and providing a cosmetically superior result.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The gold standard in breast reconstruction with autogenous tissue is the deep inferior epigastric perforators (DIEP) flap:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a free flap.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only subcutaneous fat and skin is taken.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The rectus abdominus muscle is not removed, and hence, there is no abdominal wall weakness.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cosmetically, it is the best flap, and it has the advantage of giving a &ldquo;tummy tuck&rdquo; to the patient as well.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transverse rectus abdominis myocutaneous&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(TRAM) <strong>flap</strong>:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be pedicled TRAM or free TRAM.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Either based on superior epigastric or inferior epigastric or both (supercharged TRAM).</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skin, fat, and muscle are moved to the chest.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The rectus abdominus muscle is excised, and hence, the procedure leads to abdominal wall weakness (hernias can occur).</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/22/whatsapp-image-2024-03-22-at-115354-am.jpeg\" style=\"height:387px; width:500px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; Love&rsquo;s short practice of surgery -28<sup>th</sup> edition page no 937-940</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sabiston Textbook of surgery 20<sup>th</sup> edition page no. 868 and 869 </span></strong></span></span></p>",
    "correct_choice_id": 45942,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11496,
    "choices": [
      {
        "id": 45950,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nottingham index</span></span></span></p>"
      },
      {
        "id": 45951,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gail model</span></span></span></p>"
      },
      {
        "id": 45952,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Claus model</span></span></span></p>"
      },
      {
        "id": 45953,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the above</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following models of breast cancer are used for prognosis?</span></span></span></p>",
    "unique_key": "Q6563145",
    "question_audio": null,
    "question_video": null,
    "map_id": 36911,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Nottingham Index</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Nottingham Prognostic Index</strong> being used for <strong>prognostication in diagnosed cases</strong>, and the <strong>Gail and Claus models utilized for assessing the risk</strong> of developing <strong>breast cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nottingham Prognostic Index&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">the Nottingham Prognostic Index (NPI) is a <strong>clinical tool used to determine the prognosis of breast cancer</strong>. It combines <strong>three factors</strong>: the <strong>size of the tumor</strong>, the <strong>grade of the tumor</strong>, and the <strong>number of lymph nodes involved</strong>. The NPI helps in stratifying patients into different prognostic groups and aids in making treatment decisions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Gail Model&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Gail Model is a <strong>risk assessment tool used to estimate a woman&#39;s risk of developing breast cancer</strong>. It takes into account a woman&#39;s personal medical history, her reproductive history, and the history of breast cancer among her first-degree relatives.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Claus Model&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Claus Model is another <strong>risk assessment model that estimates the probability of developing breast cancer based on family history</strong>. It particularly considers the number of affected first- and second-degree relatives and their ages at diagnosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Nottingham Prognostic Index, Gail Model, and Claus Model are all related to breast carcinoma,</strong> with the <strong>Nottingham Prognostic Index being used for prognostication</strong> in <strong>diagnosed cases</strong>, and the Gail and Claus models utilized for assessing the risk of developing breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Nottingham Prognostic index segregates the patients into four groups</strong>, and is <strong>used to predict the 10-year survival</strong>. The NPI helps clinicians in formulating treatment plans.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nottingham Prognostic Index = (0.2 x Tumor size in cm) + Grade + Nodes</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Gail and Claus models are used to assess the risk of development of breast carcinoma</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The Gail model includes the following parameters:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Number of first-degree relatives with carcinoma breast.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age at first live birth</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Number of breast biopsies</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Claus model&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">provides individual <strong>estimates of breast cancer risk according to the decade of life based on presence of first- and second- degree relatives</strong> with breast cancer and their age at diagnosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neither the Gail model&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">nor the <strong>Claus model accounts for the risk associated with mutations in the breast cancer susceptibility genes BRCA1 and BRCA2.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Van Nuys Prognostic index&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is used to identify <strong>patients with duct carcinoma in situ</strong> (DCIS) who do not need radiation therapy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This grading system is based on the following parameters:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patient&rsquo;s age</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DCIS nuclear grade and presence of micro calcification</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Size of the lesion</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Width of the surgical margin</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:48px; text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love 28<sup>th</sup> Ed. Pg 942, Schwartz&rsquo;s principles of surgery 10<sup>th</sup> edition page nos 512, 513 and 536, Sabiston textbook of surgery 20<sup>th</sup> edition page no 853.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Online resource&nbsp;</span></strong><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4473391/\" style=\"color:#0563c1; text-decoration:underline\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4473391/</span></strong></a></span></span></p>",
    "correct_choice_id": 45950,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11499,
    "choices": [
      {
        "id": 45962,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paclitaxel</span></span></span></p>"
      },
      {
        "id": 45963,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclophosphamide</span></span></span></p>"
      },
      {
        "id": 45964,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cisplatin</span></span></span></p>"
      },
      {
        "id": 45965,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adriamycin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following chemotherapeutic agents is not commonly used for chemotherapy in breast cancer?</span></span></p>",
    "unique_key": "Q7696268",
    "question_audio": null,
    "question_video": null,
    "map_id": 36912,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Cisplatin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cisplatin&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong>platinum-based chemotherapeutic agent</strong> primarily <strong>used in the treatment of testicular, ovarian, bladder, GIT and lung cancers</strong>. While it can be <strong>used in breast cancer,</strong> particularly in <strong>triple-negative breast cancer</strong>, it is <strong>not a standard first-line therapy</strong> and thus is less commonly used compared to the other agents listed here.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Paclitaxel&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paclitaxel is a <strong>taxane used commonly in breast cancer treatment</strong>. It stabilizes microtubules and prevents cell division, which is effective in treating various types of breast cancer, especially when combined with other chemotherapeutic agents.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Cyclophosphamide&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclophosphamide is an <strong>alkylating agent that is part of many breast cancer chemotherapy regimens.</strong> It works by cross-linking DNA and RNA, thereby inhibiting cancer cell growth and multiplication.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Adriamycin (Doxorubicin)&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adriamycin, or doxorubicin, is an <strong>anthracycline antibiotic commonly used in breast cancer chemotherapy.</strong> It intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis of cancer cells.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Among the <strong>chemotherapeutic agents listed, cisplatin is not commonly used as a standard first-line therapy for breast cancer</strong>, whereas <strong>paclitaxel, cyclophosphamide, and Adriamycin</strong> are commonly included in <strong>breast cancer chemotherapy regimens.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Present chemotherapy regimen used is ACT, i.e., Adriamycin, Cyclophosphamide, and Taxane (Paclitaxel).</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4 cycles of AC followed by 4 cycles of T.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other regimens which are less commonly used currently are as follows:</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">cyclophosphamide (C), methotrexate (M) and 5-fuorouracil (F) (CMF); </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">anthracycline-based regimens: CAF (A, Adriamycin [doxorubicin]), CEF (E, epirubicin);</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Taxane (docetaxel, paclitaxel)-based regimens.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indications for chemotherapy in carcinoma breast:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor size of &gt; 1cm </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor size of &gt;0.5 cm with any of</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"DE\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blood vessel/lymph vessel invasion</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"DE\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ER/PR &ndash;ve</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Her -2/neu overexpression</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High grade</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triple-negative breast carcinoma</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High recurrence score after oncotype Dx</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Any LN Positive CA breast</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 28<sup>th</sup> Ed. Pg 940, Schwartz&rsquo;s principle of surgery -10<sup>th</sup> edition page no 551</span></strong></span></span></p>",
    "correct_choice_id": 45964,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11501,
    "choices": [
      {
        "id": 45970,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen is preferred in pre-menopausal women with Ca breast</span></span></span></p>"
      },
      {
        "id": 45971,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Letrozole is preferred in post-menopausal women only</span></span></span></p>"
      },
      {
        "id": 45972,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormone therapy is indicated in ER/PR + tumors only</span></span></span></p>"
      },
      {
        "id": 45973,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No benefit in insitu breast malignancy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are true regarding hormonal therapy in the treatment of breast cancer except?</span></span></p>",
    "unique_key": "Q6431314",
    "question_audio": null,
    "question_video": null,
    "map_id": 36913,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) No benefit in insitu breast malignancy.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">No benefit in insitu breast malignancy.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>false</strong>. <strong>Hormonal therapy</strong> has been shown to be <strong>beneficial in reducing the risk of progression from in situ breast cancer</strong> (non-invasive) <strong>to invasive breast cancer</strong>, particularly for <strong>ER/PR-positive tumors</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When considering hormonal therapy in the treatment of breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Tamoxifen is preferred in pre-menopausal women with Ca breast.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>true</strong>. Tamoxifen is a Selective Estrogen Receptor Modulator (SERM) that is commonly used in pre-menopausal women due to its ability to block the effects of estrogen in breast tissue without suppressing ovarian function.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Letrozole is preferred in post-menopausal women only.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is also <strong>true</strong>. Letrozole is an aromatase inhibitor, which is particularly effective in post-menopausal women because it blocks the conversion of androgens to estrogens, which is the main source of estrogen in this group since the ovaries have ceased functioning.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Hormone therapy is indicated in ER/PR + tumors only.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>true</strong>. Hormone therapies such as tamoxifen and aromatase inhibitors are indicated for estrogen receptor (ER) and/or progesterone receptor (PR) positive tumors, as these drugs work by interfering with hormonal signals that can promote cancer growth.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormonal therapies&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">like <strong>tamoxifen and aromatase inhibitors</strong> are <strong>beneficial in the treatment of hormone receptor-positive breast cancer</strong> and can <strong>reduce the risk of recurrence and contralateral breast cancer</strong>, and they also help <strong>prevent the progression of in situ to invasive carcinoma.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase inhibitors:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Include anastrozole, exemestane, and letrozole.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Used for the treatment of breast cancer in postmenopausal women.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism of action</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective aromatase inhibitors block the conversion of the hormone androstenedione&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">into <strong>estrone by inhibition of the aromatase enzyme</strong>. This is the main mechanism of production of estrogen in postmenopausal women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The enzyme aromatase is present in adipose tissue, breast tissue, breast tumor cells, and other sites. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SERM</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> like tamoxifen are preferred in pre-menopausal women, where AI cannot be used due to their ovarian suppression effect. Tamoxifen is a selective estrogen receptor (ER) modulator that is used for hormone receptor-positive breast cancers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It exhibits selective agonistic and antagonistic activity for ER receptors:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Agonist activity at uterus, bone, liver, and pituitary</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antagonist activity at breast and blood vessels</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Used for:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary prophylaxis of breast cancer in high-risk women.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reducing the risk of carcinoma in contralateral breast&rsquo;.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reducing the risk of recurrence of carcinoma in ipsilateral and contralateral breasts.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dose: 20 mg once daily</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> for 10 years (Earlier 5 years was the duration, but latest guidelines recommend 10 years).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adverse effects:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hot flushes, most common adverse effect</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometrial carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thromboembolic events</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduced visual acuity, cataract, and retinal deposits</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormonal therapy in breast carcinoma given for ER/PR- positive cases</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduce risk of recurrence</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduce risk of contralateral breast cancer</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reduce risk of progression of in situ to invasive carcinoma</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Sabiston textbook of surgery 20<sup>th</sup> edition page no 858, Bailey and Love 28<sup>th</sup> Ed. Pg 941.</span></strong></span></span></p>",
    "correct_choice_id": 45973,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11502,
    "choices": [
      {
        "id": 45974,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Herceptin</span></span></span></p>"
      },
      {
        "id": 45975,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Palbociclib</span></span></span></p>"
      },
      {
        "id": 45976,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Buparlisib</span></span></span></p>"
      },
      {
        "id": 45977,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ipatasertib</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a new drug approved for metastatic hormone receptor-positive and HER-2 negative breast cancer?</span></span></p>",
    "unique_key": "Q6588699",
    "question_audio": null,
    "question_video": null,
    "map_id": 36914,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Palbociclib</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Palbocilib&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is the <strong>newest drug approved for metastatic</strong>, <strong>hormone receptor-positive</strong>, <strong>HER-2/neu-negative breast cancer.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is <strong>used along with fulvestrant</strong>, a <strong>selective estrogen-receptor down regulator</strong> (SERD) based on the <strong>PALOMA 3 trial</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Advances in chemotherapy for metastatic breast cancer</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment of metastatic breast cancer by targeting PI3k/AKT/m TOR pathways has led to newer chemotherapeutic drugs, which are as follows:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin-dependent kinase 4/6 inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Palbociclib:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Approved for use with aromatase inhibitor (Letrozole) or SERD (Fulvestrant)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ribociclib: Approved for use with aromatase inhibitor (Letrozole)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abemaciclib: Approved for use with SERD (Fulvestrant)</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MTOR pathway inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Everolimus:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Approved for treatment of advanced/metastatic hormone receptor-positive, HER-2-negative breast cancer</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PhophatidyI - inositol 3 kinase (PI3k)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Buparlisib &ndash;&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Not approved, but trials are underway for treatment of metastatic breast carcinoma</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">AKT (Protein kinase B) inhibitors</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ipatasertib:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Not approved, but found beneficial for metastatic triple-negative breast cancer</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Palbociclib is the newest drug approved for use in combination with hormonal therapies&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">for the <strong>treatment of metastatic hormone receptor-positive</strong>, <strong>HER2-negative breast cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 28<sup>th</sup> Ed. Table 12.6</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Journal:&nbsp;</span></strong><a href=\"https://www.uptodate.com/contents/treatment-approach-to-metastatic-hormone-receptor-positive-her2-negative-breast-cancer-endocrine-therapy?search=Palbocilib&amp;source=search_result&amp;selectedTitle=4~14&amp;uage_type=default&amp;display_rank=4\" style=\"color:#0563c1; text-decoration:underline\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://www.uptodate.com/contents/treatment-approach-to-metastatic-hormone-receptor-positive-her2-negative-breast-cancer-endocrine-therapy?search=Palbocilib&amp;source=search_result&amp;selectedTitle=4~14&amp;uage_type=default&amp;display_rank=4</span></strong></a></span></span></p>\r\n\r\n<p>&nbsp;</p>",
    "correct_choice_id": 45975,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11507,
    "choices": [
      {
        "id": 45994,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifene</span></span></span></p>"
      },
      {
        "id": 45995,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trastuzumab</span></span></span></p>"
      },
      {
        "id": 45996,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fulvestrant</span></span></span></p>"
      },
      {
        "id": 45997,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Palbociclib</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The chemotherapeutic agent of choice for a patient having breast cancer with the following results of immunohistochemistry (IHC) is:</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/picture1_AjeezFR.png\" style=\"height:188px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q7438205",
    "question_audio": null,
    "question_video": null,
    "map_id": 36915,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Trastuzumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given <strong>IHC image shows cancer cells positive for HER-2 receptors</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HER-2 receptors&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are <strong>membrane-bound receptors</strong>, and hence, <strong>cells with these receptors show dark staining of the membranes.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trastuzumab&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Herceptin) is a <strong>recombinant humanized monoclonal antibody directed against HER-2</strong>. It is effective against the HER2/neu receptor. It is used along with <strong>Pertuzumab</strong> to <strong>treat HER2/neu-positive tumours</strong> along with <strong>chemotherapy.</strong> </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>cytotoxic agent T-DM1</strong> is used in <strong>HER2/neu-positive disease</strong>: a <strong>chemotherapy agent, emtansine, is conjugated to trastuzumab</strong> to allow targeted delivery of the chemotherapy to HER2-positive cells.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Tamoxifen:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong>selective estrogen receptor modulator</strong> (SERM) and is <strong>primarily used in hormone receptor-positive breast cancer</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is not the drug of choice for HER2-positive breast cancer.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Fulvestrant:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fulvestrant is a <strong>selective estrogen receptor degrader</strong> (SERD) and is <strong>used in hormone receptor-positive breast cancer</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is not the drug of choice for HER2-positive breast cancer.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Palbociclib:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Palbociclib is a <strong>cyclin-dependent kinase 4/6</strong> (CDK4/6) <strong>inhibitor and is used in hormone receptor-positive</strong>, <strong>HER2-negative breast cancer</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is not typically used as a single-agent therapy for HER2-positive breast cancer.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormone receptors - Estrogen receptor (ER) and progesterone receptor (PR) are present in the nucleus. Therefore, ER and PR positive breast cancer cells show dark nuclear staining on IHC.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-183456.png\" style=\"height:354px; width:500px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 28<sup>th</sup> Ed. Pg 940, Schwartz&rsquo;s principle of surgery -10<sup>th</sup> edition page no 535</span></strong></span></span></p>",
    "correct_choice_id": 45995,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11514,
    "choices": [
      {
        "id": 46022,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adjuvant Chemotherapy + radiotherapy</span></span></span></p>"
      },
      {
        "id": 46023,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adjuvant Chemotherapy + radiotherapy + anastrozole + trastuzumab</span></span></span></p>"
      },
      {
        "id": 46024,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adjuvant Chemotherapy + anastrozole</span></span></span></p>"
      },
      {
        "id": 46025,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adjuvant Chemotherapy + radiotherapy + anastrozole</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old lady presents to your OPD with a lump in the left breast in the upper outer quadrant, 6 x 4 cm in size. Tumor shows fixity to Pectoralis Major muscle, but not to chest wall. Axillary examination is normal. You perform MRM, with histopathology report and genetic array showing moderately differentiated ductal CA, lymph nodal metastasis and Luminal A subtype. What further treatment will you advise?</span></span></p>",
    "unique_key": "Q9354357",
    "question_audio": null,
    "question_video": null,
    "map_id": 36916,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Adjuvant Chemotherapy + radiotherapy + anastrozole</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given scenario: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor size 6 x 4 cm implying T3 stage</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Fixity to Pectoralis major doesn&rsquo;t affect the T stage</strong>. All tumors of <strong>size &gt; 1 cm are given adjuvant chemotherapy.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Presence of lymph node metastasis&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is an indication for <strong>adjuvant radiation</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luminal A subtype is ER/PR positive and Her 2 neu negative. Hence, adjuvant hormonal therapy is advised but not Transtuzumab.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Radiotherapy in CA breast </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Radiotherapy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is shown to <strong>decrease the risk of locoregional and systemic recurrence</strong> and <strong>improve survival</strong>. The indications include: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with locally advanced breast cancers: T3, T4, N1, N2, N3 disease; </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Following BCT; </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">After mastectomy if: tumor size &ge;5&nbsp; cm; skin or chest wall involvement; </span></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">lymphovascular invasion (LVI), grade 3; </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary lymph node positive for metastasis. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In pathologically lymph node-negative tumors, radiotherapy after BCS is given to the breast only as a dose of 45&ndash;50.4 Gy (with or without a boost) delivered in 25 fractions or of 40&ndash;42.5 Gy delivered in 15 or 16 fractions (hypofractionation). </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients after mastectomy (T3N0M0), chest wall radiotherapy is given if the sentinel lymph nodes are negative. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with lymph node-positive disease locoregional radiotherapy is given covering the chest wall, supraclavicular region, internal mammary nodes and the axilla. The axilla should not be irradiated after axillary node dissection as this increases the risk of lymphoedema.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-184339.png\" style=\"height:224px; width:1000px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Ref</u>:&nbsp;</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey and Love 28<sup>th</sup> Ed. Pg 939-940</span></strong></span></span></p>",
    "correct_choice_id": 46025,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11516,
    "choices": [
      {
        "id": 46030,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given in all cases of breast conservative therapy</span></span></span></p>"
      },
      {
        "id": 46031,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If MRM shows axillary lymph nodal metastasis, radiotherapy is given to axilla as well</span></span></span></p>"
      },
      {
        "id": 46032,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adjuvant radiotherapy is shown to reduce the risk of recurrence in LABC</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>"
      },
      {
        "id": 46033,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Accelerated Partial Breast Irradiation (APBI) is a form of radiation therapy used in breast cancer treatment that targets only the lumpectomy cavity plus a margin around it, rather than the entire breast</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false about radiotherapy for breast carcinoma?</span></span></p>",
    "unique_key": "Q4662689",
    "question_audio": null,
    "question_video": null,
    "map_id": 36917,
    "difficulty_level": "difficult",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) If MRM shows axillary lymph nodal metastasis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">,</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Radiotherapy is given to axilla as well</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with lymph node-positive disease locoregional radiotherapy is given covering the chest wall, supraclavicular region, internal mammary nodes and the axilla. <strong>The axilla should not be irradiated after axillary node dissection as this increases the risk of lymphoedema. Thus, post MRM (which includes axillary dissection), axilla is not given RT.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>All patients with</strong> <strong>BCS receive radiotherapy.</strong> <strong>BCS together</strong> with <strong>radiotherapy is called breast conservation therapy</strong> (BCT): <strong>BCS&nbsp;+&nbsp;RT&nbsp;=&nbsp;BCT</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Radiotherapy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is shown to <strong>decrease the risk of locoregional and systemic recurrence</strong> and <strong>improve survival</strong>. The indications include the following: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with locally advanced breast cancers T3, T4, N1, N2, N3 disease; </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Following BCS; </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">After mastectomy if: </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumour size &ge;5&nbsp;cm; skin or chest wall involvement; lymphovascular invasion (LVI),&nbsp; &nbsp;&nbsp;&nbsp;grade 3 </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary lymph node positive for metastasis.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Accelerated partial breast irradiation (APBI).&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">APBI is a <strong>localized form of radiation delivered after lumpectomy</strong> to only the part of the breast where the tumor was removed.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">American Society for Radiation Oncology ABPI guidelines, 2016</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">women 50 years or older with T1 disease and negative resected margins with a margin width of &ge;2&nbsp;mm, invasive ductal carcinoma, no LVI, ER positive, BRCA negative and sentinel node negative; </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">women 50 years or older with low-risk DCIS (screen detected, low/intermediate nuclear grade, tumour size &le;2.5&nbsp;cm, negative resected margin widths &ge;3&nbsp;mm). </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>tumour bed is irradiated along with a narrow rim of surrounding tissue</strong> so as to <strong>avoid the potentially harmful effects of irradiation on healthy tissue</strong>. It is delivered <strong>twice daily for 5 days</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love 28<sup>th</sup> Ed. Pg 935, 939-940</span></strong></span></span></p>",
    "correct_choice_id": 46031,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11518,
    "choices": [
      {
        "id": 46038,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary vein</span></span></span></p>"
      },
      {
        "id": 46039,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thoracodorsal pedicle</span></span></span></p>"
      },
      {
        "id": 46040,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Angular vein</span></span></span></p>"
      },
      {
        "id": 46041,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Costoclavicular ligament</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The following image shows the boundaries of axillary lymph node dissection. The inferior boundary marked as &lsquo;A&rsquo; denotes:</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/22/whatsapp-image-2024-03-22-at-115355-am-1.jpeg\" style=\"height:297px; width:300px\" /></p>\r\n\r\n<p>&nbsp;</p>",
    "unique_key": "Q9123671",
    "question_audio": null,
    "question_video": null,
    "map_id": 36918,
    "difficulty_level": "difficult",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Angular vein</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>space of axillary lymph node dissection</strong> is <strong>inferiorly bounded by the angular vein</strong> (marked as &lsquo;A&rsquo;).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Boundaries of axillary lymph node dissection are as follows.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Superior: Axillary vein</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lateral: Thoracodorsal pedicle</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medial: Costoclavicular ligament (Halsted ligament)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inferior: Angular vein</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>minimum of 10 lymph nodes are removed during axillary clearance</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-184914.png\" style=\"height:422px; width:500px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Journal</span> <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244245/\" style=\"color:#0563c1; text-decoration:underline\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244245/</span></a></span></span></strong></p>",
    "correct_choice_id": 46040,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11520,
    "choices": [
      {
        "id": 46046,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Annual mammogram</span></span></span></p>"
      },
      {
        "id": 46047,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Regular checking of LFT once in 6 months</span></span></span></p>"
      },
      {
        "id": 46048,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follow-up with tumor markers once in 6 months</span></span></span></p>"
      },
      {
        "id": 46049,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Yearly bone scans</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman underwent treatment for breast cancer of 1.2 x 1 cm with positive axillary nodes. She completed radiotherapy and chemotherapy and is now receiving tamoxifen. Which investigation will you use for follow-up in the patient?</span></span></p>",
    "unique_key": "Q1428720",
    "question_audio": null,
    "question_video": null,
    "map_id": 36892,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Annual mammogram</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>follow-up of breast cancer</strong> patients after <strong>treatment is crucial for early detection of recurrence</strong> and <strong>monitoring for any complications of treatment</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Annual Mammogram</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> an <strong>annual mammogram is the standard follow-up investigation</strong> for <strong>breast cancer patients</strong>. It is <strong>used to monitor the treated breast</strong> and the <strong>contralateral breast</strong> for any new findings <strong>suggestive of recurrence or a new primary breast cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Regular Checking of Liver Function Tests (LFTs) Once in 6 Months.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Routine liver function tests</strong> are <strong>not standard in the follow-up of breast cancer</strong> patients unless there are specific clinical indications or if the patient is experiencing symptoms suggestive of metastatic disease or complications related to systemic therapies.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Follow-up with Tumor Markers Once in 6 Months&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>use of tumor markers for routine follow-up in asymptomatic patients</strong> <strong>after primary treatment</strong> for <strong>breast cancer</strong> is not recommended. They have not been shown to provide a survival benefit in this setting.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Yearly Bone Scans</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Routine bone scans</strong> are <strong>not indicated for follow-up in asymptomatic breast cancer patients after primary treatment</strong>. They are reserved for patients with symptoms or clinical findings that suggest bone metastasis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Follow-up of patients after treatment of breast cancer&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">consists of <strong>routine physical examination once in 3 months for a year and annual mammogram.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mammography&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is the <strong>only imaging modality</strong> necessary for <strong>follow-up after breast cancer surgery</strong>. There is currently no role for tumor markers, serum investigations, or any other imaging studies like bone scan in follow-up.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Guidelines for follow-up:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Physical examination:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For the first 2 years: once every 3 to 6 months</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For 3-5 years: once every 6 to 12 months after 5 years: Annually</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mammography:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initially, 6 months after surgery</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thereafter, annually.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; Love&rsquo;s short practice of surgery 27<sup>th</sup> edition Pg 879</span></strong></span></span></p>",
    "correct_choice_id": 46046,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11521,
    "choices": [
      {
        "id": 46050,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Internal mammary vein</span></span></span></p>"
      },
      {
        "id": 46051,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lateral thoracic vein</span></span></span></p>"
      },
      {
        "id": 46052,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Superior epigastric vein</span></span></span></p>"
      },
      {
        "id": 46053,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Axillary vein</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombophlebitis of the superficial veins of the breast typically affects which of the below?</span></span></p>",
    "unique_key": "Q8250825",
    "question_audio": null,
    "question_video": null,
    "map_id": 36919,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Lateral thoracic vein </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mondor&rsquo;s disease&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is <strong>thrombophlebitis of the superficial veins</strong> of the <strong>breast and anterior chest wall</strong>, the <strong>most commonly involved vein being the lateral thoracic vein</strong>. It is a <strong>benign, non-cancerous lesion, which is self-limiting.</strong> </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical feature: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pain and tenderness</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The affected area may be painful to the touch and may feel tender.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Redness and swelling</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The skin over the affected vein may appear red and swollen.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hardness and cord-like feel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The affected vein may feel hard and cord-like under the skin.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Palpable lump</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A palpable lump may be felt in the affected area.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Discoloration:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The skin over the affected vein may appear blue or purple.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Itching or burning</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Some patients may experience itching or burning in the affected area.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fever</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In rare cases, patients may experience a low-grade fever.</span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Management: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Supportive measures</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: The affected breast should be supported with a well-fitting bra or compression garment to reduce discomfort and promote healing.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pain relief</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Over-the-counter pain medications such as acetaminophen or ibuprofen can be taken to relieve pain and reduce inflammation.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Warm compresses</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Applying warm compresses to the affected area for 15-20 minutes several times a day for 4-6 weeks can help relieve pain and promote healing.</span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and love&rsquo;s short practice of surgery -27<sup>th</sup> edition page no 867, Bailey 28<sup>th</sup> Ed. Pg 930.</span></strong></span></span></p>",
    "correct_choice_id": 46051,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11528,
    "choices": [
      {
        "id": 46078,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intraductal papilloma </span></span></span></p>"
      },
      {
        "id": 46079,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Duct ectasia </span></span></span></p>"
      },
      {
        "id": 46080,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carcinoma i </span></span></span></p>"
      },
      {
        "id": 46081,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Galactorrhea</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pathologic nipple discharge in the non-lactating breast is most commonly associated with which cause?</span></span></p>",
    "unique_key": "Q1666143",
    "question_audio": null,
    "question_video": null,
    "map_id": 36920,
    "difficulty_level": "difficult",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Intraductal papilloma </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pathologic nipple discharge&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">in the <strong>non-lactating breast</strong> can be <strong>caused by several conditions</strong>, each with different clinical implications. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intraductal papilloma&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is the <strong>most common benign cause of pathologic nipple discharge,</strong> particularly when the <strong>discharge is bloody or serous</strong>. These are <strong>small benign tumors that form in a milk duct</strong> in the <strong>breast</strong> and are often <strong>found beneath the areola</strong>, <strong>close to the nipple</strong>, which can result in the <strong>discharge being noticed</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Duct Ectasia&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Duct ectasia, which is the <strong>dilatation of the milk ducts</strong>, can cause a <strong>thick, sticky discharge that may be gray to green in color</strong>. It is more common in perimenopausal women and is the second most common cause of pathologic nipple discharge after intraductal papilloma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Carcinoma&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While breast carcinoma can <strong>cause nipple discharge, it is less common than intraductal papilloma and duct ectasia</strong> as a cause for this symptom. When carcinoma is the cause, the discharge may be bloody or clear, and there are often other signs such as a breast mass or changes in the skin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Galactorrhea&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Galactorrhea is the <strong>production of breast milk in men or in women who are not breastfeeding.</strong> It is not typically associated with pathologic nipple discharge unless related to an underlying pathology like a prolactinoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intraductal papilloma&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is the <strong>most common cause of pathologic nipple discharge</strong> in the <strong>non-lactating breast</strong>, often <strong>presenting as bloody or serous discharge</strong>, and typically <strong>requires surgical excision for both diagnostic and therapeutic purposes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An <strong>intraductal papilloma</strong> is a <strong>true polyp of the epithelium-lined ducts of the breast</strong>. Most papillomas are small, with diameters &lt;1 cm, but they can grow up 4 or 5 cm in diameter.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Papilloma located close to the nipple are often accompanied by a blood stained nipple discharge and is the most common cause of bloody nipple discharge. However, they are not associated with an increased risk of breast cancer. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>treatment usually involves excision through a circumareolar incision.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Direct quote: &ldquo;Intraductal papilloma is the most common cause of pathologic nipple discharge, accounting for 35% to 48% of causes, followed by duct ectasia (17%-36%)&rdquo;- ACR appropriateness criteria, evaluation of nipple discharge</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Sabiston textbook of surgery 20<sup>th</sup> edition page no 825, 836</span></strong></span></span></p>",
    "correct_choice_id": 46078,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11535,
    "choices": [
      {
        "id": 46106,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A history of smoking&nbsp; </span></span></span></p>"
      },
      {
        "id": 46107,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A history of recent breastfeeding </span></span></span></p>"
      },
      {
        "id": 46108,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A history of hormonal contraceptive use </span></span></span></p>"
      },
      {
        "id": 46109,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A history of recent trauma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old female presents with a chief complaint of persistent breast discomfort. On examination, there is localized tenderness, erythema, and a palpable breast lump. Nipple shows slit like retraction with fish mouth appearance. Which of the following findings is most likely risk factor in this patient?</span></span></p>",
    "unique_key": "Q6814266",
    "question_audio": null,
    "question_video": null,
    "map_id": 36921,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) A history of smoking</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given scenario of <strong>tenderness, lump and slit like nipple retraction</strong> is suggestive of <strong>duct ectasia/chronic periductal mastitis</strong> which is commonly associated with <strong>smoking</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Breast feeding&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is <strong>linked to mastitis or breast abscess</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Hormonal contraceptive&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are associated with <strong>breast carcinoma</strong>, although the risk is small</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Recent trauma&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">or <strong>hematoma</strong> may lead to <strong>traumatic fat necrosis</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Duct ectasia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, characterized by the <strong>dilation of lactiferous ducts and periductal inflammation</strong>, is the <strong>most common cause of greenish nipple discharge</strong> in the <strong>non-lactating breast</strong>, particularly in <strong>women above 50 years of age</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Duct ectasia&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(periductal mastitis) involves <strong>dilatation of multiple ducts</strong>, which is often associated with <strong>periductal inflammation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common <strong>age group affected</strong>: <strong>above 50 years</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common <strong>presenting feature</strong>: <strong>nipple discharge</strong> </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-190546.png\" style=\"height:437px; width:500px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient presents with <strong>central non-cyclical pain, pus discharge from the nipple and a subareolar tender mass</strong>/ abscess or mammary duct fistula. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The examination reveals a tender, firm subareolar lump or abscess, purulent nipple discharge, thickened tender major milk ducts and a <strong>transverse slit-like nipple retraction looking like a fish&rsquo;s mouth</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ultrasonography&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">shows <strong>thickened major milk ducts</strong> with surrounding inflammation or abscess. A lump should be biopsied under ultrasound guidance to confirm the diagnosis.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The treatment for duct ectasia is <strong>Hadfield&rsquo;s operation</strong>, which refers to the cone excision of the major duct system or sub areolar resection. <strong>All lactiferous ducts under the nipple are removed.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This procedure is performed when the duct of origin for the nipple bleeding is uncertain or when there is bleeding or discharge from multiple ducts.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If a <strong>single duct is involved</strong>, then <strong>microdochectomy is the treatment of choice</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Remember:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most common cause of blood-stained discharge</strong> from a <strong>single duct is duct papilloma</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most common cause of blood-stained discharge</strong> from <strong>multiple ducts</strong> is duct carcinoma.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most common cause of serous discharge</strong> from the <strong>breast is fibrocystic disease</strong> of the breast.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Single duct single breast serous or sanguineous&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(4S) nipple discharge is considered pathological</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and love&rsquo;s short practice of surgery -27<sup>th</sup> edition page no 864, 867. 28<sup>th</sup> Ed. Pg 927.</span></strong></span></span></p>",
    "correct_choice_id": 46106,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11539,
    "choices": [
      {
        "id": 46122,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Benign neoplasm</span></span></span></p>"
      },
      {
        "id": 46123,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multiple diffuse mass</span></span></span></p>"
      },
      {
        "id": 46124,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Biphasic pathology</span></span></span></p>"
      },
      {
        "id": 46125,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peak incidence in second decade</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Choose the incorrect statement with respect to a fibroadenoma of breast:</span></span></p>",
    "unique_key": "Q6291408",
    "question_audio": null,
    "question_video": null,
    "map_id": 36922,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Multiple diffuse mass </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multiple diffuse mass&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>incorrect</strong>. <strong>Fibroadenomas</strong> typically <strong>present as a solitary, discrete mass, not multiple diffuse masses</strong>. While a patient may have more than one fibroadenoma, each is usually a distinct entity.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Benign neoplasm&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>correct</strong>. A fibroadenoma is a benign breast tumor and is one of the most common benign tumors found in the breast, especially in younger women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Biphasic pathology&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>correct</strong>. Fibroadenomas are biphasic, meaning they are composed of both stromal (connective tissue) and glandular (epithelial) components.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Peak incidence in second decade&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>correct</strong>. The peak incidence of fibroadenoma is in the second decade of life, making it a common finding in young women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenomas&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are <strong>benign breast neoplasms</strong> that typically <strong>present as solitary, discrete, and mobile masses</strong>, commonly occurring in <strong>young women in their second decade of life</strong>, characterized by <strong>biphasic pathology</strong> with <strong>both stromal and epithelial components</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a <strong>form of aberrations of normal development</strong> and <strong>involution of breast</strong> (ANDI).</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common <strong>age group affected is 15-25 years</strong> (early reproductive period) with peak incidence in the second decade.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>arises from hyperplasia of a single lobule</strong> and <strong>presents as a well circumscribed, smooth, firm, non tender, freely mobile mass</strong> (mouse in the breast).</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a biphasic tumor consisting of fibroblastic stroma and epithelium-lined gland.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Popcorn calcification is seen in mammography.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Excision is not advised</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> unless there is suspicious histology on FNAC.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Giant fibroadenoma are &gt;5cm in size, common in adolescent girls and require excision by sub mammary incision.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Popcorn calcification on mammography:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/picture1_prwkst3.png\" style=\"height:245px; width:300px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -27<sup>th</sup> edition page no 868</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Robbins basic pathology, 10<sup>th</sup> edition page no 738</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schwartz&rsquo;s principles of surgery -10<sup>th</sup> edition page no 507</span></strong></span></span></p>",
    "correct_choice_id": 46123,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11542,
    "choices": [
      {
        "id": 46134,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Can be benign or malignant </span></span></span></p>"
      },
      {
        "id": 46135,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Commonly metastasizes to axillary lymph nodes </span></span></span></p>"
      },
      {
        "id": 46136,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mixed neoplasm having both epithelial and mesenchymal elements</span></span></span></p>"
      },
      {
        "id": 46137,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment is wide excision with 2 cm margin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is false about cystosarcoma phyllodes?</span></span></p>",
    "unique_key": "Q5233040",
    "question_audio": null,
    "question_video": null,
    "map_id": 36923,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Commonly metastasizes to axillary lymph nodes</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cystosarcoma phyllodes</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, also known as <strong>phyllodes tumors</strong>, are <strong>rare fibroepithelial neoplasms</strong> of the <strong>breast</strong> that can <strong>display a broad spectrum of behaviour</strong>, ranging from <strong>benign to highly malignant.</strong> </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Commonly metastasized to axillary lymph nodes&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>false</strong>. <strong>Phyllodes tumors</strong> typically <strong>metastasize hematogenously</strong>, most commonly to the <strong>lungs</strong>, <strong>not via the lymphatic system</strong> to the <strong>axillary lymph nodes</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Can be benign or malignant&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. Phyllodes tumors can be benign, borderline, or malignant based on histological features such as stromal cellularity, atypia, mitotic activity, and the nature of the tumor borders.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Mixed neoplasm having both epithelial and mesenchymal elements&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. Phyllodes tumors are characterized by their biphasic nature, having both stromal (mesenchymal) and epithelial components.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Treatment is wide excision with 2 margin&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. The treatment of choice for phyllodes tumors is wide local excision with clear margins (&gt;2cm) to minimize the risk of local recurrence. Mastectomy may be considered for larger or recurrent tumors.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cystosarcoma phyllodes are fibroepithelial neoplasms of the breast&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">that can <strong>range from benign to malignant</strong>, are <strong>composed of both epithelial and mesenchymal elements</strong>, and typically <strong>metastasize through the bloodstream</strong> rather than the <strong>lymphatic system</strong>. The recommended treatment is wide excision with a margin to prevent recurrence.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phyllodes tumor (sero-cystic disease of brodie or cyst sarcoma phyllodes):</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It originates from hormonally responsive stromal cells of the breast and are usually benign.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Affects women &gt;40 years of age usually.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Histologically, Phyllodes tumours are classified according to histological behaviour into benign (mitotic rate &lt;4 per 10 high-power fields [HPF]), borderline (mitotic rate 4&ndash;9 per 10 HPF) and malignant (mitotic rate &gt;10 per 10 HPF) tumours.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical features:</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Large, sometimes massive, with an unevenly bosselated surface</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulceration of overlying skin occurs because of pressure necrosis</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Remains mobile on the chest wall</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment:</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumors are </span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">treated</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> by excision with margins of at least 2 cm to prevent local recurrence.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Schwartz&rsquo;s principles of surgery -10<sup>th</sup> edition page no 555, 1481</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey &amp; love&rsquo;s short practice of surgery -28<sup>th</sup> Ed. Pg 922</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.</span></span></span></p>",
    "correct_choice_id": 46135,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11544,
    "choices": [
      {
        "id": 46142,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspiration </span></span></span></p>"
      },
      {
        "id": 46143,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continue antibiotics only</span></span></span></p>"
      },
      {
        "id": 46144,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A Suction catheter drainage</span></span></span></p>"
      },
      {
        "id": 46145,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Incision and drainage under general anesthesia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A female patient presents with a breast abscess. USG revealed an abscess cavity of 40 cc volume and 4 cm in diameter. What will be your next step in management?</span></span></p>",
    "unique_key": "Q8943602",
    "question_audio": null,
    "question_video": null,
    "map_id": 36924,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Suction catheter drainage</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the <strong>management of breast abscesses</strong>, the <strong>approach depends on the size of the abscess</strong> and the patient&#39;s symptoms. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Suction Catheter Drainage&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">for <strong>abscesses larger than 3 cm or containing more than 30 mL</strong> <strong>of pus</strong>, <strong>suction catheter drainage under ultrasound guidance can be effective</strong>. This method allows for <strong>continuous drainage</strong>, can be <strong>less invasive than surgical incision and drainage</strong>, and is typically accompanied by antibiotic therapy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Aspiration&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aspiration is a <strong>less invasive procedure that can be used for smaller abscesses</strong>, typically those <strong>less than 3 cm in diameter</strong>. It can be done under local anesthesia and often requires several sessions, along with antibiotic therapy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Continue Antibiotics Only&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continuing with antibiotics <strong>alone </strong>may be <strong>considered when only mastitis is present,</strong> and the patient is not showing signs of systemic infection. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Incision and Drainage Under General Anesthesia&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Incision and drainage under <strong>general anesthesia is usually reserved for larger abscesses</strong> or <strong>when there&#39;s thick pus</strong>, <strong>resistant bacteria</strong>, a <strong>failure of other methods</strong>, or specific indications like a multiloculated abscess. It&#39;s a more invasive procedure and typically the last resort when other less invasive measures fail.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a <strong>breast abscess</strong> of <strong>significant size</strong>, as indicated by <strong>ultrasound findings</strong>, the <strong>preferred initial step in management is suction catheter drainage</strong>, which allows for <strong>minimally invasive resolution of the abscess</strong> and can <strong>enable the patient to continue breastfeeding,</strong> with incision and drainage reserved for cases where less invasive measures are unsuccessful.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The latest guidelines for the management of breast abscess specify that multiple aspirations under antibiotic cover should be attempted before an incision and drainage is done. This often allows resolution without the need for an incision scar and also allows the patient to carry on breastfeeding.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&ldquo;In abscesses &gt;3&nbsp;cm in diameter or those containing more than 30&nbsp;mL of pus (assessed on ultrasonography), a vacuum suction catheter is inserted under ultrasound guidance to drain the pus. The patient should be reviewed on alternate days by clinical examination and ultrasonography. Any residual collection should be aspirated. The antibiotics are modified according to the microbiological culture report. In patients with a suction drain, the catheter is irrigated with cold normal saline (cold to reduce pain) on each visit until complete resolution. Antibiotics should be continued for 14 days.&rdquo;&nbsp; </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Incision and drainage of abscess is performed only if</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Presence of thick pus</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bacteria resistant to antibiotics. The most common organism responsible for breast abscess is S. aureus.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If just the superficial part has been aspirated in the presence of a multiloculated abscess.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A non-healing breast abscess due to tuberculosis of breast or inflammatory carcinoma of the breast, or an immunocompromised host.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -28<sup>th</sup> edition page no 927.</span></strong></span></span></p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Online resource:&nbsp;</span><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900741/\" style=\"color:#0563c1; text-decoration:underline\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900741/</span></a><a href=\"https://www.jmedsoc.org/article.asp?issn=0972-4958;year=2012;volume=26;issue=3;spage=189;epage=191;aulast=singh\" style=\"color:#0563c1; text-decoration:underline\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://www.jmedsoc.org/article.asp?issn=0972-4958;year=2012;volume=26;issue=3;spage=189;epage=191;aulast=singh</span></a></span></span></strong></p>",
    "correct_choice_id": 46144,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11545,
    "choices": [
      {
        "id": 46146,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wait for refilling and attempt aspiration again</span></span></span></p>"
      },
      {
        "id": 46147,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Core biopsy </span></span></span></p>"
      },
      {
        "id": 46148,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Supportive management </span></span></span></p>"
      },
      {
        "id": 46149,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mastectomy and SLNB</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What will be your next step in the management of a large breast cyst in a 60-year-old woman which reveals haemorrhagic fluid on aspiration?</span></span></p>",
    "unique_key": "Q6369876",
    "question_audio": null,
    "question_video": null,
    "map_id": 36925,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Core biopsy </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>management of a breast cyst yielding hemorrhagic fluid upon aspiration</strong> involves <strong>further diagnostic procedures</strong> to rule out malignancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Core Biopsy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is the <strong>correct step in the management of a breast cyst</strong> with <strong>hemorrhagic fluid</strong>. A <strong>core biopsy allows for histological evaluation</strong> to <strong>exclude malignancies</strong> such as <strong>cystadenocarcinoma</strong>, especially in <strong>older women</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Wait for Refilling and Attempt Aspiration Again&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This option would not be appropriate for a <strong>hemorrhagic fluid aspirate</strong>, as the presence of blood necessitates further evaluation to rule out malignancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Supportive Management&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Supportive management <strong>alone would not be adequate without further diagnostic evaluation in the presence of hemorrhagic fluid</strong>, as it could indicate an underlying malignancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Mastectomy and Sentinel Lymph Node Biopsy (SLNB)&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mastectomy and SLNB are <strong>major surgical interventions</strong> that are <strong>not indicated solely based on the aspiration of hemorrhagic fluid from a breast cyst</strong>. These procedures are considered only after a definitive diagnosis of malignancy has been established.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When hemorrhagic fluid is aspirated from a large breast cyst</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, a <strong>core biopsy</strong> is indicated to <strong>rule out malignancy</strong>, such as <strong>cystadenocarcinoma</strong>, and to guide subsequent management decisions based on histopathological findings.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a large breast cyst, if the aspirate is blood stained then core biopsy or excision should be performed and the resulting tissue should be sent for histopathology for exclusion of cystadenocarcinoma, most commonly in elderly women.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, if the aspirate is clear or there is no evidence of refilling then it can be left as such.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&ldquo;A smooth-walled cyst without any solid component in its wall is classified as BI-RADS 2 and requires only observation without biopsy.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The presence of a solid component in the cyst wall is classified as a complex cyst and necessitates a core biopsy to rule out cystadenocarcinoma. This should be distinguished from a complicated cyst, which is defined as a cyst containing intracystic floating debris that moves within the cyst with change of posture.&rdquo;</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -27<sup>th</sup> edition pg 869</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey 28<sup>th</sup> Ed. Pg 921</span></strong></span></span></p>",
    "correct_choice_id": 46147,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11548,
    "choices": [
      {
        "id": 46158,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Macrodochectomy</span></span></span></p>"
      },
      {
        "id": 46159,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Microdochectomy</span></span></span></p>"
      },
      {
        "id": 46160,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hadfield procedure</span></span></span></p>"
      },
      {
        "id": 46161,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nipple sparing mastectomy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A surgeon inserts a probe into the duct from which the discharge is emerging. He makes a tennis racquet incision and dissects the flap to reach the duct. Finally, he excises the duct. What is this procedure known as?</span></span></p>",
    "unique_key": "Q3171459",
    "question_audio": null,
    "question_video": null,
    "map_id": 36926,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Microdochectomy </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Microdochectomy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Correct option. This is a <strong>surgical procedure where a single lactiferous duct that is causing pathological nipple discharge is excised</strong>. A <strong>probe is inserted into the discharging duct</strong>, followed by a <strong>periareolar incision</strong>, dissection to the duct, and its removal.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Microdochectomy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is the <strong>surgical removal</strong> (excision) of a <strong>discharging lactiferous duct</strong>. It is typically done for intraductal papilloma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Macrodochectomy:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a <strong>procedure where a larger segment of the ductal system in the breast is removed</strong>, not specifically for isolated discharging ducts.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hadfield procedure:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This procedure is typically <strong>used for the management of chronic breast abscess</strong> or <strong>duct ectasia</strong> and involves the <strong>removal of all major ducts beneath the nipple</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Nipple Sparing Mastectomy:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this procedure, the <strong>breast tissue is removed while preserving the nipple and areola</strong>. It is a type of mastectomy for breast cancer treatment, not indicated for isolated duct issues.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Microdochectomy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is the <strong>surgical removal of a problematic lactiferous duct</strong> causing <strong>pathological nipple discharge</strong>, <strong>intended to resolve</strong> the <strong>discharge</strong> and <strong>exclude underlying pathology</strong>. It is typically done for <strong>intra-ductal papilloma.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>probe or a stiff nylon suture</strong> is <strong>inserted into the duct from which the discharge is emerging</strong>. A <strong>tennis racket incision</strong> can be made to <strong>encompass the entire duct or a Peri areolar incision</strong> is used and the <strong>nipple flap dissected to reach the duct</strong>. The duct is then excised.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Online resource&nbsp;</span></strong><a href=\"http://www.jcrp.org.tw/pic/paper/166/publishfile.pdf\" style=\"color:#0563c1; text-decoration:underline\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">http://www.jcrp.org.tw/pic/paper/166/publishfile.pdf</span></strong></a></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey &amp; love&rsquo;s short practice of surgery -27<sup>th</sup> edition page no 865</span></strong></span></span></p>",
    "correct_choice_id": 46159,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11553,
    "choices": [
      {
        "id": 46178,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ductal carcinoma in situ (DCIS)</span></span></span></p>"
      },
      {
        "id": 46179,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lobular carcinoma in situ (LCIS)</span></span></span></p>"
      },
      {
        "id": 46180,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Giant fibroadenoma</span></span></span></p>"
      },
      {
        "id": 46181,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Galactocele</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral, multicentric type of lesions are usually seen in:</span></span></p>",
    "unique_key": "Q9766689",
    "question_audio": null,
    "question_video": null,
    "map_id": 36927,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Lobular carcinoma in situ (LICIS) is usually multicentric and bilateral.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lobular Carcinoma In Situ - LCIS:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Correct option. <strong>LCIS is often multicentric</strong>, meaning occurring in <strong>different quadrants of the same breast or in both breasts</strong>, and <strong>bilateral</strong>, meaning it occurs in <strong>both breasts</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Ductal Carcinoma In Situ - DCIS:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DCIS is usually <strong>unilateral and solitary</strong>, but can present as multifocal (within the same quadrant) of the breast but is less commonly multicentric (multiple quadrants) or bilateral.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Giant Fibroadenoma:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a benign tumor that usually <strong>presents as a single, well-circumscribed mass</strong>, and it is neither typically multicentric nor bilateral.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Galactocele:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>milk-filled cyst that occurs postpartum</strong>, not typically associated with multicentric or bilateral lesions.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lobular carcinoma in situ&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(LCIS) commonly <strong>presents as multicentric and bilateral lesions</strong>, which requires a <strong>careful evaluation of both breasts</strong>, while <strong>ductal carcinoma in situ</strong> (DCIS) is more likely to be <strong>multifocal within the same quadrant</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multicentricity</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: occurrence of a second breast cancer outside the breast quadrant of the primary cancer (or at least 4 cm away).</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multifocality</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: occurrence of a second cancer within the same breast quadrant as the primary cancer (or within 4 cm of it).</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/22/whatsapp-image-2024-03-22-at-115355-am-2.jpeg\" style=\"height:216px; width:400px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Characteristic of in situ ductal (DCIS) and lobular (LCIS) carcinoma of the breast</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-191938.png\" style=\"height:653px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Schwartz&rsquo;s principles of surgery -10<sup>th</sup> edition page no 519</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Online resource </span></strong><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841603/\" style=\"color:#0563c1; text-decoration:underline\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841603/</span></strong></a></span></span></p>",
    "correct_choice_id": 46179,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11556,
    "choices": [
      {
        "id": 46190,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,2,3,4</span></span></span></p>"
      },
      {
        "id": 46191,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,2, and 4</span></span></span></p>"
      },
      {
        "id": 46192,
        "text": "<p style=\"margin-left:6px; text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,2, and 3</span></span></span></p>"
      },
      {
        "id": 46193,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,3, and 4</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Consider following statements about Paget&rsquo;s disease of breast:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is an in-situ cancer</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Presence of Paget cells is needed for diagnosis.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Underlying carcinoma is usually LCIS.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment is mastectomy or wide local excision.</span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the above are true statements?</span></span></span></p>",
    "unique_key": "Q5985027",
    "question_audio": null,
    "question_video": null,
    "map_id": 36928,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) 1,2, and 4.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paget&rsquo;s disease&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is usually associated with <strong>underlying ductal carcinoma in situ</strong> (DCIS).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paget&rsquo;s disease&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong>superficial manifestation</strong> of an <strong>underlying breast carcinoma</strong>. It accounts for 1% or less of breast malignancies.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical features:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Presents a chronic, eczematous eruption of the nipple and progresses to an ulcerated, weeping lesion.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Usually is associated with extensive DCIS and may be associated with an invasive cancer that may metastasize to axillary lymph nodes.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A palpable mass may or may not be present.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diagnosis:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>nipple biopsy specimen</strong> will show a <strong>population of cells that are identical to the underlying DCIS cells</strong> (pagetoid features or pagetoid change). <strong>Paget cells are pathognomonic</strong> -<strong>Large, pale, vacuolated cells in the rete pegs of the epithelium.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment depends on the status of the underlying carcinoma. Paget&rsquo;s disease without associated underlying malignancy is treated by central core excision, removing a cone of major milk ducts along with the nipple and areola down to the P. major muscle, followed by radiotherapy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paget&rsquo;s disease&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">with underlying <strong>malignancy is treated by mastectomy and evaluation of the axillary nodal status</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Differential diagnosis:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Eczema</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Contact dermatitis</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Post radiation dermatitis</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Superficial spreading melanoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Differentiated by the presence of S-100 antigen immunostaining in melanoma in contrast to carcinoembryonic antigen (CEA) immunostaining in Paget&rsquo;s.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Paget&#39;s disease&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">of the <strong>breast is an in situ cancer</strong> that requires the <strong>presence of Paget cells</strong> for diagnosis and is usually <strong>associated with an underlying ductal carcinoma</strong>, <strong>not lobular</strong>. Treatment often involves mastectomy or wide local excision depending on the extent of the underlying disease.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Schwartz&rsquo;s principles of surgery -10<sup>th</sup> edition page no 521</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sabiston textbook of surgery 20<sup>th</sup> edition page no 883</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bailey &amp; love&rsquo;s short practice of surgery -28<sup>th</sup> edition page no 924</span></strong></span></span></p>",
    "correct_choice_id": 46191,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11558,
    "choices": [
      {
        "id": 46198,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormone receptor ER/PR status</span></span></span></p>"
      },
      {
        "id": 46199,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Size of lesion</span></span></span></p>"
      },
      {
        "id": 46200,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age of patient</span></span></span></p>"
      },
      {
        "id": 46201,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Distance from margin (tumor free margin)</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The van Nuys grading system for ductal carcinoma in situ does not include:</span></span></p>",
    "unique_key": "Q2051523",
    "question_audio": null,
    "question_video": null,
    "map_id": 36929,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Hormone receptor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Staining for estrogen&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">and <strong>progesterone receptors is not part of the Van Nuys system</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>components of the van Nuys Prognostic Index</strong> (VNPI) for <strong>grading ductal carcinoma in situ</strong> (DCIS) are as follows:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patient&rsquo;s age</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Type of DCIS (histologic variant based on nuclear grade and presence of necrosis)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Presence of microcalcification</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Extent of resection margin/Distance from margin</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Size of tumor</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with a high score in this grading system&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">benefit from <strong>radiotherapy after excision</strong>, whereas from <strong>radiotherapy after excision</strong>, whereas those with <strong>low-grade tumors</strong>, whose <strong>tumor is completely excised</strong>, need no further treatment.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>score, ranging from 1 for lesions with the best prognosis to 3 for lesions with the worst prognostic predictors</strong>. Scores range from 4 (least likely to recur) to 12 (most likely to recur).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-192441.png\" style=\"height:298px; width:1000px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note: The type of microcalcification seen on imaging, helps in determining the nuclear grade of DCIS.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linear branching type of microcalcification is associated with high nuclear grade.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fine granular type of microcalcification is associated with low nuclear grade.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -27<sup>th</sup> edition Pg 872</span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sabiston textbook of surgery 20<sup>th</sup> edition page no 853</span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Online resource </span><a href=\"http://www.archintsurg.org/text.asp?2016/6/3/137/202366\" style=\"color:#0563c1; text-decoration:underline\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">http://www.archintsurg.org/text.asp?2016/6/3/137/202366</span></a></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Online resource </span><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132440/\" style=\"color:#0563c1; text-decoration:underline\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132440/</span></a></span></span></strong></p>",
    "correct_choice_id": 46198,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11561,
    "choices": [
      {
        "id": 46210,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucinous carcinomas are usually hormone negative.</span></span></span></p>"
      },
      {
        "id": 46211,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cutaneous edema in inflammatory carcinoma is the result of blockage of the subdermal&nbsp;&nbsp;&nbsp; lymphatics with carcinoma cells.</span></span></span></p>"
      },
      {
        "id": 46212,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcifications frequently are associated with ductal carcinoma in situ.</span></span></span></p>"
      },
      {
        "id": 46213,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lobular carcinoma in situ is multifocal and bilateral.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements regarding breast carcinoma is false?</span></span></p>",
    "unique_key": "Q1262659",
    "question_audio": null,
    "question_video": null,
    "map_id": 36930,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Mucinous carcinomas are usually hormone negative.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucinous Carcinomas:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Incorrect. <strong>Mucinous carcinomas</strong>, <strong>contrary to the statement</strong>, are often <strong>hormone receptor-positive</strong>, which makes <strong>hormonal therapy a viable treatment option</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Inflammatory Carcinoma:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Correct</strong>. Inflammatory breast carcinoma is characterized by cutaneous edema, commonly known as peau d&#39;orange, due to lymphatic obstruction by cancer cells.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Ductal Carcinoma In Situ:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Correct</strong>. Calcifications are often associated with ductal carcinoma in situ and are frequently detected on mammography as the earliest sign of this type of breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Lobular Carcinoma In Situ:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Correct</strong>. LCIS is known for being multifocal (multiple tumors within the same quadrant) and bilateral (occurring in both breasts).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucinous carcinomas&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">of the <strong>breast</strong> are typically <strong>hormone receptor-positive</strong>, which <strong>influences treatment options</strong> and generally <strong>carries a favourable prognosis</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucinous carcinomas&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are usually <strong>hormone-positive</strong>. They are also called <strong>colloid carcinoma.</strong> It is a <strong>low-grade tumour with good prognosis</strong> and is typically seen in the <strong>elderly, presenting as a bulky mass.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey &amp; love&rsquo;s short practice of surgery -27<sup>th</sup> edition page no 872</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Online resource&nbsp;</span></strong><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428244/\" style=\"color:#0563c1; text-decoration:underline\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428244/</span></strong></a></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Refer link&nbsp;</span></strong><a href=\"https://academic.oup.com/ajcp/article/146/suppl_1/314/2246854\" style=\"color:#0563c1; text-decoration:underline\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://academic.oup.com/ajcp/article/146/suppl_1/314/2246854</span></strong></a></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schwartz&rsquo;s principles of surgery- 10th edition page no:520</span></strong></span></span></p>",
    "correct_choice_id": 46210,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11564,
    "choices": [
      {
        "id": 46222,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">85%</span></span></span></p>"
      },
      {
        "id": 46223,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">95%</span></span></span></p>"
      },
      {
        "id": 46224,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">99%</span></span></span></p>"
      },
      {
        "id": 46225,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">99.9%</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Positive predictive value of triple assessment for breast cancer:</span></span></p>",
    "unique_key": "Q2191898",
    "question_audio": null,
    "question_video": null,
    "map_id": 36931,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) 99.9%</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients presenting with a <strong>breast lump, nipple discharge</strong> or other symptoms are assessed by a combination of clinical examination (including history), radiological imaging and tissue sampling taken for either cytological or histological analysis. This <strong>combined approach is called &lsquo;triple assessment&rsquo;</strong>. The positive predictive value and diagnostic accuracy of this combination approach is 100%.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-192933.png\" style=\"height:320px; width:600px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 28<sup>th</sup> Edition fig 58.2.</span></strong></span></span></p>",
    "correct_choice_id": 46225,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11572,
    "choices": [
      {
        "id": 46254,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spiculations</span></span></span></p>"
      },
      {
        "id": 46255,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">III-defined margins </span></span></span></p>"
      },
      {
        "id": 46256,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Macrocalcification </span></span></span></p>"
      },
      {
        "id": 46257,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Irregular mass</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following features in mammography suggest malignancy except:</span></span></p>",
    "unique_key": "Q6739031",
    "question_audio": null,
    "question_video": null,
    "map_id": 36932,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Macrocalcification </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Macrocalcification&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Incorrect in this context. <strong>Macrocalcifications</strong> are typically <strong>larger calcium deposits within the breast</strong> and are <strong>more commonly associated with benign conditions</strong> rather than malignancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Spiculations:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spiculations are <strong>radiographic features that resemble spikes radiating from a mass</strong> and are highly suggestive of <strong>malignancy</strong> due to the invasive nature of certain cancers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Ill-defined Margins:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Cancers often have irregular</strong>, <strong>poorly defined edges</strong> on <strong>mammograms</strong>, which can indicate an <strong>aggressive growth pattern</strong> that does not respect normal tissue boundaries.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. (Irregular Mass):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An <strong>irregularly shaped mass on a mammogram</strong> is concerning for <strong>malignancy due to its non-uniform appearance</strong>, as benign masses are more likely to be round and well-circumscribed.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In <strong>mammography</strong>, features that <strong>raise suspicion for breast cancer include spiculations</strong>, <strong>ill-defined margins</strong>, and <strong>irregular masses</strong>, while <strong>macrocalcifications</strong> are generally associated with <strong>benign breast conditions</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Microcalcification&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(&lt;0.5 mm in diameter) in <strong>mammography</strong> is suggestive of <strong>malignancy</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Table: Mammographic appearance of benign and malignant masses</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-193304.png\" style=\"height:442px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Following is the sequence of malignancy in decreasing order ie. from highest risk to the least risk:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cluster microcalcification (maximum risk)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linear microcalcification</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Segmental micro calcification</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diffuse microcalcification (minimum risk)</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-193350.png\" style=\"height:481px; width:400px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Grainger &amp; Allison&rsquo;s Diagnostic Radiology 6<sup>th</sup> edition page nos. 1679 and 1674</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schwartz&rsquo;s principle of surgery -10<sup>th</sup> edition page no. 509</span></strong></span></span></p>",
    "correct_choice_id": 46256,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11580,
    "choices": [
      {
        "id": 46286,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4b</span></span></span></p>"
      },
      {
        "id": 46287,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4c</span></span></span></p>"
      },
      {
        "id": 46288,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3</span></span></span></p>"
      },
      {
        "id": 46289,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4a</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The likelihood of a lesion on a mammogram being carcinomatous is 40%. The radiologist will report it as what BIRADS grade?</span></span></p>",
    "unique_key": "Q2271891",
    "question_audio": null,
    "question_video": null,
    "map_id": 36933,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 4b</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a lesion having 40% likelihood of being carcinomatous, the breast imaging reporting and system (BIRADS) category/grade is 4b.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/20/screenshot-2024-03-20-193623.png\" style=\"height:590px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&ldquo;In the <strong>UK</strong>, all <strong>women aged between 50 and 70 years</strong> are invited for <strong>mammographic screening every 3&nbsp;years</strong>. In low- and middle-income countries, population-based mammographic screening is not available. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In some Asian countries, clinical breast examination by a trained healthcare professional along with increasing breast health awareness by breast self-examination is being encouraged as a mode of screening. In India, national screening involves multi disease screening for cancer of the mouth, breast and cervix for all women aged 30&ndash;65 years&rdquo;</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 28<sup>th</sup> Ed pg 943.</span></strong></span></span></p>",
    "correct_choice_id": 46286,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11583,
    "choices": [
      {
        "id": 46298,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10%</span></span></span></p>"
      },
      {
        "id": 46299,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">20%</span></span></span></p>"
      },
      {
        "id": 46300,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">25%</span></span></span></p>"
      },
      {
        "id": 46301,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">30%</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman is planned for breast conservation surgery for T2N1M0 cancer of size 4.5 cm. The patient is inquiring regarding the need for breast reconstruction after wide local excision is done. For a woman with average size breasts, what proportion of breast can be excised, without the need for oncoplastic reconstruction?</span></span></p>",
    "unique_key": "Q3895017",
    "question_audio": null,
    "question_video": null,
    "map_id": 36934,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) 20%.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wide local excision&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(WLE) of <strong>up to 20%</strong> of the <strong>breast volume can be achieved by excision of the tumour</strong> with <strong>adequate margins</strong> and <strong>closure of the defect</strong> by approximation of the breast tissue with absorbable sutures. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Volume loss greater than 20%&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">or an <strong>unfavourable breast-to-tumour ratio</strong> requires an <strong>oncoplastic procedure to fill the defect</strong> so created by mobilising the breast tissue. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oncoplasty&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is defined as <strong>tumour excision with wide margins</strong> followed by <strong>repair of the defect by local rearrangement</strong>/ replacement of the breast tissue and the nipple&ndash;areola complex to maintain shape and symmetry. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This may be achieved by <strong>volume displacement</strong> (level 1) or by <strong>volume replacement</strong> using a <strong>distant or local fap</strong> (level 2)</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/21/screenshot-2024-03-21-095738.png\" style=\"height:632px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 28<sup>th</sup> Ed Pg 935, 937.</span></strong></span></span></p>",
    "correct_choice_id": 46299,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11585,
    "choices": [
      {
        "id": 46306,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mammography</span></span></span></p>"
      },
      {
        "id": 46307,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">USG </span></span></span></p>"
      },
      {
        "id": 46308,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI </span></span></span></p>"
      },
      {
        "id": 46309,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Choose the radiographic modality that you will use to assess a patient&rsquo;s breast containing silicone implants:</span></span></p>",
    "unique_key": "Q3422322",
    "question_audio": null,
    "question_video": null,
    "map_id": 36935,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) MRI </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is the <strong>preferred imaging modality for evaluating the integrity of breast implants</strong> and for <strong>assessing the breast tissue in women with implants</strong>. It is more sensitive and provides a detailed image without the interference of the implant material.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Mammography:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>mammography</strong> is the <strong>standard imaging modality for breast cancer screening</strong>, it has limitations in evaluating breasts with silicone implants, as the implants can obscure visualization of the breast tissue.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B (USG):</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ultrasound</strong> may help in <strong>evaluating certain areas of the breast</strong> and <strong>can be useful in distinguishing between fluid-filled cysts and solid masses</strong>, but it does not provide as comprehensive an assessment as MRI, especially in the presence of implants.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D (CT):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Computed tomography</strong> (CT) is <strong>not typically used for routine breast imaging due to its lower sensitivity for detecting small breast cancers</strong> and because it exposes the patient to a higher dose of radiation compared to mammography.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Magnetic resonance imaging&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(MRI) is the <strong>best imaging modality</strong> for the <strong>breasts of women with implants.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI of the breast is also used in:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Screening of individuals&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">with a <strong>positive family history/high risk of breast cancer</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Assessing loco-regional spread (multifocality and multicentricity) of carcinoma</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Differentiating scar form recurrence in women who have received breast conservation therapy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and love&rsquo;s short practice of surgery -28th edition page no 916-917</span></strong></span></span></p>",
    "correct_choice_id": 46308,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11589,
    "choices": [
      {
        "id": 46322,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Imprint cytology</span></span></span></p>"
      },
      {
        "id": 46323,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sentinel LN biopsy </span></span></span></p>"
      },
      {
        "id": 46324,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fine-needle aspiration cytology</span></span></span></p>"
      },
      {
        "id": 46325,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tru Cut biopsy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following histopathological modalities is the best to confirm the diagnosis of breast carcinoma?</span></span></p>",
    "unique_key": "Q8782448",
    "question_audio": null,
    "question_video": null,
    "map_id": 36936,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Tru Cut biopsy </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tru Cut/core-needle biopsy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is the <strong>investigation of choice for confirming the diagnosis of breast carcinoma</strong>. If it is inconclusive, <strong>excisional biopsy can be done</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tru cut needle biopsy:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 14G-16 G needle is used.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It permits the analysis of breast tissue architecture.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The advantages include a low complication rate, minimal scarring, and a lower cost as compared to excisional breast biopsy.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A (Imprint Cytology):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This technique involves <strong>pressing a tissue sample onto a glass slide to transfer cells,</strong> which are then <strong>stained and examined under a microscope</strong>. While it can provide rapid results, it is not as definitive as a core-needle biopsy because it does not preserve tissue architecture.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B (Sentinel Lymph Node Biopsy):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This procedure is used to <strong>determine the spread of breast cancer by examining the first lymph node</strong>(s) to which cancer cells are likely to spread from the primary tumor. It is not used for the initial diagnosis of breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C (Fine-Needle Aspiration Cytology - FNAC):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FNAC uses a <strong>thin needle to extract cells from a breast lump</strong>. It is <strong>less invasive</strong> than a <strong>core biopsy</strong> and can quickly suggest a diagnosis, but it may not be as definitive, particularly for distinguishing between in situ and invasive carcinomas.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fine-needle aspiration cytology (FNAC) is a cytological investigation done using a 22-30G needle and is not the investigation of choice. FNAC cannot determine if a tumor is invasive or in situ. It is, however, the initial investigation in many cases. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Image-guided biopsy is used only in the case of non-palpable lesions.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Schwartz principle of surgery -9<sup>th</sup> edition page no 529, Bailey 28<sup>th</sup> Ed pg 918.</span></strong></span></span></p>",
    "correct_choice_id": 46325,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11591,
    "choices": [
      {
        "id": 46330,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stop taking OCP</span></span></span></p>"
      },
      {
        "id": 46331,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DO mammography annually</span></span></span></p>"
      },
      {
        "id": 46332,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic counseling &amp; BRCA testing</span></span></span></p>"
      },
      {
        "id": 46333,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate prophylactic mastectomy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 37-year-old unmarried female, nulliparous having regular sexual intercourse, on OCPs since last 3 years, gives the history that her mother had carcinoma breast at 50 years of age and sister had ovarian cancer at 40 years of age. What will you advise as the next step? </span></span></p>",
    "unique_key": "Q7329512",
    "question_audio": null,
    "question_video": null,
    "map_id": 36937,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Genetic counseling and BRCA testing</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic Counseling &amp; BRCA Testing&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given her <strong>family history of breast</strong> and <strong>ovarian cancer</strong>, <strong>genetic counseling</strong> and <strong>BRCA testing are indicated.</strong> This will help to determine her risk for developing these cancers and guide appropriate surveillance and preventive strategies.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Stop taking OCP:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral contraceptive pills (OCPs) have been <strong>associated with a slightly increased risk of breast cancer</strong>, but they also <strong>offer protective effects against ovarian cancer</strong>. The decision to stop OCPs should be individualized based on a detailed risk assessment.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Do Mammography Annually:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While annual mammography is <strong>important for breast cancer screening</strong>, <strong>starting annual mammograms at 37</strong> without other indications might not be necessary, and it does not address her genetic risk.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Immediate Prophylactic Mastectomy:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prophylactic mastectomy may be <strong>considered for those with a confirmed high genetic risk</strong> (BRCA positive), but it is not the immediate next step before genetic risk is assessed.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a patient with a <strong>family history of breast and ovarian cancer</strong>, the <strong>next step is genetic counseling</strong> and <strong>BRCA testing to assess hereditary cancer risk</strong> and guide further preventive measures, rather than immediate prophylactic surgery or alteration of contraceptive practices.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indications for genetic risk evaluation </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An individual at any age with a known pathogenic/likely pathogenic variant in a cancer susceptibility gene within the family </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast cancer diagnosed age &le;50 years</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">TNBC diagnosed age &le;60 years </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Two breast cancer primaries </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast cancer at any age with one or more relative with breast cancer diagnosed &le;50 years, invasive ovarian cancer, male breast cancer, pancreatic cancer, high-grade or metastatic prostate cancer </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast cancer at any age with two or more affected relatives </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Male breast cancer</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 28<sup>th</sup> Ed. Summary box 58.5</span></strong></span></span></p>",
    "correct_choice_id": 46332,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11594,
    "choices": [
      {
        "id": 46342,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oil of evening primrose</span></span></span></p>"
      },
      {
        "id": 46343,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Danazol</span></span></span></p>"
      },
      {
        "id": 46344,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen</span></span></span></p>"
      },
      {
        "id": 46345,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lumpectomy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of these are components in management of cyclical mastalgia in women suffering from ANDI breast except:</span></span></p>",
    "unique_key": "Q7266795",
    "question_audio": null,
    "question_video": null,
    "map_id": 36938,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Lumpectomy</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lumpectomy&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong>surgical procedure to remove a breast lump</strong> and is <strong>not typically indicated for the management of mastalgia</strong>, which is usually treated medically.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Oil of Evening Primrose:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Evening primrose oil is <strong>rich in gamma-linolenic acid</strong> and is <strong>used as a dietary supplement</strong> to manage the symptoms of <strong>cyclical mastalgia</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Danazol:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Danazol is a <strong>synthetic steroid that alters the hormonal milieu and is often used in the treatment of severe mastalgia</strong>. It&#39;s an effective, though less commonly used treatment due to its side effect profile.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tamoxifen:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen is a <strong>selective estrogen receptor modulator</strong> used in the <strong>management of breast pain</strong>, particularly when it&#39;s severe or resistant to other treatments.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For <strong>women suffering from cyclical mastalgia due to ANDI</strong> (aberrations of normal development and involution), <strong>management typically includes supportive measures and medications such as evening primrose oil</strong>, <strong>tamoxifen</strong>, or<strong> danazol</strong>. Lumpectomy is not a component of managing cyclical mastalgia as it is a surgical intervention reserved for the removal of lumps with potential or confirmed malignancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Management of Mastalgia: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reassure adequate support</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tight sports brassiere during the day </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Use a VAS breast pain chart to record severity </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Consider medication </span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flax seeds or Oil of evening primrose </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Topical NSAID cream (diclofenac or piroxicam)- Useful in mild to moderate mastalgia </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Consider systemic medication if pain score &gt;3 on a VAS of 0-10 </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen 10&nbsp;mg daily For 3&ndash;6 months </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Danazol 50&ndash;300&nbsp;mg daily For 3&ndash;6 months </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Meloxifene 30&nbsp;mg twice For 3&ndash;6 months used in both cyclical a week and non-cyclical mastalgia and for treating nodularity</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LHRH agonist of Short duration: use for 3 months with anti estrogen: recalcitrant pain not relieved by the tamoxifen or raloxifene.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey 28<sup>th</sup> E. table 58.2</span></strong></span></span></p>",
    "correct_choice_id": 46345,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 15782,
    "choices": [
      {
        "id": 63088,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Wound exploration&nbsp;</span></span></span></span></span></p>"
      },
      {
        "id": 63089,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Indirect laryngoscopy for vocal palsy&nbsp;</span></span></span></p>"
      },
      {
        "id": 63090,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Serum calcium level&nbsp;</span></span></span></p>"
      },
      {
        "id": 63091,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Serum TSH, free T3 and T4 level&nbsp;</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">2 days post total thyroidectomy, patient complains of peri-oral tingling. What would be the next step?&nbsp;</span></span></span></span></span></p>",
    "unique_key": "Q3986023",
    "question_audio": null,
    "question_video": null,
    "map_id": 36942,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: C. Serum calcium level&nbsp;</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">&ldquo;This is due to removal of the parathyroid glands or infarction through damage to the parathyroid end arteries; often both factors occur together. Vascular injury is probably far more important than inadvertent removal. </span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">The incidence of permanent hypoparathyroidism should be less than 1% and most cases present dramatically 2&ndash;5 days after operation; very rarely, the onset is delayed for 2&ndash;3 weeks or a patient with marked hypocalcaemia may be asymptomatic. The complication is limited to total thyroidectomy, as when lobectomy is performed the contralateral parathyroid glands are sufficient to maintain calcium levels. </span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">In particular, total thyroidectomy with central neck dissection places the parathyroid glands and their vascular supply at great risk and should only be performed when there is evidence of metastatic disease or high risk of occult disease in the regional lymph nodes.&rdquo;&nbsp;</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">For mild hypocalcemia, oral calcium and severe hypocalcemia, intravenous Calcium gluconate are supplemented.&nbsp;</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:black\">Ref</span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"background-color:white\"><span style=\"color:black\">: Bailey 28<sup>th</sup>&nbsp;Ed. Pg. 866.</span></span></span></span></span></span></p>",
    "correct_choice_id": 63090,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 15783,
    "choices": [
      {
        "id": 63092,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Ligation of ITA away from the gland&nbsp;</span></p>"
      },
      {
        "id": 63093,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Ligation of STA away from the gland&nbsp;</span></p>"
      },
      {
        "id": 63094,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Ligation of ITA close to the gland&nbsp;</span></p>"
      },
      {
        "id": 63095,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Ligation of STA close to the gland&nbsp;</span></p>"
      }
    ],
    "text": "<p><span style=\"background-color:white;color:black;font-size:12.0pt;\">Which of these manoeuvres will prevent post op hypoparathyroidism in thyroidectomy (STA= Superior thyroid artery, ITA= Inferior thyroid artery)?&nbsp;&nbsp;</span></p>",
    "unique_key": "Q1720729",
    "question_audio": null,
    "question_video": null,
    "map_id": 36943,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"background-color:white;color:black;font-size:12.0pt;\"><strong>Ans: C&nbsp;Ligation of ITA close to the gland</strong></span></p><p>&nbsp;</p><p><span style=\"background-color:white;color:black;font-size:12.0pt;\">Truncal ligation of the inferior thyroid artery away from the gland can lead to hypoparathyroidsm due to ischemia. Both superior and inferior parathyroid glands receive their blood supply from ITA which arises from the subclavian arteries. Hence, during thyroidectomy, only the capsular branches closer to the thyroid gland should be ligated.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"background-color:white;color:black;font-size:12.0pt;\">Sometimes the parathyroid glands may have variable blood supply from thyroid-ima artery.</span></p><p>&nbsp;</p><p><span style=\"background-color:white;color:black;font-size:12.0pt;\"><strong>Reference</strong>: Gray\u2019s anatomy: the anatomical basis of clinical practice , 41<sup>st</sup>&nbsp;edition, page 618&nbsp;</span></p><p><br><span style=\"background-color:white;color:black;font-size:12.0pt;\">Schwartz\u2019s principle of surgery 10<sup>th</sup>&nbsp;edition, pages 1553-1554&nbsp;</span></p>",
    "correct_choice_id": 63094,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 15784,
    "choices": [
      {
        "id": 63096,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">Emergency cricothyrotomy&nbsp;</span></span></span></span></span></p>"
      },
      {
        "id": 63097,
        "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Emergency tracheostomy&nbsp;</span></span></span></p>"
      },
      {
        "id": 63098,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Shift to OT and remove sutures of wound&nbsp;</span></span></span></p>"
      },
      {
        "id": 63099,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">Needle thoracotomy in triangle of safety&nbsp;</span></span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">After total thyroidectomy, in post-operative recovery room, patient experienced acute breathlessness and cyanosis. His O2 saturation dropped to 85%. What is the next step?&nbsp;</span></span></span></span></span></p>",
    "unique_key": "Q5652580",
    "question_audio": null,
    "question_video": null,
    "map_id": 36944,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: C. Shift to OT and remove sutures of wound&nbsp;</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">&ldquo;Haemorrhage is the most frequent life-threatening complication of thyroidectomy. Around 1 in 50 patients will develop a haematoma, and in almost all cases this will develop in the first 24 hours. If an arterial bleed occurs, the tension in the central compartment pressure can rise until it exceeds venous pressure. Venous oedema of the larynx can then develop and cause airway obstruction, leading to death. </span></span></span></span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">If a haematoma develops, clinical staff should know to remove skin sutures in order to release some pressure and seek senior advice immediately. Endotracheal intubation should be used to secure the airway while the haematoma is evacuated and the bleeding point controlled.&rdquo;&nbsp;</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ref: </span></span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"color:black\">Bailey 28<sup>th</sup>&nbsp;Ed. Pg 865.</span></span>&nbsp;</span></span></span></p>",
    "correct_choice_id": 63098,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11668,
    "choices": [
      {
        "id": 46638,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroid</span></span></span></p>"
      },
      {
        "id": 46639,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Prostate</span></span></span></p>"
      },
      {
        "id": 46640,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Gastric</span></span></span></p>"
      },
      {
        "id": 46641,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Colorectal</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">AGES, AMES, MACIS are all prognostic indicators of which carcinoma?</span></span></span></p>",
    "unique_key": "Q3405687",
    "question_audio": null,
    "question_video": null,
    "map_id": 36952,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: A. Thyroid </span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Prognostic indicators of well differentiated thyroid cancers:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">AGES: Age, Histological Grade. Extrathyroidal invasion and metastases, and tumour Size</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">AMES: Age (men&lt;40y , women &lt;50y),Metastases, Extrathyroidal spread and Size of tumours (&lt; or &gt;5cm)</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">MACIS scale (post op modification); distant Metastases, Age at presentation,(&lt;40 or &gt;40 years old), Completeness of original surgical resection, extrathyroidal Invasion, and size of original lesion in cms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reference:</span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> Schwartz&rsquo;s Principles of surgery:10<sup>th</sup> edition, page no 1543</span></span></span></p>",
    "correct_choice_id": 46638,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11606,
    "choices": [
      {
        "id": 46390,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroglossal tract only</span></span></span></p>"
      },
      {
        "id": 46391,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Central part of hyoid bone and thyroglossal tract </span></span></span></p>"
      },
      {
        "id": 46392,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroglossal tract and part of thyroid</span></span></span></p>"
      },
      {
        "id": 46393,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroglossal tract and associated cervical lymph nodes</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A child with a midline swelling in the neck, has to undergo a sistrunk procedure. Along with en bloc cystectomy, what other structures will the surgeon resect?</span></span></span></p>",
    "unique_key": "Q1210567",
    "question_audio": null,
    "question_video": null,
    "map_id": 36953,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Answer: B. Central part of hyoid bone and thyroglossal tract </span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sistrunk operation involves en bloc cystectomy with excision of the entire thyroglossal tract till the base of the tongue along with the central hyoid bone.&nbsp; It is the procedure of choice for the surgical management of thyroglossal cysts. Aim of surgery is to prevent recurrence and malignant transformation.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common malignancy in a thyroglossal cyst is papillary carcinoma. In such cases, sistrunk operation with total thyroidectomy is done.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Schwartz&rsquo;s principles of surgery 10<sup>th</sup> edition page no 1522</span></span></p>",
    "correct_choice_id": 46391,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11609,
    "choices": [
      {
        "id": 46402,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Lahey&rsquo;s method</span></span></span></p>"
      },
      {
        "id": 46403,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Crile&rsquo;s method</span></span></span></p>"
      },
      {
        "id": 46404,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pizzillo<span style=\"color:black\"> method</span></span></span></p>"
      },
      {
        "id": 46405,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Kocher&rsquo;s method</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A doctor uses this method to palpate the midline swelling in the neck. Choose the correct option.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/picture1_ufYFscg.png\" style=\"height:666px; width:800px\" /></span></span></span></p>",
    "unique_key": "Q5702353",
    "question_audio": null,
    "question_video": null,
    "map_id": 36954,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: </span></span></strong><strong><span style=\"font-size:12.0pt\">B. Crile&rsquo;s method</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The following image depicts Crile&rsquo;s method of palpation. Here, the patient is asked to swallow, while the examiner palpates the gland with the thumb. This method is sensitive in detecting a slight enlargement of the thyroid gland or small nodules.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Other methods:</span></span></span></span></p>\r\n\r\n<ol style=\"list-style-type:upper-alpha\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Lahey&rsquo;s method: the lobes of the gland are pushed to one side for palpation. For palpating the left lobe, the examiner should push the lobe laterally </span></span><span style=\"font-size:12.0pt\">with the left<span style=\"color:black\"> hand and the lobe is palpated </span>using the right<span style=\"color:black\"> hand.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Pizillo method: employed only in patients with short necks, usually in obese patients</span></span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Kocher&rsquo;s method: done to </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">demonstrate the pressure<span style=\"color:black\"> effect of the thyroid gland on the trachea or larynx. Lateral compression will result in stridor.</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ref: S. Das A manual on clinical surgery. Pg 378-380</span></span></strong></span></span></p>",
    "correct_choice_id": 46403,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11619,
    "choices": [
      {
        "id": 46442,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Cystic lesion</span></span></span></p>"
      },
      {
        "id": 46443,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Follicular lesion</span></span></span></p>"
      },
      {
        "id": 46444,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Lesion suspicious of malignancy</span></span></span></p>"
      },
      {
        "id": 46445,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Non neoplastic lesion</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 27 year old female underwent an FNAC for a discrete thyroid swelling. The report showed a Thy2 lesion. What is your inference?</span></span></span></p>",
    "unique_key": "Q1966484",
    "question_audio": null,
    "question_video": null,
    "map_id": 36939,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans: D. Non neoplastic lesion</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FNAC reporting according to the Royal College of Pathologists UK:</span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_eORTQDr.jpg\" style=\"height:541px; width:800px\" /></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Reference:</span></strong><span style=\"font-size:12.0pt\"> Bailey and Love 27<sup>th</sup> edition, page 805</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sabiston textbook of surgery 2oth edition, page 898</span></span></p>",
    "correct_choice_id": 46445,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11630,
    "choices": [
      {
        "id": 46486,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">4-6 hours</span></span></span></p>"
      },
      {
        "id": 46487,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">20-24 hours</span></span></span></p>"
      },
      {
        "id": 46488,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">12-14 hours</span></span></span></p>"
      },
      {
        "id": 46489,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">8-10 days</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A patient underwent a thyroid radionuclide scan. She consumed I<sup>123 </sup>at 7 AM. What is the half life of this drug?</span></span></span></p>",
    "unique_key": "Q6313881",
    "question_audio": null,
    "question_video": null,
    "map_id": 36948,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: C. 12-14 hours</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">The half-life of I<sup>123 </sup>is 12-14 hours. Both I<sup>123 </sup>and I<sup>131 </sup>are used to image the thyroid gland.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_mFuR2cs.jpg\" style=\"height:355px; width:800px\" /></span></span></span></p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reference:</span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> Schwartz&rsquo;s principles of surgery &ndash; 10<sup>th</sup> edition page number 1529</span></span></span></p>",
    "correct_choice_id": 46488,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11631,
    "choices": [
      {
        "id": 46490,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Sternal incision is always required to operate.</span></span></span></p>"
      },
      {
        "id": 46491,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Most of the retrosternal goiters can be removed by neck incision</span></span></span></p>"
      },
      {
        "id": 46492,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">It receives blood supply from the thoracodorsal artery</span></span></span></p>"
      },
      {
        "id": 46493,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Operated in all patients regardless of symptoms</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Following options are a few statements about retrosternal goiter. Choose the correct statement.</span></span></span></p>",
    "unique_key": "Q2323484",
    "question_audio": null,
    "question_video": null,
    "map_id": 36949,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: B. Most of the retrosternal goiters can be removed by neck incision</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most of the retrosternal goiters&nbsp; can be removed by neck incision (transcervical.)</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option A: median sternotomy approach is indicated in:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Primary mediastinal goitre</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Malignant retrosternal goitre</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Very large retrosternal goiter</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Recurrence in mediastinum for a primary mediastinal goitre whose boundaries or completely within the chest, resection is often achieved through a median sternotomy or thoracotomy to ensure that the vessels supplying the tumour are properly ligated. Removing the tumour through a cervical approach can result in uncontrolled bleeding and is generally avoided.</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C: blood supply to retrosternal goitre is from the thyroid vessel.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option D: surgical removal of the retrosternal goiter is indicated in patients with significant airway compression, in young patients who have symptoms such as dyspnea or dysphagia.</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reference:</span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> Bailey and Love 27<sup>th</sup> edition, pages 810,811</span></span></span></p>",
    "correct_choice_id": 46491,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11633,
    "choices": [
      {
        "id": 46498,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 24 year old woman with FNAC report of Bethesda category 4</span></span></span></p>"
      },
      {
        "id": 46499,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 60 year old man with FNAC report of Thy2</span></span></span></p>"
      },
      {
        "id": 46500,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 15 year old with recurrence of thyroid cyst</span></span></span></p>"
      },
      {
        "id": 46501,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 66 year old man with positive Pemberton&rsquo;s sign</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P<span style=\"color:black\">atients present in your OPD, with the following reports. To which patient will you least likely advise surgery?</span></span></span></p>",
    "unique_key": "Q6645327",
    "question_audio": null,
    "question_video": null,
    "map_id": 36951,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: B. A 60 year old man with FNAC report of Thy2</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">FNAC report Thy2 is suggestive of non neoplastic origin and is not an indication for surgery.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Indications for surgical management of thyroid swellings are in the following:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Neoplasia: FNAC positive Thy3-5 and clinical suspicion</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Age</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Male sex</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hard texture</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Fixity</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Recurrent laryngeal nerve palsy</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Recurrent cyst</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Lymphadenopathy</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Toxic adenoma</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Pressure symptoms</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cosmesis </span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Patient&rsquo;s wishes</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reference:</span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> bailey and love 27<sup>th</sup> edition, page 810</span></span></span></p>",
    "correct_choice_id": 46499,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11641,
    "choices": [
      {
        "id": 46530,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">In the TE groove as it forms one part of the Beahrs triangle</span></span></span></p>"
      },
      {
        "id": 46531,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">At the level of the Berry&rsquo;s ligament as it enters the larynx</span></span></span></p>"
      },
      {
        "id": 46532,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">As the nerve loops around the aorta</span></span></span></p>"
      },
      {
        "id": 46533,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Under the tubercle of Zuckerlandl on the posterolateral position of the gland</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A surgeon is performing a thyroid surgery. Which of the following points poses the highest risk for recurrent laryngeal nerve injury?</span></span></span></p>",
    "unique_key": "Q9361223",
    "question_audio": null,
    "question_video": null,
    "map_id": 36945,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: B. At the level of the Berry&rsquo;s ligament as it enters the larynx</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Berry&#39;s ligament is formed by posterior condensation of the pretracheal fascia and is attached to the larynx. It has the highest risk for RLN injury.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">RLN is a branch of the vagus nerve. On the left, it recurs over the arch of aorta, and on the right over the subclavian artery.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Beahrs triangle also known as the recurrent laryngeal nerve triangle is formed by the:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Common carotid artery</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Inferior thyroid arteries</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Recurrent laryngeal nerve</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/picture1_2nXhQUx.png\" style=\"height:751px; width:800px\" /></span></span></span></p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reference:</span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> Bailey and Love 27<sup>th</sup> edition, page 801</span></span></span></p>",
    "correct_choice_id": 46531,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11642,
    "choices": [
      {
        "id": 46534,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Horner\u2019s syndrome</span></p>"
      },
      {
        "id": 46535,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Transient hypocalcemia</span></p>"
      },
      {
        "id": 46536,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Recurrent laryngeal nerve injury</span></p>"
      },
      {
        "id": 46537,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Post op hematoma</span></p>"
      }
    ],
    "text": "<p><span style=\"color:black;font-size:12.0pt;\">A 30 year old female underwent a </span><span style=\"font-size:12.0pt;\">retro-esophageal</span><span style=\"color:black;font-size:12.0pt;\"> goitre resection. She was found to have ptosis and loss of hemifacial sweating. What is your diagnosis?</span></p>",
    "unique_key": "Q9274743",
    "question_audio": null,
    "question_video": null,
    "map_id": 36955,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"background-color:white;color:black;font-size:12.0pt;\"><strong>Ans: A. Horner\u2019s syndrome</strong></span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\">The cervical sympathetic trunk is </span><span style=\"font-size:12.0pt;\">at risk</span><span style=\"color:black;font-size:12.0pt;\"> of injury in invasive thyroid cancers and </span><span style=\"font-size:12.0pt;\">retro-esophageal</span><span style=\"color:black;font-size:12.0pt;\"> goiters and may result in Horner\u2019s syndrome.</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\"><strong>Reference:</strong> Schwartz\u2019s principles of surgery 10<sup>th</sup> edition, page 1556</span></p>",
    "correct_choice_id": 46534,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11643,
    "choices": [
      {
        "id": 46538,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Medullary</span></span></span></p>"
      },
      {
        "id": 46539,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Papillary</span></span></span></p>"
      },
      {
        "id": 46540,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Anaplastic</span></span></span></p>"
      },
      {
        "id": 46541,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Follicular</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">In which of the following conditions will FNAC not differentiate benign from malignant goitre?</span></span></span></span></span></p>",
    "unique_key": "Q4056652",
    "question_audio": null,
    "question_video": null,
    "map_id": 36956,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: D. Follicular</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">FNAC is not useful in the diagnosis of follicular carcinoma of thyroid as it cannot differentiate between benign and malignant follicular lesions. Tru Cut biopsy is used to differentiate between them as follicular thyroid malignancy is defined by capsular and vascular invasion.</span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Other limitations of FNAC in thyroid disorders:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Can&rsquo;t distinguish between follicular carcinoma and adenoma</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cannot differentiate between hurthle cell carcinoma and adenoma</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Not useful in Riedel&rsquo;s thyroiditis</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Schwartz&rsquo;s principles of surgery 10<sup>th</sup> edition, page 1544</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Bailey and Love 27<sup>th</sup> edition page 818</span></span></span></p>",
    "correct_choice_id": 46541,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11652,
    "choices": [
      {
        "id": 46574,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">CECT</span></span></span></p>"
      },
      {
        "id": 46575,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">FNAC</span></span></span></p>"
      },
      {
        "id": 46576,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Open biopsy</span></span></span></p>"
      },
      {
        "id": 46577,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">RAI scan</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 55-year-old hypothyroid female patient presents with a painless, hard anterior neck mass, which progresses over weeks to years associated with dysphagia. On physical examination a hard, woody thyroid gland with fixation to the surrounding tissues was noticed. How will you investigate further?</span></span></span></p>",
    "unique_key": "Q5555171",
    "question_audio": null,
    "question_video": null,
    "map_id": 36940,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: C. Open biopsy</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The clinical scenario is suggestive of Riedel&rsquo;s thyroiditis, which is confirmed by an open thyroid biopsy. FNAC is inadequate due to the firm and fibrous nature of the gland.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Riedel&rsquo;s thyroiditis is invasive autoimmune fibrous thyroiditis where thyroid gland tissue is replaced by fibrous tissue. It is IgG4 related systemic disease characterised by:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Elevated serum IgG4 levels</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Lymphoplasmacytic infiltrate</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Abundance of IgG4 bearing plasma cells</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">It is associated with other focal sclerosing syndromes including mediastinal, retroperitoneal, periorbital, retro orbital fibrosis, and sclerosing cholangitis.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Clinical features:</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Occurs predominantly between 30-60 years</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Painless, hard anterior neck mass</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Progresses over weeks to years, to produce compressive symptoms like dysphagia, dyspnea, choking and hoarseness</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Symptoms of hypothyroidism and hypoparathyroidism as gland is replaced by fibrous tissue.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Physical exam reveals a hard, &ldquo;woody&rdquo; thyroid gland with fixation to surrounding tissues</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Treatment: </span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Surgery, high dose tamoxifen and thyroxine replacement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ref:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Bailey 28<sup>th</sup> Ed. Pg 872</span></span></span></span></span></p>",
    "correct_choice_id": 46576,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11653,
    "choices": [
      {
        "id": 46578,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Level V cervical node</span></span></span></p>"
      },
      {
        "id": 46579,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Level VI cervical node</span></span></span></p>"
      },
      {
        "id": 46580,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ectopic thyroid in anterior sternocleidomastoid muscle</span></span></span></span></span></p>"
      },
      {
        "id": 46581,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Mediastinal node</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Which of these represents lateral aberrant thyroid?</span></span></span></p>",
    "unique_key": "Q9318887",
    "question_audio": null,
    "question_video": null,
    "map_id": 36941,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: B. Level VI cervical node</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&ldquo;There is an extensive lymphatic network within and around the gland. Although some lymph channels pass directly to the deep cervical nodes, the subcapsular plexus drains principally to the central compartment </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">juxta thyroid<span style=\"color:black\"> &ndash; &lsquo;Delphian&rsquo; and paratracheal nodes and nodes on the superior and inferior thyroid veins (level VI) &ndash; and from there to the deep cervical (levels II, III, IV and V) and mediastinal groups of nodes (level VII)&rdquo;.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <span style=\"color:black\">Bailey 28<sup>th</sup> Ed. Pg 850.</span></span></span></p>",
    "correct_choice_id": 46579,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11654,
    "choices": [
      {
        "id": 46582,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Papillary</span></span></span></p>"
      },
      {
        "id": 46583,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Anaplastic</span></span></span></p>"
      },
      {
        "id": 46584,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Follicular</span></span></span></p>"
      },
      {
        "id": 46585,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Medullary</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Which is the most common thyroid malignancy that may be found in iodine deficient (endemic goitre) areas?</span></span></span></p>",
    "unique_key": "Q9504957",
    "question_audio": null,
    "question_video": null,
    "map_id": 36946,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: C. Follicular</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Follicular thyroid carcinoma is most common in iodine deficient areas whereas papillary carcinoma is most common in iodine sufficient areas.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Other most commons carcinomas:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most common primary thyroid cancer: papillary</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most common thyroid malignancy associated with radiation: papillary</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most common malignancy associated with lymphatic spread: papillary</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most common malignancy associated with blood and bone mets: follicular</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most common malignancy associated with multi nodular goitre: follicular</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Thyroid malignancy associated with amyloid stroma: medullary </span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Thyroid malignancy associated with MEN 2 syndrome: medullary</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most aggressive thyroid malignancy with worst prognosis: anaplastic</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroid malignancy with best prognosis: papillary</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ref</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">: Bailey Ed. 28<sup>th</sup> Pg. 866-868</span></span></span></span></span></p>",
    "correct_choice_id": 46584,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11656,
    "choices": [
      {
        "id": 46590,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">No further intervention </span></span></span></p>"
      },
      {
        "id": 46591,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Perform central neck dissection</span></span></span></p>"
      },
      {
        "id": 46592,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Perform RAI ablation</span></span></span></p>"
      },
      {
        "id": 46593,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Perform a total thyroidectomy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A patient presents with a Thy3 lesion on FNAC. He was posted for </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">hemithyroidectomy<span style=\"color:black\">. HPE shows the following findings. What is your next step of management?</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/picture1_6rUC0g5.png\" style=\"height:566px; width:800px\" /></span></span></span></p>",
    "unique_key": "Q8346443",
    "question_audio": null,
    "question_video": null,
    "map_id": 36947,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: D. Perform a total thyroidectomy</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Capsular invasion seen in image confirms follicular carcinoma, hence total thyroidectomy to be done.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">As FNAC shows Thy3 lesion, which is a follicular neoplasm, the frozen section of the excised specimen has to be evaluated. The presence of vascular invasion confirms follicular carcinoma.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Surgical management of differentiated thyroid cancers (DTCS) are as follows:</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_mRhxAzB.jpg\" style=\"height:607px; width:800px\" /></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference: </span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">schwartz&rsquo;s principles of surgery 11<sup>th</sup> edition page number 1651</span></span></span></span></span></p>",
    "correct_choice_id": 46593,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11664,
    "choices": [
      {
        "id": 46622,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Pregnant lady with papillary thyroid cancer</span></p>"
      },
      {
        "id": 46623,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Autonomous toxic nodule after 45 years</span></p>"
      },
      {
        "id": 46624,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">In follicular carcinoma of thyroid, after total thyroidectomy</span></p>"
      },
      {
        "id": 46625,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">In primary thyrotoxicosis after 45 years</span></p>"
      }
    ],
    "text": "<p><span style=\"color:black;font-size:12.0pt;\">Radioactive iodine ablation of thyroid is an absolute contraindication in?</span></p>",
    "unique_key": "Q3183830",
    "question_audio": null,
    "question_video": null,
    "map_id": 36950,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"background-color:white;color:black;font-size:12.0pt;\"><strong>Ans: A. Pregnant lady with papillary thyroid cancer</strong></span></p><p>&nbsp;</p><p><span style=\"background-color:white;color:black;font-size:12.0pt;\">It is contraindicated in pregnancy due to exposure of the fetus to radiation.</span></p><p>&nbsp;</p><p><span style=\"background-color:white;color:black;font-size:12.0pt;\"><strong>Therapeutic uses of RAI are:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"background-color:white;color:black;font-size:12.0pt;\">In primary thyrotoxicosis after 45 years</span></li><li><span style=\"background-color:white;color:black;font-size:12.0pt;\">In autonomous toxic nodule after 45 years, it is useful as remaining gland will still function adequately after RT</span></li><li><span style=\"color:black;font-size:12.0pt;\">In follicular carcinoma of thyroid, after total thyroidectomy, if there are secondaries elsewhere in the body, as in bones or lungs, then I<sup>131 </sup>is given.</span></li></ul><p>&nbsp;</p><p><span style=\"background-color:white;color:black;font-size:12.0pt;\"><strong>Ref</strong>: Bailey 28<sup>th</sup> Ed. Pg 862,870</span></p>",
    "correct_choice_id": 46622,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11666,
    "choices": [
      {
        "id": 46630,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Perform a re exploration of the thyroid gland</span></p>"
      },
      {
        "id": 46631,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Call her for a bi annual follow up</span></p>"
      },
      {
        "id": 46632,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">USG guided FNAC</span></p>"
      },
      {
        "id": 46633,
        "text": "<p><span style=\"color:black;font-size:12.0pt;\">Radioactive iodine ablation</span></p>"
      }
    ],
    "text": "<p><span style=\"color:black;font-size:12.0pt;\">A 45 year old woman has come to your clinic for a follow up after she underwent a total thyroidectomy 2 months back, for papillary thyroid carcinoma. On doing a whole body iodine scan, the report suggested a positive iodine scan. How will you proceed further in this case?</span></p>",
    "unique_key": "Q4085249",
    "question_audio": null,
    "question_video": null,
    "map_id": 36968,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"background-color:white;color:black;font-size:12.0pt;\"><strong>Ans: D. Radioactive iodine ablation</strong></span></p><p>&nbsp;</p><ul><li><span style=\"background-color:white;color:black;font-size:12.0pt;\">RAI ablation is undertaken when a whole body iodine scan is positive after a total thyroidectomy, for any differentiated thyroid cancer.</span></li><li><span style=\"background-color:white;color:black;font-size:12.0pt;\">The presence of ang metastatic or residual thyroid tissue after total thyroidectomy can be detected by observing the uptake of RAI in the entire body. To achieve uptake of radioiodine, TSH levels need to be greatly increased.</span></li><li><span style=\"background-color:white;color:black;font-size:12.0pt;\">A positive whole body thyroid scan after total thyroidectomy indicates that there is either a metastatic or residual disease present. These patients will be treated by RAI ablation.</span></li><li><span style=\"background-color:white;color:black;font-size:12.0pt;\">A negative whole body iodine scan after total thyroidectomy indicates that there are no metastases or residual thyroid tissue present. These patients are followed up regularly with USG-neck, serum TG and TSH.</span></li></ul><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\">If the tumour is resistant to RAI, then EBRT(external </span><span style=\"font-size:12.0pt;\">beam</span><span style=\"color:black;font-size:12.0pt;\"> radiotherapy) is done.</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\"><strong>References:</strong></span><span style=\"font-size:12.0pt;\"> </span><span style=\"color:black;font-size:12.0pt;\">Bailey and Love: 27<sup>th</sup> edition, page 819</span></p>",
    "correct_choice_id": 46633,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11675,
    "choices": [
      {
        "id": 46666,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Anaplastic carcinoma of thyroid</span></span></span></p>"
      },
      {
        "id": 46667,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Medullary carcinoma of thyroid</span></span></span></p>"
      },
      {
        "id": 46668,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Papillary carcinoma of thyroid</span></span></span></p>"
      },
      {
        "id": 46669,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroid lymphomas</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">External low dose neck radiation predisposes to which kind of cancer most commonly?</span></span></span></p>",
    "unique_key": "Q7901580",
    "question_audio": null,
    "question_video": null,
    "map_id": 36971,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: C. Papillary carcinoma of thyroid.</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">History of low dose RT therapy to the head and neck for acne and tonsillitis and a cold nodule on RAI uptake scan are suggestive of papillary carcinoma.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">The great majority of thyroid cancers have no known aetiological factor. The most important identifiable aetiological factor in differentiated thyroid carcinoma (particularly papillary) is irradiation of the thyroid under 5 years of age. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference: </span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Bailey and Love 28<sup>th</sup> Edition: page 867</span></span></span></span></span></p>",
    "correct_choice_id": 46668,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11677,
    "choices": [
      {
        "id": 46674,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Local invasion of surrounding structures</span></span></span></p>"
      },
      {
        "id": 46675,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Cervical Lymph node enlargement </span></span></span></p>"
      },
      {
        "id": 46676,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Anaplastic thyroid cancer</span></span></span></p>"
      },
      {
        "id": 46677,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Hurthle Cell follicular carcinoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Sudden rapid enlargement of a pre- existent thyroid swelling was noticed in a 75 year old woman. She now has difficulty </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">swallowing<span style=\"color:black\"> and </span>talking<span style=\"color:black\">. What is the probable diagnosis?</span></span></span></p>",
    "unique_key": "Q9266860",
    "question_audio": null,
    "question_video": null,
    "map_id": 36973,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans: C. Anaplastic thyroid cancer</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anaplastic carcinoma is the most aggressive thyroid carcinoma with a poor prognosis. It usually occurs in elderly women above the age of 65 years and most often causes dysphagia. </span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Clinical features: </span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Rapidly enlarging neck mass</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Dysphagia</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cervical tenderness</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">History of untreated DTC</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hoarseness of voice and tracheal obstruction</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Diagnosis: </span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">FNAC. </span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Management:</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">&nbsp;If metastasis is absent: total thyroidectomy + LN dissection</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">If metastasis is&nbsp; present : palliative care with chemotherapy and radiotherapy</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">If tracheal obstruction : </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">isthmusectomy<span style=\"color:black\"> to relieve tracheal obstruction</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Bailey and love 27<sup>th</sup> edition, page 820</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Schwartz&rsquo;s principles of surgery 10<sup>th</sup> edition page 1550</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Sabiston textbook of surgery 20<sup>th</sup> edition pg 910</span></span></span></span></span></p>",
    "correct_choice_id": 46676,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11598,
    "choices": [
      {
        "id": 46358,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroglossal cyst</span></span></span></p>"
      },
      {
        "id": 46359,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Sub hyoid bursitis</span></span></span></p>"
      },
      {
        "id": 46360,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Cystic hygroma</span></span></span></p>"
      },
      {
        "id": 46361,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Dermoid cysts attached to hyoid bone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Which of the following swellings do not move with deglutition?</span></span></span></p>",
    "unique_key": "Q7240334",
    "question_audio": null,
    "question_video": null,
    "map_id": 36966,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans: C. Cystic hygroma</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The thyroid gland is enclosed in a pre tracheal fascia, which is derived from the deep cervical fascia in the neck. The pre tracheal fascia condenses posteriorly to the Berry&rsquo;s ligament that attaches the thyroid gland to the trachea. Hence, on deglutition, the swelling moves.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Reference: Schwartz&rsquo;s principles of surgery 10<sup>th</sup> edition page no. 1522</span></strong></span></span></p>",
    "correct_choice_id": 46360,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11613,
    "choices": [
      {
        "id": 46418,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroid antibodies</span></span></span></p>"
      },
      {
        "id": 46419,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">USG neck</span></span></span></p>"
      },
      {
        "id": 46420,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Fine needle aspiration cytology</span></span></span></p>"
      },
      {
        "id": 46421,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Radioactive iodine uptake</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A patient with 3x2 cm nodular thyroid swelling underwent a thyroid profile. Normal T4 and TSH levels were seen. What is the next best step in management?</span></span></span></p>",
    "unique_key": "Q4767807",
    "question_audio": null,
    "question_video": null,
    "map_id": 36972,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: </span></span></strong><strong><span style=\"font-size:12.0pt\">B. USG neck</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">USG is the next best step in the evaluation of a euthyroid patient with a solitary thyroid nodule. USG helps to classify the risk of the nodule into benign and malignant.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Benign nodules are easily compressible and can be seen to deform by applying pressure with the probe while performing USG. Malignant nodules tend to be hard and firm.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">USG findings of a nodule that are considered suspicious of malignancy are:</span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hypervascularity</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Spiculations</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Infiltrative margins</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hypoechoic compared to surrounding parenchyma</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:120px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference: Bailey and Love:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> edition 27, page 808, 809</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Sabiston textbook of surgery 20<sup>th</sup> edition, page 890</span></span></span></p>",
    "correct_choice_id": 46419,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11628,
    "choices": [
      {
        "id": 46478,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">80%</span></span></span></p>"
      },
      {
        "id": 46479,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">20%</span></span></span></p>"
      },
      {
        "id": 46480,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">90%</span></span></span></p>"
      },
      {
        "id": 46481,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">10%</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A radionuclide scan done in a patient with a thyroid nodular swelling, shows the following image. </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">How much is the<span style=\"color:black\"> risk of this pathology being benign?</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_zipAvOB.jpg\" style=\"height:887px; width:800px\" /></span></span></span></p>",
    "unique_key": "Q8456133",
    "question_audio": null,
    "question_video": null,
    "map_id": 36964,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans: A. 80%</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The uptake by the thyroid of a low dose of either radiolabeled iodine (<sup>123</sup>I) or the cheaper technetium (<sup>99m</sup>Tc) will demonstrate the distribution of activity in the whole gland. </span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Routine isotope scanning is unnecessary and inappropriate for distinguishing benign from malignant lesions because the majority (80%) of &lsquo;cold&rsquo; swellings are benign and some (5%) functioning or &lsquo;warm&rsquo; swellings will be malignant. Its principal value is in the toxic patient with a nodule or nodularity of the thyroid. </span></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reference:</span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> page 854 Bailey and Love edition 28<sup>th</sup> </span></span></span></p>",
    "correct_choice_id": 46478,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11638,
    "choices": [
      {
        "id": 46518,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Due to parathyroid gland</span></span></span></p>"
      },
      {
        "id": 46519,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Rough handling of thyroid during surgery</span></span></span></p>"
      },
      {
        "id": 46520,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Infections</span></span></span></p>"
      },
      {
        "id": 46521,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Inadequate patient preparation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Most usual cause of thyroid storm in thyroidectomy is?</span></span></span></p>",
    "unique_key": "Q4536448",
    "question_audio": null,
    "question_video": null,
    "map_id": 36969,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: D. Inadequate patient preparation</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The usual cause of thyroid storm in thyroidectomy is inadequate patient preparation, before surgery. Patient preparation of operatively involves ensuring a euthyroid state.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Thyroid storm/ thyrotoxic crisis:</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">It is an emergency caused by an acute exacerbation of hyperthyroidism. The precipitating factors include;</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">When a thyrotoxic patient has been inadequately prepared for thyroidectomy.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Abrupt cessation of anti thyroid medications</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Stress like</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Infections</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Thyroid or non thyroid surgery</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Trauma in patients with untreated thyrotoxicosis</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Acute iodine load</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Amiodarone administration</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Exposure to iodinated contrast agents</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Following RAI therapy</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Clinical features:</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Fever</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Tachycardia</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Altered mental state ( delirium, psychosis, coma)</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">GI symptoms: nausea, vomiting, diarrhoea</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Atrial fibrillation and cardiac failure: most common cause of death.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_JJR1jOY.jpg\" style=\"height:563px; width:800px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> bailey and love 27<sup>th</sup> edition page 815</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Schwartz&rsquo;s principles of surgery 10<sup>th</sup> edition, page 1534</span></span></span></p>",
    "correct_choice_id": 46521,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11639,
    "choices": [
      {
        "id": 46522,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Partial resection of each lobe removing the bulk of the gland</span></span></span></p>"
      },
      {
        "id": 46523,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Total resection of lobes on one side, with partial resection of the other side</span></span></span></p>"
      },
      {
        "id": 46524,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Total resection of one lobe with partial resection of three lobes</span></span></span></p>"
      },
      {
        "id": 46525,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Resection of two lobe with the removal of isthmus</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">The following statement best describes Hartley-Dunhill procedure:</span></span></span></p>",
    "unique_key": "Q9255033",
    "question_audio": null,
    "question_video": null,
    "map_id": 36970,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: B. Total resection of lobes on one side, with partial resection of the other side</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The Hartley Dunhill procedure involves total lobectomy on the affected side with subtotal resection of the less affected side.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Other thyroid surgeries:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Lobectomy: all or one thyroid lobe is removed</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hemithyroidectomy: total lobectomy of one lobe +isthmusectomy</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Subtotal thyroidectomy: 2x subtotal lobectomy (leaving greater than 4g of thyroid tissue on each lobe) + isthmusectomy.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Near total thyroidectomy: total lobectomy but leaving less than 1g tissue adjacent to the RLN at the ligament of Berry on one lobe + isthmusectomy (Hartley-dunhill procedure)</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Total thyroidectomy: 2x total lobectomy + isthmusectomy</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reference:</span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> Bailey and Love 27<sup>th</sup> edition, page 807</span></span></span></p>",
    "correct_choice_id": 46523,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11646,
    "choices": [
      {
        "id": 46550,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">1,4,5</span></span></span></p>"
      },
      {
        "id": 46551,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">2,3</span></span></span></p>"
      },
      {
        "id": 46552,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">2,3,4</span></span></span></p>"
      },
      {
        "id": 46553,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">1,2,3,4</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A histopathology section of thyroid gland is shown here. The arrow marks certain cells of the thyroid gland. Which carcinoma will arise from the following cells?</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/picture1_JlmzGEb.png\" style=\"height:626px; width:800px\" /></span></span></span></p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"color:black\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Papillary</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"color:black\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Follicular</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"color:black\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hurthle cell</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"color:black\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anaplastic</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"color:black\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Medullary</span></span></span></span></span></li>\r\n</ol>",
    "unique_key": "Q6695266",
    "question_audio": null,
    "question_video": null,
    "map_id": 36959,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: &nbsp;D. 1,2,3,4</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The above cells marked by the arrow are follicular cells of thyroid gland. Papillary, follicular and anaplastic thyroid carcinomas are all cancers of follicular epithelium of thyroid. Hurthle cell carcinoma is a variant of follicular thyroid carcinoma.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Classification of thyroid neoplasms:</span></span></span></span></span></p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"color:black\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benign: follicular adenoma</span></span></span></span></span></li>\r\n</ol>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Malignant:</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_lbhW22D.jpg\" style=\"height:522px; width:800px\" /></span></span></span></p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reference : </span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Bailey and Love 27<sup>th</sup> edition page 816</span></span></span></p>",
    "correct_choice_id": 46553,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11648,
    "choices": [
      {
        "id": 46558,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Grave&rsquo;s disease</span></span></span></p>"
      },
      {
        "id": 46559,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Non </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">hodgkin&#39;s<span style=\"color:black\"> lymphoma</span></span></span></p>"
      },
      {
        "id": 46560,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Medullary carcinoma</span></span></span></p>"
      },
      {
        "id": 46561,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Hashimoto&rsquo;s thyroiditis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 20 year old female presented with a painless enlargement in the midline of her neck. The histology of the tissue is as follows. How will you diagnose this case?</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/picture1_N2t4oyv.png\" style=\"height:601px; width:800px\" /></span></span></span></p>",
    "unique_key": "Q3398039",
    "question_audio": null,
    "question_video": null,
    "map_id": 36957,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: D. Hashimoto&rsquo;s thyroiditis</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">On HPE, hashimoto&rsquo;s thyroiditis presents with the following features:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Follicular destruction</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reduced colloid with increased interstitial connective tissue</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Small lymphocyte and plasma cell infiltration</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">A well developed germinal centre maybe seen</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hurthle cells that have abundant eosinophilic granular cytoplasm lining the follicles.</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hashimoto&rsquo;s thyroiditis is the most common cause of hypothyroidism in iodine sufficient areas. It is also known as lymphomatosa or lymphocytic thyroiditis. It&#39;s an autoimmune disease that results in the destruction of the thyroid gland and gradual and progressive thyroid failure.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Clinical features:</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most prevalent between 45-65 years </span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">More common in females</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Painless thyroid enlargement</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hashitoxicosis: when the autoantibodies attack and damage the follicles. There is a sudden release of thyroid hormones from these follicles. This leads to a transient phase of thyrotoxicosis.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Hypothyroidism: these patients tend to be in a state of hypothyroidism.</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Diagnosis:</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">TSH raised</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">T3 and T4 low</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Autoantibodies against thyroid receptors, thyroid peroxidase, thyroglobulin</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Management: </span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Thyroid hormone replacement therapy</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">In patients with long standing goiter, there is a risk of compressive features and development of thyroid lymphoma. Such cases need total thyroidectomy. It may also predispose to papillary thyroid carcinoma.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Other antibodies seen in other diseases:</span></span></span></span></span></p>\r\n\r\n<ol style=\"list-style-type:upper-alpha\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Grave&rsquo;s disease: TSI (TSH receptor stimulating immunoglobulins)</span></span></span></span></span></li>\r\n</ol>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Transient congenital hypothyroidism (maternal autoimmune thyroid disease): TRBAb</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Robbins and Cotran Pathologic Basis of Diseases. Page no 1087</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Schwartz&rsquo;s Principles of Surgery- 1oth edition page no 1535</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Sabiston Textbook of surgery 20<sup>th</sup> edition- page 891</span></span></span></p>",
    "correct_choice_id": 46561,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11651,
    "choices": [
      {
        "id": 46570,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Total/Near total thyroidectomy</span></span></span></p>"
      },
      {
        "id": 46571,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Long term antithyroid medication</span></span></span></p>"
      },
      {
        "id": 46572,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Subtotal<span style=\"color:black\"> thyroidectomy</span></span></span></p>"
      },
      {
        "id": 46573,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Radioactive iodine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 40-year-old lady </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">with painless<span style=\"color:black\"> neck swelling presented with palpitations and weight loss. Her thyroid function tests were done which revealed elevated T3, T4, low TSH and negative TSH-RAb. Iodine scan showed multiple thyroid nodules with increased iodine uptake. She was started on initial anti-thyroid treatment. What will be your next step in management?</span></span></span></p>",
    "unique_key": "Q2976714",
    "question_audio": null,
    "question_video": null,
    "map_id": 36960,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: A. Total/Near total thyroidectomy</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The given scenario is suggestive of toxic multinodular goitre. The next step of management once a euthyroid state is achieved is a near total thyroidectomy. Toxic nodular goitres are often large, uncomfortable, and are prone to recurrence. </span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">In a developing country like India, a near total thyroidectomy eliminates the risk of recurrence and simplifies follow-up. However, it causes immediate thyroid failure and necessitates lifelong thyroxine replacement.</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option B: Toxic multi nodular goiters show decreased response to anti thyroid drugs or may even enlarge further. Hence, surgery is recommended.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Option C: sub total thyroidectomies have high recurrence.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option D: Large goiters show decreased response to radioactive iodine, and also have an increased chance of recurrence.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ref:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Bailey 28<sup>th</sup> Ed. Pg 861-862</span></span></span></span></span></p>",
    "correct_choice_id": 46570,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11657,
    "choices": [
      {
        "id": 46594,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Antivirals</span></span></span></p>"
      },
      {
        "id": 46595,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Antibiotics</span></span></span></p>"
      },
      {
        "id": 46596,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">NSAIDs</span></span></span></p>"
      },
      {
        "id": 46597,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Antithyroid drugs</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 40 year old female presented with malaise, fever, painful neck swelling. She had recently recovered from an episode of URTI. Lab reports show elevated ESR, and elevated T4 levels. How will you manage this patient?</span></span></span></p>",
    "unique_key": "Q3124079",
    "question_audio": null,
    "question_video": null,
    "map_id": 36961,
    "difficulty_level": "difficult",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: C. NSAIDs</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The given scenario is suggestive of De Quervain&rsquo;s thyroiditis for which NSAIDs is the DOC. Here, T3 and T4 may be raised because of the release of preformed hormones from the destructed follicles.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Dequevrain&rsquo;s thyroiditis (sub acute or viral thyroiditis) is a granulomatous enlargement of the thyroid gland, usually following a viral infection. It is an inflammatory condition and not an infection as the thyroid gland is inherently resistant to infection due to the extensive blood supply and lymphatics, high iodide content and fibrous capsule.</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">This disease predominantly occurs in women between 30-40 years. The condition is self limiting and management is symptomatic, ie. aspirin and other NSAIDs. Steroids may be indicated in severe painful cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Reference:</span></span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> Bailey and Love&rsquo;s short practice of surgery 27<sup>th</sup> edition, page 822</span></span></span></p>",
    "correct_choice_id": 46596,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11658,
    "choices": [
      {
        "id": 46598,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroglobulin levels can be used to monitor patients for recurrence.</span></span></span></p>"
      },
      {
        "id": 46599,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Hematogenous spread is more common than lymphatic</span></span></span></p>"
      },
      {
        "id": 46600,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Mortality rate is twice that of papillary</span></span></span></p>"
      },
      {
        "id": 46601,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Osteoblastic bone metastasis is seen</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Choose the incorrect option with respect to follicular carcinoma:</span></span></span></p>",
    "unique_key": "Q4707032",
    "question_audio": null,
    "question_video": null,
    "map_id": 36962,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: D. Osteoblastic bone metastasis is seen</span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Osteolytic bone metastasis is seen in follicular thyroid carcinoma and not osteoblastic lesions. Thyroglobulin trends may be used to monitor patients with differentiated thyroid cancer for a recurrence. </span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Following total thyroidectomy, thyroglobulin levels must be undetectable. All thyroid carcinoma, except medullary thyroid carcinoma have osteolytic bone metastasis. Medullary thyroid cancer has osteoblastic bony metastasis.</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Follicular thyroid malignancy:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">It is more common in iodine deficient areas. It is associated with P 53, PTEN, PAX/PPAR-gamma, RaS, miRNA </span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">It commonly presents as solitary thyroid nodules and the mean age of presentation is 50 years. It can also occur in long-standing cases of multinodular goitre.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">FNAC is unable to distinguish between benign and malignant follicular lesions as malignancy is defined by capsular and vascular invasion hence trucut biopsy is required to confirm malignancy.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The histological findings include:</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Encapsulated</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Uniform micro follicles or sheets of cells devoid of colloid</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Capsular and vascular invasion indicates malignancy</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Tumour thrombus within middle thyroid/Jugular veins may be seen at the time of surgery.</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Vascular dissemination is common, with metastasis to bone, lungs, liver and elsewhere. The prognosis depends largely on the extent of invasion and stage at presentation.</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Serum thyroglobulin levels are used for monitoring tumour recurrence, as they aren&rsquo;t detectable after complete treatment.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Bailey and Love 27<sup>th</sup> edition page 818</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Schwartz&rsquo;s principles of surgery 10<sup>th</sup> edition page 1544</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Sabiston textbook of surgery 20<sup>th</sup> edition pg 904</span></span></span></p>",
    "correct_choice_id": 46601,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11659,
    "choices": [
      {
        "id": 46602,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Prophylactic neck dissection is done.</span></span></span></p>"
      },
      {
        "id": 46603,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Calcium supplementation is given post op</span></span></span></p>"
      },
      {
        "id": 46604,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Hemithyroidectomy is done</span></span></span></p>"
      },
      {
        "id": 46605,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroxine is withheld after surgery</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">A 35 year old patient came to the surgeon with a thyroid swelling </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">for<span style=\"color:black\"> 1 year. O/E the patient appeared euthyroid. Lymphadenopathy was a significant finding. The swelling was 3.5cm in size and was firm and immobile. A biopsy of the swelling showed the following histopathological picture. Choose the incorrect statement regarding management and post-op care.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_tjA8Umq.jpg\" style=\"height:507px; width:800px\" /></span></span></span></p>",
    "unique_key": "Q9109507",
    "question_audio": null,
    "question_video": null,
    "map_id": 36963,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: C. Hemithyroidectomy is done</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The above picture shows papillary formation with a fibrovascular stalk, characteristic orphan Anne nuclei and psammoma bodies, diagnostic of papillary carcinoma of the thyroid. Though the tumour is less than 4 cm, there is lymphadenopathy and hence total thyroidectomy with central neck dissection should be done.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Calcium supplementation is usually prescribed routinely to all patients after thyroidectomy to prevent symptoms of hypocalcemia.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Patients who are scheduled to receive RAI within 2-3 weeks of surgery may be discharged home without any thyroid hormone replacement. Thyroid hormone withdrawal raises the TSH level which stimulates radio iodine uptake and improves the efficacy of RAI.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Papillary thyroid cancer:</span></span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most common thyroid cancer</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most common in iodine sufficient areas, children and in those exposed to ionising radiation.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The mean age of presentation is 3<sup>rd</sup> to 4<sup>th</sup> decade and is more common in women than men. Dysphagia, dysphonia and dyspnea are associated with local invasion.</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">It usually presents as a cold nodule on the scan. Histological findings include:</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Branching papillae</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Follicles with fibrovascular stalk</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Psammoma bodies</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Nuclear changes:</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Optically clear: ground glass or Orphan Anne nuclei</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Pseudo-inclusions</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Nuclear grooves</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Lymph node mets are common. Lateral aberrant thyroid denotes a&nbsp; cervical lymph node invaded by papillary carcinoma. The most common sites of metastasis: lung&gt; liver &gt; bone&gt; brain.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Has excellent prognosis </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">with a 10 year<span style=\"color:black\"> survival rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Schwartz&rsquo;s principles of surgery 10<sup>th</sup> edition page 1647</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Sabiston textbook of surgery 20<sup>th</sup> edition pg 907</span></span></span></p>",
    "correct_choice_id": 46604,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11660,
    "choices": [
      {
        "id": 46606,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Medullary carcinoma</span></span></span></p>"
      },
      {
        "id": 46607,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Anaplastic carcinoma</span></span></span></p>"
      },
      {
        "id": 46608,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Hurthle cell carcinoma</span></span></span></p>"
      },
      {
        "id": 46609,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Thyroid lymphoma</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">HPE was done on a 50 year old patient </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">with a history<span style=\"color:black\"> of a diffuse enlargement of thyroid gland. Lab studies revealed low T3, T4, high TSH and the presence of anti TPO antibodies. The HPE showed enlarged cells with abundant eosinophilic cytoplasm. Which of the following malignancies is commonly associated with this condition?</span></span></span></p>",
    "unique_key": "Q9592121",
    "question_audio": null,
    "question_video": null,
    "map_id": 36965,
    "difficulty_level": "difficult",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: D. Thyroid lymphoma</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The case is suggestive of hashimoto&rsquo;s thyroiditis. Thyroid lymphomas are associated in long standing cases. These are usually non-hodgkin lymphomas often associated with long standing Hashimoto&rsquo;s thyroiditis.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">clinical features: </span></span></strong></span></span></span></p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Fatigue, 2. Weight gain, 3. Constipation, 4. Dry skin, 5. Hair loss, 6. Muscle and joint pain, 7. Depression, 8. Menstrual irregularities, 9. Enlarged thyroid gland.</span></span></span></span></span></li>\r\n</ol>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Diagnosis:</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Trucut biopsy preferred over FNAC since FNAC cannot characterize lymphomas.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Treatment:</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">R-CHOP regimen of chemotherapy is the first line of management. i.e., Rituximab, Cyclophosphamide, Hydroxydaunorubicin (Adriamycin), oncovin (vincristine), prednisolone.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Chemotherapy and radiotherapy are often sufficient. Total thyroidectomy can be done in recurrent cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Schwartz&rsquo;s principles of surgery 10<sup>th</sup> edition page 1538</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Bailey and Love 27<sup>th</sup> edition page 821</span></span></span></p>",
    "correct_choice_id": 46609,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 11661,
    "choices": [
      {
        "id": 46610,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Papillary carcinoma</span></span></span></p>"
      },
      {
        "id": 46611,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Medullary carcinoma</span></span></span></p>"
      },
      {
        "id": 46612,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Anaplastic carcinoma</span></span></span></p>"
      },
      {
        "id": 46613,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Follicular carcinoma </span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old male presented with rapidly growing neck mass. On examination, the mass was hard and bilateral neck nodes were palpable. He also gives history of recent unexplained diarrhea. <span style=\"color:black\">Which of the following thyroid malignancies will present with the following findings on histopathological examination?</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_a76Ac3u.jpg\" style=\"height:427px; width:600px\" /></span></span></span></p>",
    "unique_key": "Q9692242",
    "question_audio": null,
    "question_video": null,
    "map_id": 36967,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: B. Medullary carcinoma</span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The following picture is suggestive of medullary thyroid cancer. HPE shows the presence of amyloid deposits that are derived from the altered calcitonin molecules. </span></span></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Medullary thyroid cancer is a tumour of the parafollicular or C cells of the thyroid gland. </span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Aetiology: </span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Most of the MTCs are sporadic. Some have familial predisposition, derived from familial MTC, MEN2A, MEN2B.</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Clinical features: </span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Painful neck mass with cervical lymphadenopathy</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Dysphagia, Dyspnea or dysphonia if local invasion present</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Cushingoid habitus due to ectopic ACTH production</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Diarrhea due to increased intestinal motility by serotonin</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Metastasis through hematogenous route</span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Microscopically: sheets of neoplastic cells separated by collagen and amyloid stroma</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Diagnosis: </span></span></strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Raised calcitonin level, FNAC </span></span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Tumour markers: CEA, calcitonin</span></span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Treatment: </span></span></strong></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T<span style=\"color:black\">otal thyroidectomy with central neck node dissection. External beam RT can be used in patients with unresectable </span>tumours<span style=\"color:black\">. Targeted therapy using vandetanib, sorafenib, sunitinib and </span>cabozantinib<span style=\"color:black\"> can be considered too.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"background-color:white\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Reference:</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"> Schwartz&rsquo;s Principles of Surgery : 11<sup>th</sup> edition, page 1655 1656</span></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Robbins basic pathology 1oth edition, page 768</span></span></span></p>",
    "correct_choice_id": 46611,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 11671,
    "choices": [
      {
        "id": 46650,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">It has a much poorer prognosis compared to follicular thyroid cancer</span></span></span></p>"
      },
      {
        "id": 46651,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">The investigation of choice for its diagnosis is FNAC</span></span></span></p>"
      },
      {
        "id": 46652,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">They are often bilateral and multifocal</span></span></span></p>"
      },
      {
        "id": 46653,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Total thyroidectomy is the surgery of choice</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Which of the following statements is </span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">false<span style=\"color:black\"> with respect to the cancer shown in the below histopathological slide?</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_fhf1TGA.jpg\" style=\"height:397px; width:600px\" /></span></span></span></p>",
    "unique_key": "Q8721204",
    "question_audio": null,
    "question_video": null,
    "map_id": 36958,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans: </span></span></strong><strong><span style=\"font-size:12.0pt\">B. &nbsp;The investigation of choice for its diagnosis is FNAC</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The above clinical picture is that of a Hurthle cell follicular carcinoma. Hurthle cell carcinoma is a variant of follicular cell carcinoma.</span></span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">It has a poorer prognosis compared to follicular carcinomas as they are more likely to metastasize.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">They are often bilateral and multifocal.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">The HPE slide shows </span></span><span style=\"font-size:12.0pt\">predominance<span style=\"color:black\"> of oxyphil/Hurthle/Askanazy cells containing abundant mitochondria. </span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">They cannot be diagnosed on FNAC due to capsular and vascular invasion.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Surgical management is as follows:</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/26/screenshot-2023-04-26-123631_2Xcqwsm.jpg\" style=\"height:327px; width:800px\" /></span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ref</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">: Bailey 28<sup>th</sup> Ed. Pg 868-869</span></span></span></span></p>",
    "correct_choice_id": 46651,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 17342,
    "choices": [
      {
        "id": 69328,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thymus and inferior parathyroid gland </span></span></span></p>"
      },
      {
        "id": 69329,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thymus and superior parathyroid gland </span></span></span></p>"
      },
      {
        "id": 69330,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only superior parathyroid glands</span></span></span></p>"
      },
      {
        "id": 69331,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only inferior parathyroid glands</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given below is a picture of the pharyngeal pouches and arches. Which of the following structures are arises from the 3rd pharyngeal pouch?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/picture1_19yEKTy.jpg\" style=\"height:299px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q2762611",
    "question_audio": null,
    "question_video": null,
    "map_id": 17030,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Thymus and inferior parathyroid gland </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>3rd pharyngeal pouch</strong> gives <strong>rise to both the thymus and inferior parathyroid gland</strong>. This <strong>developmental origin</strong> explains their <strong>close proximity in the neck</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Thymus and superior parathyroid gland</strong>. <strong>Incorrect</strong>. The <strong>superior parathyroid gland</strong> arises from the <strong>4th pharyngeal pouch</strong>, not the 3rd.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The parathyroid glands develop from the third and fourth pharyngeal pouches</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. The <strong>thymus also develops from the third pouch</strong>. As it <strong>descends,</strong> the <strong>thymus</strong> takes the associated <strong>parathyroid gland with it</strong>, which explains why the <strong>inferior parathyroid</strong>, which <strong>arises from the third pharyngeal pouch</strong>, normally lies <strong>inferior to the superior gland</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The developing thyroid lobes amalgamate with the structures that arise in the fourth pharyngeal pouch, i.e., the superior parathyroid gland and the ultimobranchial body.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28th Ed. Pg 850</span></strong></span></span></p>",
    "correct_choice_id": 69328,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased"
    ]
  },
  {
    "id": 17343,
    "choices": [
      {
        "id": 69332,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyro-thymic tract </span></span></span></p>"
      },
      {
        "id": 69333,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intra-thyroidal </span></span></span></p>"
      },
      {
        "id": 69334,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Near upper pole</span></span></span></p>"
      },
      {
        "id": 69335,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mediastinal</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most common site for ectopic inferior parathyroid gland?</span></span></p>",
    "unique_key": "Q3962707",
    "question_audio": null,
    "question_video": null,
    "map_id": 17031,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Thyro-thymic tract </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is the correct answer. The <strong>thyro-thymic tract</strong> refers to the <strong>path of descent that the inferior parathyroid glands</strong> <strong>follow</strong> during <strong>embryonic development</strong>, from the <strong>third pharyngeal pouch down to their final position near the lower poles of the thyroid gland</strong>. It is common for <strong>ectopic parathyroid</strong> glands to be <strong>found along this tract</strong>, which may <strong>extend into the thymus</strong>, hence the term <strong>&#39;thyro-thymic.</strong>&#39;</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common site of <strong>ectopic parathyroid is thyro-thymic tract</strong>. Usually the <strong>inferior parathyroids</strong> are in <strong>abnormal location, due to longer descent</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/picture2.jpg\" style=\"height:528px; width:700px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Intra-thyroidal</strong> - While <strong>parathyroid glands</strong> can be <strong>found within the thyroid gland itself</strong>, this is less common than in the thyro-thymic tract. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Near upper pole</strong> - <strong>Parathyroid glands</strong> are generally <strong>located near the poles of the thyroid gland</strong>. However, the <strong>&#39;near upper pole&#39; is not the most common site for ectopic parathyroid glands</strong>. Typically, the superior parathyroids are located near the upper pole of the thyroid, while the inferior parathyroids are located near the lower pole.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Mediastinal</strong> - <strong>Mediastinal ectopic parathyroid glands</strong> are those that have <strong>descended past the normal location into the chest cavity</strong>. This is a less common site for ectopic glands compared to the thyro-thymic tract but is still a possible location for ectopic inferior parathyroid glands.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most common site for ectopic inferior parathyroid glands</strong> is the <strong>thyro-thymic tract</strong>, <strong>reflecting the embryological descent of these glands</strong> from the <strong>third pharyngeal pouch</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Bailey 28<sup>th</sup> Ed. Fig 56.1</span></strong></span></span></p>",
    "correct_choice_id": 69332,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17344,
    "choices": [
      {
        "id": 69336,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumour lysis syndrome </span></span></span></p>"
      },
      {
        "id": 69337,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parathyroid Adenoma</span></span></span></p>"
      },
      {
        "id": 69338,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Secondary hyperparathyroidism </span></span></span></p>"
      },
      {
        "id": 69339,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multiglandular Parathyroid hyperplasia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45 years old postmenopausal woman, presented to the OPD with back pains. Initial screening shows serum calcium levels of 11.7mg%, Vit. D is 55 ng/ml and elevated PTH. What might be the most common cause of such clinical manifestations?</span></span></p>",
    "unique_key": "Q4466728",
    "question_audio": null,
    "question_video": null,
    "map_id": 17032,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Parathyroid Adenoma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated serum calcium&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">and <strong>PTH with normal Vit. D</strong> Levels are suggestive of <strong>primary hyperparathyroidism</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Causes:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:lower-roman\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH secreting adenoma: <strong>M/C cause</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multiglandular hyperplasia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: seen in <strong>MEN syndrome</strong></span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parathyroid Adenoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> - A <strong>parathyroid adenoma</strong> is a <strong>benign tumor of a parathyroid gland</strong> that <strong>causes primary hyperparathyroidism.</strong> It results in the <strong>overproduction of PTH</strong>, which in turn can lead to <strong>hypercalcemia</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tumour Lysis Syndrome</strong> - This condition occurs when a <strong>large number of tumor cells are lysed rapidly</strong>, releasing their <strong>contents into the bloodstream.</strong> This can lead to <strong>hypercalcemia</strong> due to the <strong>high influx of intracellular calcium into the bloodstream.</strong> This is seen in setting of chemotherapy for leukemias, which does not match the clinical scenario. In this case, PTH levels would not be elevated.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Secondary Hyperparathyroidism</strong> - This condition arises due to <strong>another disease that causes low calcium levels</strong>, prompting the <strong>parathyroid glands to overproduce PTH to compensate</strong>. Common causes include chronic kidney disease and vitamin D deficiency, which are not indicated in this patient due to her normal vitamin D levels.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Multiglandular Parathyroid Hyperplasia</strong> - This refers to the <strong>enlargement and increased activity of more than one parathyroid gland</strong>. It&#39;s often seen in genetic conditions such as Multiple Endocrine Neoplasia (MEN) syndromes. While this could cause elevated PTH levels, it is less common than a single adenoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>parathyroid adenoma</strong> is the <strong>most common cause of primary hyperparathyroidism,</strong> which is characterized by <strong>elevated PTH and calcium levels</strong>, with <strong>normal vitamin D levels</strong>, especially in the context of a <strong>postmenopausal woman with back pains</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Causes of hypercalcemia: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/picture3.jpg\" style=\"height:499px; width:1000px\" /></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 875</span></strong></span></span></p>",
    "correct_choice_id": 69337,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17345,
    "choices": [
      {
        "id": 69340,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal calculi </span></span></span></span></p>"
      },
      {
        "id": 69341,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Painful bones</span></span></span></span></p>"
      },
      {
        "id": 69342,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mental confusion</span></span></span></span></p>"
      },
      {
        "id": 69343,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skin rash</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are seen in symptomatic primary hyperparathyroidism except?</span></span></p>",
    "unique_key": "Q5351690",
    "question_audio": null,
    "question_video": null,
    "map_id": 17033,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Skin rash </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skin rash&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is <strong>not typically associated with PHPT</strong>. The classical symptoms are related to the <strong>effects of high calcium levels on bones</strong>, <strong>kidneys</strong>, <strong>gastrointestinal tract</strong>, and the <strong>central nervous system</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Renal calculi</strong> - Renal calculi are a <strong>common manifestation of primary hyperparathyroidism</strong> (PHPT). The condition can lead to hypercalcemia, which in turn can cause calcium to precipitate in kidneys leading to calcium oxalate stones.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Painful bones</strong> - Patients with <strong>PHPT can experience bone pain</strong> and <strong>skeletal fragility</strong>. This is due to excess PTH stimulating bone resorption, which can lead to osteitis fibrosa cystica, a condition where bones become weak and deformed.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Mental confusion</strong> - <strong>Elevated calcium levels</strong> associated with <strong>PHPT</strong> can result in <strong>neuropsychiatric manifestations</strong>, including <strong>mental confusion, fatigue, depression, and memory impairment</strong>, often referred to as <strong>&quot;psychiatric moans&quot;</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skin rash&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is <strong>not a typical manifestation of symptomatic primary hyperparathyroidism,</strong> which is classically characterized by <strong>symptoms involving the bones, kidneys, gastrointestinal tract,</strong> and <strong>central nervous system</strong>, summarized by the <strong>phrase &lsquo;painful bones, renal stones, abdominal groans, fatigue overtones and psychiatric moans&rsquo;</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients are typically identified <strong>incidentally</strong> with elevated total calcium or following routine assessment of<strong> bone densitometry (DEXA scan)</strong>. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most patients will, however, have some vague constitutional symptoms, such as fatigue, muscle weakness, depression or some mild memory impairment on questioning. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of kidney stones remains the <strong>most common clinical manifestation</strong> of symptomatic PHPT.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. PG 875</span></span></strong></span></span></p>",
    "correct_choice_id": 69343,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17346,
    "choices": [
      {
        "id": 69344,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypercalcemia </span></span></span></span></p>"
      },
      {
        "id": 69345,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal serum creatinine </span></span></span></span></p>"
      },
      {
        "id": 69346,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased urinary excretion of phosphate</span></span></span></span></p>"
      },
      {
        "id": 69347,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased serum ALP</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following will be seen in the biochemical panel of a patient with primary Hyperparathyroidism except?</span></span></p>",
    "unique_key": "Q8293327",
    "question_audio": null,
    "question_video": null,
    "map_id": 17034,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Decreased urinary excretion of phosphate</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with <strong>primary hyperparathyroidism</strong> (PHPT), the following findings would typically be observed in a biochemical panel:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased urinary excretion of phosphate</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is <strong>incorrect in the context of PHPT</strong>. Typically, <strong>increased PTH levels lead to decreased renal reabsorption of phosphate</strong>,<strong> resulting in increased urinary excretion of phosphate,</strong> not decreased. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hypercalcemia</strong> - This is a <strong>hallmark feature of PHPT</strong> due to the <strong>overproduction of parathyroid hormone</strong> (PTH), leading to <strong>increased calcium reabsorption in the kidneys</strong>, <strong>increased calcium release from bones</strong>, and <strong>increased calcium absorption from the intestine</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Normal serum creatinine</strong> - PHPT <strong>does not necessarily affect renal function</strong>; therefore, <strong>serum creatinine levels may remain within normal ranges</strong> unless there is <strong>concomitant kidney disease</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Increased serum ALP (Alkaline Phosphatase)</strong> - <strong>Serum ALP</strong> may be <strong>elevated in PHPT if there is bone involvement</strong>. PTH stimulates bone turnover, which can raise ALP levels as it is an enzyme associated with bone formation.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In <strong>primary hyperparathyroidism</strong>, the <strong>biochemical profile usually includes hypercalcemia, normal serum creatinine</strong>, <strong>increased urinary excretion of phosphate</strong>, and possibly <strong>increased serum alkaline phosphatase</strong> if <strong>bone disease is present</strong>. Decreased urinary excretion of phosphate is not a feature of PHPT.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PHPT is a biochemical diagnosis</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Only when the disease has been confirmed biochemically should localization studies be undertaken.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PHPT is defined as an elevated total</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, or more specifically ionized, calcium in the presence of an inappropriately elevated or unsuppressed PTH. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is associated with a low serum phosphate in the setting of normal creatinine and vitamin D levels; <strong>24-hour urinary excretion of calcium may be normal or elevated</strong>. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is important to perform a 24-hour urinary collection to rule out the presence of the rare familial hypocalciuric hypercalcemia (FHH). </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alkaline phosphatase may be elevated in patients&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">in whom there is concomitant bone disease.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 876</span></span></strong></span></span></p>",
    "correct_choice_id": 69346,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17347,
    "choices": [
      {
        "id": 69348,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cervical exploration</span></span></span></span></p>"
      },
      {
        "id": 69349,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parathyroid venous sampling</span></span></span></span></p>"
      },
      {
        "id": 69350,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">4D CT scan neck </span></span></span></span></p>"
      },
      {
        "id": 69351,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sestamibi scan</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50 years old female was diagnosed with primary hyperparathyroidism. USG neck revealed a single adenoma of the left parathyroid gland. What&rsquo;s the most preferred technique to determine its localization?</span></span></p>",
    "unique_key": "Q1735227",
    "question_audio": null,
    "question_video": null,
    "map_id": 17035,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Sestamibi scan</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>use of Sestamibi</strong> (2-methoxy-2-methylpropylisonitrile [MIBI]) for <strong>parathyroid localisation</strong> was <strong>first described in 1989</strong> and is now regarded as the <strong>most accurate and reliable method for imaging the parathyroid glands</strong>. It is <strong>safe and reproducible</strong> and, while it has a <strong>sensitivity and specificity similar to ultra-sonography</strong>, it may image glands in ectopic positions better</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preoperative localisation studies for PHPT were considered less important than identifying an experienced surgeon. However, with a shift away from the traditional four&nbsp;</span></span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">gland (cervical neck) exploration to more minimally invasive procedures, <strong>accurate preoperative identification is critically important to guide surgical strategy</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective venous sampling for PTH can allow accurate localisation of adenomas but an <strong>experienced interventional radiologist is vital for success</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multiphase CT imaging (4D-CT) has become widely utilized to localise disease. <strong>It gives both anatomical and functional information </strong>about the parathyroid gland. The <strong>potential disadvantage of 4D-CT scanning is the higher radiation dose</strong> when compared with traditional imaging modalities.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed., Pg. 875, 876 </span></span></strong></span></span></p>",
    "correct_choice_id": 69351,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17349,
    "choices": [
      {
        "id": 69356,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sternocleidomastoid muscle</span></span></span></span></p>"
      },
      {
        "id": 69357,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Behind thyroid gland </span></span></span></span></p>"
      },
      {
        "id": 69358,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Forearm</span></span></span></span></p>"
      },
      {
        "id": 69359,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abdomen</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In total parathyroidectomy for multi-glandular disease, all 4 parathyroid glands are removed and bits are re-implanted in which part of the body?</span></span></p>",
    "unique_key": "Q1466179",
    "question_audio": null,
    "question_video": null,
    "map_id": 17037,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Forearm</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the <strong>surgical treatment of multi-glandular parathyroid disease</strong>, particularly when a <strong>total parathyroidectomy is performed</strong>, the various sites for <strong>auto-transplantation of parathyroid tissue</strong> are considered based on <strong>accessibility and the ability to monitor</strong> and <strong>potentially resect the tissue if hyperparathyroidism recurs.</strong> </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Auto-transplantation into the non-dominant forearm</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, specifically into the <strong>brachioradialis muscle</strong>, allows for easy monitoring of the graft function <strong>and also facilitates re-operation if there is recurrent hyperparathyroidism.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sternocleidomastoid muscle</strong> - This is <strong>not a common site for auto-transplantation of parathyroid tissue</strong>. While it is easily accessible during neck surgery, it is less preferred due to the potential for difficulty in monitoring and resecting the tissue if necessary.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Behind the thyroid gland</strong> - <strong>Re-implantation</strong> behind the <strong>thyroid gland is not a standard practice</strong> because it can make it challenging to distinguish between recurrent disease in the neck and the transplanted tissue.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Abdomen</strong> - Although the <strong>abdomen is a site that could technically be used for transplantation</strong>, it is not preferred due to the complexity of re-operation in this area and the inability to easily monitor the graft.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In <strong>total parathyroidectomy for multi-glandular parathyroid disease</strong>, the <strong>standard practice is to re-implant small pieces of parathyroid tissue</strong> into the <strong>brachioradialis muscle</strong> of the <strong>non-dominant forearm</strong> to facilitate monitoring and potential future re-operation.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&ldquo;All four glands can be resected and a forearm auto-transplant created. Small pieces of parathyroid are sutured into pockets created in the brachioradialis muscle of the non-dominant forearm.&rdquo;</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 880 </span></span></strong></span></span></p>",
    "correct_choice_id": 69358,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17350,
    "choices": [
      {
        "id": 69360,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Brachioradialis muscle of non-dominant forearm</span></span></span></span></p>"
      },
      {
        "id": 69361,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Brachioradialis muscle of dominant forearm</span></span></span></span></p>"
      },
      {
        "id": 69362,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sternocleidomastoid</span></span></span></span></p>"
      },
      {
        "id": 69363,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All 4 glands are reimplanted in normal anatomical locations</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 67 years old male underwent a total thyroidectomy for papillary carcinoma of the thyroid gland. The parathyroid glands were accidentally removed. Where can the surgeon re implant these glands? </span></span></p>",
    "unique_key": "Q8153220",
    "question_audio": null,
    "question_video": null,
    "map_id": 17038,
    "difficulty_level": "difficult",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Sternocleidomastoid</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If the <strong>parathyroid glands are accidentally removed during thyroid surgery</strong>, they can be <strong>re-implanted into the sternocleidomastoid muscle</strong>. This keeps the parathyroid tissue in the neck, allowing for a more physiological parathyroid function and potentially easier surgical access if there are problems in the future.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If the <strong>parathyroid glands</strong> are <strong>inadvertently removed during thyroidectomy</strong>, they may be <strong>re-implanted into the sternocleidomastoid muscle to maintain more physiological parathyroid function</strong> and allow for <strong>surgical accessibility</strong> if needed in the future.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In <strong>total parathyroidectomy</strong> for <strong>&ldquo;multiglandular hyperplasia&rdquo;,</strong> all <strong>four glands</strong> can be <strong>resected and a forearm auto-transplant created</strong>. Small pieces of parathyroid are sutured into pockets created <strong>in the brachioradialis muscle of the non-dominant forearm</strong>. This will allow easier diagnosis of recurrence of hyperparathyroidism</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Pg 880</span></span></strong></span></span></p>",
    "correct_choice_id": 69362,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17351,
    "choices": [
      {
        "id": 69364,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More than half the maximum pre-operative value in 30 mins</span></span></span></span></p>"
      },
      {
        "id": 69365,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More than half the maximum preoperative value in 10 mins </span></span></span></span></p>"
      },
      {
        "id": 69366,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More than one third the maximum preoperative value in 30 mins</span></span></span></span></p>"
      },
      {
        "id": 69367,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More than one third the maximum pre-operative value in 10 mins</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 37-year-old female patient is undergoing a focused parathyroidectomy for parathyroid adenoma. According to the Miami criteria, for the resection to be considered appropriate, the intra operative drop in parathyroid hormone level should be around?</span></span></p>",
    "unique_key": "Q7428689",
    "question_audio": null,
    "question_video": null,
    "map_id": 17039,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) More than half the maximum pre-operative value in 10 mins </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When performing a <strong>focused parathyroidectomy for a parathyroid adenoma</strong>, the <strong>intraoperative measurement of parathyroid hormone</strong> (PTH) levels is crucial to confirm the successful removal of the adenoma. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More than half the maximum preoperative value in 10 mins&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- This is the correct answer according to the <strong>Miami criteria</strong>. A significant <strong>drop in PTH levels to less than half of the highest pre-operative value within 10 minutes post-excision</strong> suggests successful <strong>removal of the hyperfunctioning gland</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>Miami criteria</strong> were developed to <strong>determine the extent of resection</strong>. A <strong>drop in the PTH</strong> into the <strong>normal range and to less than half the maximum preoperative PTH at 10 minutes</strong> appears to <strong>accurately predict single-gland disease</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/picture4.jpg\" style=\"height:285px; width:700px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 880</span></span></strong></span></span></p>",
    "correct_choice_id": 69365,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17353,
    "choices": [
      {
        "id": 69372,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age &lt; 50years</span></span></span></span></p>"
      },
      {
        "id": 69373,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum calcium 0.5 mg% above upper limit</span></span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">/dL</span></span></span></span></p>"
      },
      {
        "id": 69374,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DEXA Scan T score -2.5 at lumbar spine </span></span></span></span></p>"
      },
      {
        "id": 69375,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">24-hour urinary calcium &gt;10 mmol</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male was undergoing routine scanning when he was diagnosed with asymptomatic primary hyperparathyroidism. All of the following are criteria for surgical intervention in a case of primary HPTH except?</span></span></p>",
    "unique_key": "Q7265331",
    "question_audio": null,
    "question_video": null,
    "map_id": 17041,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Serum calcium 0.5 mg% above upper limit</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>guideline for surgical intervention</strong> typically requires a <strong>serum calcium level that is more than 1 mg%</strong> above the <strong>upper limit of normal</strong>. A <strong>smaller elevation</strong>, such as <strong>0.5 mg%, does not usually indicate</strong> the <strong>need for surgery in asymptomatic patients.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the management of <strong>asymptomatic primary hyperparathyroidism</strong> (HPTH), indications for <strong>surgical intervention</strong> include several criteria.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Age &lt; 50 years</strong> - This is one of the indications for surgery. <strong>Younger patients are more likely to benefit from surgical intervention</strong> due to the potential for longer-term complications of the disease if left untreated.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>DEXA Scan T score -2.5 at lumbar spine</strong> - A <strong>T-score of -2.5 or lower at any major site</strong> (lumbar spine, hip, or forearm) is an <strong>indication for surgery</strong> because it reflects significant bone loss, which could be attributable to HPTH.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>24-hour urinary calcium &gt;10 mmol/dL</strong> - This <strong>indicates increased calcium excretion</strong>, which <strong>increases the risk for kidney stones</strong>, and is a criterion for considering surgery in the management of HPTH.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In <strong>asymptomatic primary hyperparathyroidism</strong>, <strong>surgical intervention</strong> is indicated for <strong>patients younger than 50 years</strong>, those with a <strong>serum calcium more than 1 mg%</strong> above the <strong>upper limit of normal</strong>, a <strong>DEXA scan T-score of -2.5 or less at any major site</strong>, or a <strong>24-hour urinary calcium excretion greater than 10 mmol/dL</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum calcium should be more than 1 mg% above upper limit of normal.</span></span></strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients not fulfilling below criteria, medical management can be tried for asymptomatic primary hyperparathyroidism.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/12/picture5.jpg\" style=\"height:450px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 879</span></span></strong></span></span></p>",
    "correct_choice_id": 69373,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17354,
    "choices": [
      {
        "id": 69376,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary thyroid carcinoma </span></span></span></span></p>"
      },
      {
        "id": 69377,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multi-glandular parathyroid gland hyperplasia</span></span></span></span></p>"
      },
      {
        "id": 69378,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulinoma</span></span></span></span></p>"
      },
      {
        "id": 69379,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prolactinoma</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are components of MEN 1 syndrome except?</span></span></p>",
    "unique_key": "Q5298242",
    "question_audio": null,
    "question_video": null,
    "map_id": 17042,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Medullary thyroid carcinoma </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Medullary thyroid carcinoma</strong> - This is <strong>not a component of MEN 1 syndrome</strong>. <strong>Medullary thyroid carcinoma</strong> is typically associated with <strong>MEN 2 syndrome.</strong> <strong>MEN 1</strong> primarily involves <strong>parathyroid, pancreatic, and pituitary tumors</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Multi-glandular parathyroid gland hyperplasia</strong> - This is a <strong>classic feature of MEN 1</strong>. Almost all patients with MEN 1 develop parathyroid hyperplasia, leading to primary hyperparathyro</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Insulinoma</strong> - Insulinomas are <strong>pancreatic endocrine tumors</strong> that can <strong>occur</strong> as a <strong>part of MEN 1</strong>. Although less common than <strong>gastrinoma</strong>, they are one of the characteristic features of this syndrome.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Prolactinoma</strong> - Prolactinomas are <strong>pituitary tumors that often occur in MEN 1</strong>. They are the <strong>most common type of pituitary adenomas found in this syndrome</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary thyroid carcinoma&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is <strong>not a component of MEN 1 syndrome</strong>, which is characterized by the <strong>triad of parathyroid hyperplasia</strong>, <strong>pancreatic endocrine tumors</strong> (like gastrinomas&gt;insulinomas), and <strong>pituitary tumors</strong> (commonly prolactinomas).</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN type 1 is a rare autosomal dominant syndrome consisting of tumors of the parathyroids, endocrine pancreas and the pituitary <strong>(the three Ps)</strong>.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can also be associated with adrenal adenomas or carcinoma, foregut carcinoids and lipomas.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Men 1 is a tumour suppressor gene</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Mutations of MEN 1 gene coding for <strong>MENIN protein</strong> are responsible for MEN 1.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients typically present with young onset (20&ndash;30 years of age) of symptomatic hyperparathyroidism and over 95% of patients will have PHPT before the age of 40 years.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 882</span></span></strong></p>",
    "correct_choice_id": 69376,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17356,
    "choices": [
      {
        "id": 69384,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Unilateral pheochromocytoma</span></p>"
      },
      {
        "id": 69385,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Bilateral pheochromocytoma</span></p>"
      },
      {
        "id": 69386,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Pancreatic cancer</span></p>"
      },
      {
        "id": 69387,
        "text": "<p><span style=\"font-size:18px;\">Medullary thyroid cancer</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Which is the most common feature of MEN 2A syndrome?</span></p>",
    "unique_key": "Q5763140",
    "question_audio": null,
    "question_video": null,
    "map_id": 17044,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>Ans. D) Medullary thyroid cancer</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong><u>Explanation</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>MEN type 2A&nbsp;</strong>consists of <strong>medullary thyroid carcinoma</strong> (MTC), <strong>unilateral or bilateral pheochromocytomas</strong> and <strong>PHPT due to multiglandular disease</strong>.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>PHPT&nbsp;</strong>occurs in <strong>approximately 20% of patients</strong> and is <strong>associated with mutations in codon 634</strong> in the <strong>RET proto-oncogene</strong>.</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong>MEN 2 syndrome:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><ul><li><p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Medullary Thyroid carcinoma (90-100%)</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:18px;\">Pheochromocytoma (10-60%)</span></p></li></ul><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:18px;\"><strong><u>Ref</u>: Bailey and Love, 28<sup>th</sup> Ed. Pg 882</strong></span></p>",
    "correct_choice_id": 69387,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17357,
    "choices": [
      {
        "id": 69388,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucosal neuromas belong to MEN 3 syndrome </span></span></span></span></p>"
      },
      {
        "id": 69389,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN syndrome is more common at an older age</span></span></span></span></p>"
      },
      {
        "id": 69390,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN 4 syndrome is associated with a cyclin dependent kinase inhibitor CDKI mutation</span></span></span></span></p>"
      },
      {
        "id": 69391,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumors are aggressive and bilateral in nature</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Choose the incorrect statement with respect to MEN syndrome?</span></span></p>",
    "unique_key": "Q6386730",
    "question_audio": null,
    "question_video": null,
    "map_id": 17045,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) MEN syndrome is more common at an older age</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN syndrome is more common at an older age&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- This is the incorrect statement. <strong>MEN syndromes</strong> typically <strong>present at a younger age</strong>, often with symptoms manifesting in <strong>individuals between 20&ndash;30 years of age</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Mucosal neuromas belong to MEN 3 syndrome&nbsp;</strong>- Mucosal neuromas are a feature of <strong>MEN 2B</strong>, which is also referred to as <strong>MEN 3 by some classifications</strong>. MEN 2B includes medullary thyroid carcinoma, pheochromocytoma, mucosal neuromas, and a marfanoid habitus.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>MEN 4 syndrome is associated with a cyclin dependent kinase inhibitor (CDKI) mutation</strong> - This is <strong>correct</strong>. MEN 4 is associated with mutations in the CDK inhibitor genes, which can lead to a phenotype similar to MEN 1, with tumors in multiple glands.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Tumors are aggressive and bilateral in nature&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- This is generally <strong>true</strong> for MEN syndromes, where tumors can be aggressive and often present bilaterally, especially in the case of pheochromocytomas in MEN 2.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN syndromes&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are characterized by the <strong>early onset of tumors in multiple endocrine glands,</strong> with <strong>familial autosomal dominant inheritance</strong>. <strong>MEN 2B</strong>, sometimes referred to as<strong> MEN 3</strong>, includes <strong>mucosal neuromas</strong>. <strong>MEN 4</strong> involves <strong>CDKI mutations</strong>, and <strong>MEN syndromes</strong> often feature <strong>aggressive and bilateral tumors</strong>. MEN syndromes are not more common at an older age; they usually present in younger individuals, often before the age of 40.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN SYNDROME</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Familial disorders, AD inheritance</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aggressive, B/L, At younger age</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Associated with multiple malignancies</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN 1:</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN 1 gene coding for MENIN PROTEIN </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>P</strong>ituitary tumours: Non-functional or Functional (<strong>P</strong>rolactinoma)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>P</strong>arathyroid tumours: <strong>M/C feature of MEN 1</strong> (80 %-100 %) due to <strong>Multiglandular hyperplasia</strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">P</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>P</strong>ancreatic Tumours: Non-functional or functional <strong>(Gastrinoma)</strong></span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN 4:</span></span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cyclin Dependent Kinase inhibitor mutation. Rest same as MEN 1</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN 2 SYNDROME </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RET Mutation:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary Thyroid Carcinoma <strong>(90-100%)</strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pheochromocytoma (10-60%)</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Sub-Types:</strong> MEN2A and MEN2B/3</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN2A:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Also has hyperparathyroidism due to multiglandular disease.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prophylactic Thyroidectomy by the age of 5 year</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN 2B/3: </span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Also has <strong>&lsquo;MMM&rsquo;</strong>: <strong>M</strong>arfanoid Habitus, <strong>M</strong>ucosal Neuromas, <strong>M</strong>ega colon /Hirschsprung: <strong>Prophylactic Thyroidectomy by the age of 1 year</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 882-883 </span></span></strong></span></span></p>",
    "correct_choice_id": 69389,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17358,
    "choices": [
      {
        "id": 69392,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Seen in MEN 1 syndrome </span></span></span></span></p>"
      },
      {
        "id": 69393,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor shows warm modularity on thyroid scan</span></span></span></span></p>"
      },
      {
        "id": 69394,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diarrhea is commonly seen due to serotonin secretion</span></span></span></span></p>"
      },
      {
        "id": 69395,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Familial variant is multifocal and bilateral</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Choose the true statement about medullary thyroid cancers?</span></span></p>",
    "unique_key": "Q7597530",
    "question_audio": null,
    "question_video": null,
    "map_id": 17046,
    "difficulty_level": "difficult",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Familial variant is multifocal and bilateral </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Familial variant is multifocal and bilateral&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- This is true. The <strong>familial form of MTC</strong>, as <strong>part of MEN 2 syndrome</strong>, is often <strong>multifocal and bilateral</strong> and can be <strong>more aggressive than the sporadic form Familial cancers</strong> tend to be <strong>more aggressive compared to sporadic cancers</strong>. Moreover, MEN syndromes are often bilateral and appear at a younger age.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Seen in MEN 1 syndrome&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- This statement is false. <strong>Medullary thyroid cancer</strong> (MTC) is <strong>not seen in MEN 1 syndrome</strong>; instead, it is a characteristic of <strong>MEN 2 syndrome</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tumor shows warm modularity on thyroid scan</strong> - This is typically <strong>not true for MTC</strong>. <strong>Thyroid scans</strong>, which often <strong>use radioiodine</strong>, typically <strong>do not show uptake in MTC</strong> because the C cells do not absorb iodine. These tumors are often &quot;cold&quot; nodules on the scan.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Diarrhea is commonly seen due to serotonin secretion</strong> - While <strong>diarrhea is a symptom of MTC</strong>, it is not common (Seen in &lt;30%).</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The familial variant of medullary thyroid cancer is often multifocal and bilateral, associated with MEN 2 syndrome, and tends to present at a younger age compared to sporadic cases.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary thyroid cancers are tumours of the <strong>parafollicular (C cells)</strong> derived from the neural crest that are not unlike those of a carcinoid tumour. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High levels of serum calcitonin and carcinoembryonic antigen are produced</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Calcitonin levels fall after resection and rise again with recurrence, making it a valuable tumour marker in the follow-up of patients with this disease. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diarrhea is a feature in 30% of cases and this may be due to 5-hydroxytryptamine or prostaglandins produced by the tumour cells. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary carcinoma may occur in combination with adrenal phaeochromocytoma and hyperparathyroidism (usually due to hyperplasia) in the syndrome known as <strong>multiple endocrine neoplasia type 2A (MEN-2A). </strong></span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The familial form of the disease frequently affects children and young adults, whereas the sporadic cases occur at any age with no sex predominance.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The highest risk mutations are associated with early-onset disease and prophylactic total thyroidectomy is recommended during childhood.</span></span></strong></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 870-871</span></span></strong></span></span></p>",
    "correct_choice_id": 69395,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17360,
    "choices": [
      {
        "id": 69400,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Autosomal dominant inheritance</span></span></span></span></p>"
      },
      {
        "id": 69401,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperparathyroidism is seen in MEN 1 and MEN 2B</span></span></span></span></p>"
      },
      {
        "id": 69402,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gastrinoma is the most common functional endocrine tumor of pancreas in MEN 1</span></span></span></span></p>"
      },
      {
        "id": 69403,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pheochromocytoma is seen in both MEN 2A and 2B</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Choose the incorrect statement about MEN syndrome?</span></span></p>",
    "unique_key": "Q4552649",
    "question_audio": null,
    "question_video": null,
    "map_id": 17048,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Hyperparathyroidism is seen in MEN 1 and MEN 2B</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Multiple Endocrine Neoplasia</strong> (MEN) <strong>syndromes</strong> are characterized by the <strong>occurrence of tumors in multiple endocrine glands</strong>. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperparathyroidism is seen in MEN 1 and MEN 2B&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- This statement is <strong>incorrect</strong>. <strong>Hyperparathyroidism</strong> is commonly seen in <strong>MEN 1 and MEN 2A syndromes</strong>, <strong>not MEN 2B</strong>. <strong>MEN 2B</strong> is characterized by <strong>medullary thyroid carcinoma</strong> (MTC), <strong>pheochromocytoma</strong>, and <strong>mucosal neuromas</strong>, without <strong>hyperparathyroidism.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Autosomal dominant inheritance</strong> - This is <strong>correct</strong>. MEN syndromes are inherited in an autosomal dominant pattern.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Gastrinoma is the most common functional endocrine tumor of the pancreas in MEN 1</strong> - This is <strong>true</strong>. Gastrinomas are the most common functional pancreatic endocrine tumor in MEN 1, often leading to Zollinger-Ellison syndrome.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pheochromocytoma is seen in both MEN 2A and 2B</strong> - This is <strong>correct</strong>. Pheochromocytoma is a feature of both MEN 2A and MEN 2B syndromes.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify that <strong>hyperparathyroidism is a feature of MEN 1</strong> and <strong>MEN 2A</strong>, <strong>not MEN 2B</strong>. <strong>MEN syndromes</strong> are <strong>inherited in an autosomal dominant pattern</strong>, and specific tumors are associated with each subtype.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN (Autosomal dominant) Syndrome:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN 1:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pituitary + Parathyroid + Pancreas</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN 2A:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MTC + Pheochromocytoma + Parathyroid hyperplasia</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN 2B:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MTC + Pheochromocytoma + Mucosal neuromas</span></span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 882</span></span></strong></span></span></p>",
    "correct_choice_id": 69401,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17361,
    "choices": [
      {
        "id": 69404,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-functional adenoma</span></span></span></span></p>"
      },
      {
        "id": 69405,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cushing&rsquo;s adenoma</span></span></span></span></p>"
      },
      {
        "id": 69406,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pheochromocytoma</span></span></span></span></p>"
      },
      {
        "id": 69407,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metastasis</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Choose the most common tumour arising from adrenal gland?</span></span></span></span></p>",
    "unique_key": "Q8208281",
    "question_audio": null,
    "question_video": null,
    "map_id": 17049,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Non-functional adenoma</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-functional adenoma&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- These are the <strong>most common type of adrenal tumor</strong>. <strong>Non-functional adenomas</strong> are usually <strong>benign and do not secrete hormones</strong>, so they often <strong>do not cause symptoms</strong> and are found incidentally during imaging studies for other reasons, hence the term <strong>&quot;incidentaloma.&quot;</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Cushing&rsquo;s adenoma</strong> - These are <strong>functional adenomas</strong> that <strong>produce cortisol</strong>, leading to <strong>Cushing&rsquo;s syndrome</strong>. They are less common than non-functional adenomas.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pheochromocytoma</strong> - This is a <strong>rare tumor that arises from the chromaffin cells</strong> of the <strong>adrenal medulla</strong> and <strong>produces catecholamines</strong>, <strong>leading to episodes of hypertension</strong>, <strong>palpitations, and headaches</strong>. They are less common than non-functional adenomas.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metastasis</strong> - While the <strong>adrenal glands</strong> are a <strong>common site for metastasis</strong> from other <strong>primary tumors</strong>, such as lung and breast cancer, this is not a primary tumor of the adrenal gland itself.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most <strong>common tumor arising from the adrenal gland</strong> is the <strong>non-functional adenoma</strong>, often discovered incidentally on imaging studies.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease is termed an <strong>incidentaloma</strong>. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The types include benign and malignant tumours of the cortex and medulla or of extra-adrenal origin. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These tumours can be either non-functioning (silent) or functioning (secreting excess hormones).</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Radiological features suspicious of adrenal malignancy </span></span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diameter &gt; 40&nbsp;mm and &gt; 10&nbsp;HU density </span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Contrast-enhanced washout CT </span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI chemical shift:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">no change in signal intensity on out-of-phase imaging </span></span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FDG-PET:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">positive uptake</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Management: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All patients should be discussed in a multidisciplinary setting. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenalectomy is the standard of care for patients with unilateral tumours causing hormone excess (functional adenomas). </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenalectomy is recommended for all tumours &gt; 40&nbsp;mm in diameter</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, tumours showing imaging characteristics of malignancy and tumours showing significant growth. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Laparoscopic adrenalectomy is recommended for unilateral adrenal masses with radiological findings suspicious of malignancy and a diameter &lt; 6 cm without local invasion.</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Small (&lt; 40mm) benign non-functioning tumours do not require surgery, but patients should undergo a follow-up CT/MRI at 6 months.</span></span></strong></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 890</span></span></strong></p>",
    "correct_choice_id": 69404,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17362,
    "choices": [
      {
        "id": 69408,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">EUS </span></span></span></span></p>"
      },
      {
        "id": 69409,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI</span></span></span></span></p>"
      },
      {
        "id": 69410,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DOPA PET</span></span></span></span></p>"
      },
      {
        "id": 69411,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MIBG Scan</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is preferred investigation modality for localisation of pheochromocytoma?</span></span></span></span></p>",
    "unique_key": "Q6926797",
    "question_audio": null,
    "question_video": null,
    "map_id": 17050,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) MRI</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI (Magnetic Resonance Imaging)&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- <strong>MRI</strong> is a preferred <strong>modality for imaging pheochromocytoma</strong> due to its <strong>superior soft tissue contrast</strong>, which <strong>helps in the identification</strong> and <strong>characterization of these tumors</strong>, particularly when they are <strong>located in the adrenal glands</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>EUS (Endoscopic Ultrasound)</strong> - EUS is <strong>not typically used for the localization of pheochromocytoma</strong>. It is more commonly used for gastrointestinal lesions and for assessing the pancreas.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>DOPA PET (Dihydroxyphenylalanine Positron Emission Tomography)</strong> - While <strong>DOPA PET scans</strong> can be <strong>very sensitive for detecting pheochromocytoma,</strong> especially when other <strong>imaging is inconclusive</strong>, they are not the first-line investigation due to cost and availability.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>MIBG Scan (Metaiodobenzylguanidine Scan)</strong> - MIBG scans are <strong>highly specific for pheochromocytoma</strong>, particularly for <strong>extra-adrenal and metastatic disease</strong>. However, they are usually reserved for when initial imaging with CT or MRI is inconclusive.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The preferred initial imaging modality for localizing pheochromocytoma is MRI, due to its detailed soft tissue imaging capabilities, which are beneficial for assessing tumor size and the risk of malignancy.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Once a biochemical diagnosis is established, imaging by CT or MRI is undertaken to </span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">determine tumour location and assess its size and risk of malignancy.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Size is not a predictor of malignancy for pheochromocytoma. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malignant Pheochromocytoma and Paragangliomas (PPGLs) are diagnosed by the presence of local invasion or metastatic disease</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. Tumours appear vascular and frequently possess cystic areas or central necrosis. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If initial imaging is negative or reveals extra-adrenal disease, <strong>functional investigation with 123I-MIBG </strong>(meta-iodo benzyl guanidine; 80&ndash;90% sensitive) <strong>or 111 In-octreotide scanning </strong>(50&ndash;70% sensitive) is undertaken. <strong>Routine use is not advocated in well-localised adrenal lesions.</strong> </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More recently, <strong>6-[18F] Fluoro-dopamine PET scanning</strong> has shown promise, particularly in the setting of PGLs, where conventional imaging and MIBG scanning are negative.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Bailey and Love, 28<sup>th</sup> Ed. Pg 900-901</span></span></strong></p>",
    "correct_choice_id": 69409,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17363,
    "choices": [
      {
        "id": 69412,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated plasma catecholamines</span></span></span></span></p>"
      },
      {
        "id": 69413,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Plasma dopamine levels positive</span></span></span></span></p>"
      },
      {
        "id": 69414,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased 24 hours&rsquo; urinary excretion of fractionated metanephrine</span></span></span></span></p>"
      },
      {
        "id": 69415,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated urinary catecholamines</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55 years old patient presented with severe headache, palpitations and sweating. On CECT abdomen, an adrenal tumour was detected. Which of the following findings is unlikely to be seen in this case? </span></span></p>",
    "unique_key": "Q6650053",
    "question_audio": null,
    "question_video": null,
    "map_id": 17051,
    "difficulty_level": "beginner",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Decreased 24 hours&rsquo; urinary excretion of fractionated metanephrine</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Triad of pheochromocytoma</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Headache + Palpitations + Sweating</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with symptoms of <strong>severe headache, palpitations, and sweating</strong>, and an <strong>adrenal tumor detected on imaging</strong>, the following findings are <strong>expected in pheochromocytoma</strong>:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased 24 hours urinary excretion of fractionated metanephrine&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- This is <strong>unlikely to be seen in a case of pheochromocytoma.</strong> Typically, there is an <strong>increased excretion of metanephrines in the urine</strong>, as they are <strong>metabolites of catecholamines.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Elevated plasma catecholamines</strong> - This would likely be <strong>seen in a patient with a pheochromocytoma</strong>, as these tumors secrete high levels of catecholamines, leading to the classic triad of symptoms.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Plasma dopamine levels positive</strong> - <strong>Elevated plasma dopamine</strong> can be <strong>seen in certain cases of pheochromocytomas</strong>, especially <strong>malignant ones</strong>, as it can be a marker of tumor burden.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Elevated urinary catecholamines</strong> - <strong>Elevated urinary catecholamines</strong> would be <strong>expected in a patient with a pheochromocytoma</strong>, as the <strong>tumor secretes catecholamines</strong> that are metabolized and excreted in the urine.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the setting of an <strong>adrenal tumor and symptoms of headache, palpitations, and sweating, increased levels of urinary metanephrines</strong> are typical and help confirm the diagnosis of pheochromocytoma.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased 24 hours&rsquo; urinary excretion of fractionated metanephrine seen. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The diagnosis of Pheochromocytoma is confirmed by elevated catecholamine metabolites (metanephrine) in plasma and/or raised 24-hour urinary excretion of fractionated metanephrines. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measurement of plasma and urinary metanephrines is more sensitive&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(99% and 97%, respectively) than plasma and urinary catecholamine measurement (86% and 84%, respectively). </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Measurements of one or more of these substances that are four times greater than the upper limit of the reference range are 100% diagnostic. </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Plasma dopamine can be regarded as a marker of tumour burden in malignant PPGLs.</span></span></strong></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 900 </span></span></strong></span></span></p>",
    "correct_choice_id": 69414,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  },
  {
    "id": 17364,
    "choices": [
      {
        "id": 69416,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% are unilateral</span></span></span></span></p>"
      },
      {
        "id": 69417,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% are inherited</span></span></span></span></p>"
      },
      {
        "id": 69418,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% are extra adrenal</span></span></span></span></p>"
      },
      {
        "id": 69419,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% are malignant</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following does not fit into the 10% rule of pheochromocytomas?</span></span></p>",
    "unique_key": "Q8090414",
    "question_audio": null,
    "question_video": null,
    "map_id": 17052,
    "difficulty_level": "intermediate",
    "subjects_id": [
      12
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 10% are unilateral</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% are unilateral&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">- This is <strong>incorrect</strong> because the <strong>majority of pheochromocytomas are unilateral</strong>. The <strong>&quot;10% rule&quot; states that 10% are bilateral, not unilateral.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>&quot;10% rule&quot;</strong> for <strong>pheochromocytomas</strong> suggests that <strong>approximately 10% are bilateral</strong>, <strong>inherited</strong>, <strong>extra-adrenal, malignant,</strong> and <strong>occur in children</strong>, which means that stating <strong>10% are unilateral does not fit this rule</strong>.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rule of 10% for pheochromocytomas:</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% are bilateral </span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% inherited</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% extra-adrenal (Organ of Zuckerkandl)</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% malignant</span></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">10% occur in children.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bailey and Love, 28<sup>th</sup> Ed. Pg 899-900. </span></span></strong></span></span></p>",
    "correct_choice_id": 69416,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": []
  }
];
        let quizName = 'Breast And Endocrine';
        const quizFilename = 'breast-and-endocrine-448d9471.html';
        let hierarchy = ["Cerebellum", "qBank", "Surgery"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        // --- NEW: History Management ---
        function saveProgress() {
            if (isQuizCompleted) return; // Don't save after completion
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            userHistory[quizFilename] = {
                questionStates,
                stats,
                currentQuestionIndex,
                currentMode,
                status: 'incomplete',
                lastSeen: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }

        function loadProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const savedState = userHistory[quizFilename];
            if (savedState) {
                questionStates = savedState.questionStates;
                stats = savedState.stats;
                currentQuestionIndex = savedState.currentQuestionIndex;
                currentMode = savedState.currentMode;
                console.log('Progress loaded.');
                return true;
            }
            return false;
        }

        function clearProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            if(userHistory[quizFilename]) {
                delete userHistory[quizFilename];
                localStorage.setItem('userHistory', JSON.stringify(userHistory));
                console.log('Previous progress cleared.');
            }
        }

        function markQuizAsCompleted() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const totalQuestions = questionsData.length;
            const correct = stats.correctAnswers || 0;
            
            userHistory[quizFilename] = {
                score: correct,
                total: totalQuestions,
                status: 'completed',
                completedOn: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }
        // --- End of History Management ---

        const urlParams = new URLSearchParams(window.location.search);
        const startAt = parseInt(urlParams.get('startAt'));
        const resume = urlParams.get('resume') === 'true';

        function goBack() {
            if (!isQuizCompleted) saveProgress(); // Save progress before leaving
            window.location.href = document.referrer || 'index.html';
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            if (!isNaN(startAt) && startAt >= 0 && startAt < questionsData.length) {
                currentQuestionIndex = startAt;
            }

            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                processAnswer();
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
            saveProgress(); // NEW: Save on answer selection
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            showSolution();
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            stats.correctAnswers = correct; // Update global stats
            stats.incorrectAnswers = incorrect;
            markQuizAsCompleted(); // NEW: Mark quiz as complete in history
            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                clearProgress(); // NEW: Clear history on retake
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                        saveProgress();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (resume) {
                if (loadProgress()) {
                    document.getElementById('modeModal').style.display = 'none';
                    initializeQuiz(); // Resume directly into the saved mode and state
                } else {
                    // If resume fails (e.g., cleared history), start fresh
                    clearProgress();
                    document.getElementById('modeModal').style.display = 'flex';
                }
             } else if (!window.location.pathname.endsWith('custom_quiz.html')) {
                clearProgress(); // Clear old progress if not resuming
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>